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Abstract	  	  	   Branched-­‐chain	   amino	   acids	   are	   indispensible	   amino	   acids	   that	   are	   known	   for	  having	   anabolic	   effects	   in	   skeletal	  muscle.	   These	   effects	   BCAAs	   elicit	   in	   existing	   skeletal	  muscle	  are	  well	  documented	   in	   literature.	  However,	  much	   less	   is	  known	  about	  how	   they	  affect	   the	  process	  of	  myogensis	  and	  muscle	  regeneration.	  Data	  generated	   in	  our	   lab	  have	  shown	  that	   the	   intact	  BCAA	  catabolic	  pathway	   is	  required	   for	  proper	  skeletal	  muscle	  cell	  differentiation.	  In	  the	  current	  study,	  the	  main	  enzymes	  involved	  in	  the	  catabolism	  of	  BCAAs	  were	  assessed,	   in	   addition	   to	   the	  activity	  of	   the	   rate-­‐limiting	  enzyme	   (Branched-­‐chain	  α-­‐ketoacid	  dehydrogenase	  -­‐	  BCKD)	  in	  the	  pathway.	  Increasing	  the	  flux	  of	  BCAAs	  through	  this	  pathway	  via	  siRNA	  mediated	  knockdown	  of	  a	  negative	  regulator	  of	  the	  pathway	  augmented	  differentiation.	   It	   is	  evident	  that	  BCAA	  catabolism	  is	   intricately	   involved	  in	  the	  process	  of	  muscle	   cell	   differentiation.	   Further	   study	   into	   the	   regulation	   of	   BCAA	   catabolism	   during	  differentiation	   is	  warranted;	   to	  aid	   in	   the	  development	  of	  nutritional	  based	   interventions	  for	  populations	  suffering	  from	  muscle	  wasting	  condition.…………	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Introduction	  	   Branched-­‐chain	   amino	   acids	   (BCAA)	   (isoleucine,	   leucine	   and	   valine)	   are	   found	   in	  high-­‐quality	  protein	  sources,	  and	  are	  well	  known	  components	  of	  a	  healthy	  diet.	  Not	  only	  do	  BCAAs	   comprise	   a	   large	   percentage	   of	   the	   amino	   acids	   (AA)	   incorporated	   into	   body	  proteins,	   they	   additionally	   exhibit	   cell	   signalling	   characteristics.	   BCAA’s	   signalling	  characteristics	   have	   been	   studied	   extensively	   in	   mature	   skeletal	   muscle,	   although	   little	  attention	  has	  been	  given	  to	  their	  role	  in	  muscle	  recovery/development.	  Research	  in	  our	  lab	  and	   others	   shows	   that	   the	   BCAA	   catabolic	   pathway	  must	   be	   tightly	   regulated	   to	   ensure	  proper	   physiological	   functioning.	   BCAA	   metabolism	   is	   altered	   in	   many	   diseased	   states	  including	  obesity	  and	  type	  2	  diabetes	  (Lynch	  &	  Adams,	  2014a;	  Mccormack	  et	  al.,	  2013;	  She	  et	  al.,	  2009),	  heart	  disease	  (Wang	  et	  al.,	  2016),	  and	  genetic	  disorders	  like	  maple	  syrup	  urine	  disease	   (MSUD)(Indo	   et	   al.,	   1987).	   Many	   of	   these	   diseases	   associated	   with	   a	   disrupted	  BCAA	  catabolic	  pathway	  include	  some	  form	  of	  skeletal	  muscle	  impairment.	  However,	  little	  is	   known	   whether	   the	   catabolic	   pathway	   of	   BCAAs	   plays	   a	   distinct	   role	   in	   muscle	   cell	  differentiation.	  Two	  mitochondrial-­‐localized	  enzymes	  regulate	  the	  first	  two	  steps	  in	  BCAA	  catabolism.	   Branched-­‐chain	   amino	   acid	   transferase-­‐2	   (BCAT2),	   the	   first	   enzyme	   in	   the	  pathway,	  catalyzes	  the	  transamination	  of	  all	  three	  BCAAs	  into	  their	  keto-­‐acid	  equivalents.	  The	   second	   enzyme	   in	   the	   pathway,	   Branched-­‐chain	   α-­‐keto-­‐acid	   dehydrogenase	   (BCKD),	  oversees	   the	   irreversible	   decarboxylation	   of	   all	   three	  BCAA	  derived	   keto-­‐acids	   into	   acyl-­‐CoA	   derivatives.	   	   The	   activity	   of	   BCKD	   in	   skeletal	  muscle	   is	   low	   under	   basal	   conditions,	  however,	   interventions	   that	   increase	   its	   activity,	   solely	   in	   skeletal	  muscle,	   have	  dramatic	  effects	  on	  whole	  body	  BCAA	  levels	  (Ishikawa	  et	  al.,	  2017).	  Therefore,	  investigating	  BCKD’s	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activity,	   in	  addition	  to	  its	  abundance,	  may	  yield	  greater	   insight	   into	  its	  role	   in	  muscle	  cell	  differentiation.	   The	   tightly	   controlled	   BCAA	   catabolic	   pathway	   is	   highly	   dependent	   upon	  BCKD	  activity.	  Two	  enzymes,	  a	  kinase	  and	  a	  phosphatase,	  antagonistically	  regulate	  BCKD	  activity.	  Altering	  the	  expression	  of	   the	  BCKD	  regulating	  enzymes	  could	  help	  elucidate	  the	  relevance	  of	  BCKD	  activity	  during	  muscle	  cell	  differentiation.	  	  Evidence	   has	   shown	  BCAA	  metabolites	   possess	   anabolic-­‐signalling	   characteristics,	  although	  the	  specific	  role	  they	  play	  in	  muscle	  cell	  differentiation	  remains	  to	  be	  determined.	  The	   regulatory	   properties	   of	   these	   metabolites	   could	   have	   positive	   effects	   on	   skeletal	  muscle	  mass,	  which,	   for	   a	   number	   of	   diseases,	   is	   an	   important	   indicator	   of	   both	   disease	  progression,	   and	   general	   quality	   of	   life.	   Thus,	   understanding	   the	  mechanisms	  underlying	  BCAA	  mediated	  muscle	  recovery/development	  may	  aid	  in	  uncovering	  potential	  therapeutic	  targets	  for	  the	  purpose	  of	  maintaining	  muscle	  mass.	  	  	   	  
	  3	  
Literature	  Review	  	  
Skeletal	  muscle’s	  contribution	  to	  health	  
	  	   Skeletal	  muscle	  (SM)	  is	  the	  largest	  metabolic	  contributor	  to	  whole-­‐body	  protein	  and	  energy-­‐metabolism.	  Many	  metabolic	  disorders	  have	  their	  principle	  effects	  stemming	  from,	  or	  exerted	  on	  SM.	  Functions	  of	  SM	  include	  the	  regulation	  of	  glucose	  homeostasis	  in	  addition	  to	  being	   the	  body’s	  principle	   reservoir	   for	  amino	  acids.	   SM	  mass	  and	  strength	  are	  highly	  associated	  with	  a	  number	  of	  metabolic	  diseases	  and	  overall	  risk	  of	  mortality	  (Atherton	  et	  al.,	   2016).	   Thus,	   attenuation	   of	   SM	   losses	   in	   both	   strength	   and	   mass	   has	   attracted	   vast	  research	  interests.	  	  
Factors	  regulating	  skeletal	  muscle	  mass	  	   To	   address	   the	   topic	   of	   disease-­‐mediated	   muscle	   atrophy/loss,	   one	   must	   first	  understand	  the	  consequences	  of	  muscle	  disuse	  atrophy.	  Muscle-­‐disuse	  atrophy	  can	  lead	  to	  problems	  on	  its	  own,	  including	  decreases	  in	  physical-­‐working	  capacity,	  decreases	  in	  quality	  of	   life,	   metabolic	   disorders,	   and	   increases	   in	   all-­‐cause	   mortality	   (Atherton,	   2016).	   A	  consequence	   of	   many	   diseased	   states	   involves	   some	   periods	   of	   immobilization.	  Immobilization	   itself	   is	   an	   atrophic-­‐inducing	   condition.	   Wall	   et	   al.,	   (2013)	   conducted	   a	  study	   that	   involved	   short-­‐term	   immobilization	   lasting	   a	  mere	   14-­‐days.	   They	   showed	  8%	  reductions	   in	   cross-­‐sectional	   area	   (CSA)	   and	   23%	   reductions	   in	   strength	   of	   quadriceps	  fibers	  (Wall	  et	  al.,	  2013).	  Additionally,	  muscle	  unloading	  has	  been	  shown	  to	  suppress	  the	  post-­‐absorptive	   (fasted-­‐state)	   and	   postprandial	   responses	   (fed-­‐state)	   to	   muscle	   protein	  synthesis	   (MPS),	   while	   increasing	   muscle	   protein	   degradation	   (MPD)	   in	   animal	   models	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(Atherton,	   2016).	   Immobilization-­‐induced	   losses	   in	   muscle	   mass	   are	   in	   part	   mediated	  through	  the	  up-­‐regulation	  of	  the	  ubiquitin	  proteasome	  and	  autophagy-­‐lysosomal	  pathways	  (Jackman	  &	  Kandarian,	  2004).	  
The Effects of Nutrition and Exercise on Skeletal Muscle Mass Two	   antagonistic	   processes	   determine	   protein	   balance	   within	   skeletal	   muscle:	   1)	  muscle	   protein	   degradation	   (MPD),	   and	   2)	   muscle	   protein	   synthesis	   (MPS).	   These	   two	  processes	   together	   are	   referred	   to	   as	   protein	   turnover.	   	   When	   protein	   balance	   leans	  towards	  a	  positive	  balance,	  muscle	  anabolism	  occurs,	  while	  muscle	  catabolism	  occurs	  when	  there	   is	   a	   negative	   balance.	   Protein	   turnover	   is	   highly	   responsive	   to	   two	   main	   stimuli:	  exercise	   and	   dietary	   protein	   ingestion.	   	   Many	   studies	   have	   sought	   out	   to	   assess	   how	   to	  optimally	  increase	  muscle	  protein	  balance	  via	  manipulation	  of	  these	  two	  factors.	  	  In	   young	   healthy	   adults,	   exercise	   has	   been	   shown	   to	   stimulate	   muscle	   protein	  synthesis,	   leading	   to	   muscle	   hypertrophy	   (Adegoke	   et	   al.,	   2012;	   Marcotte	   et	   al.,	   2015;	  Phillips	  et	  al.,	  1999;	  Wilkinson	  et	  al.,	  2008).	  Provision	  of	  dietary	  protein	  at	  the	  cessation	  of	  exercise	   has	   been	   shown	   to	   augment	  MPS	   rates,	   while	   having	  moderate	   effects	   on	  MPD	  (Moore,	   Prior,	   et	   al.,	   2009;	   Moore,	   Tarnopolsky,	   et	   al.,	   2009;	   Pendergast	   et	   al.,	   2011;	   S.	  Phillips	  et	  al.,	  2016;	  S.	  M.	  Phillips	  et	  al.,	  1997;	  Tipton	  et	  al.,	  1999).	  Simply	  put,	  muscle	  mass	  is	   a	   function	   of	   exercise	   training,	   and	   an	   adequate	   intake	   of	   dietary	   proteins.	   Resistance	  exercise	  (RE)	  is	  the	  preferred	  method	  to	  accumulate	  muscle	  mass,	  compared	  to	  endurance	  exercise.	  A	   single	  bout	  of	  RE	  has	  been	   shown	   to	   stimulate	  MPS	   rates	  by	  40-­‐150%	  above	  basal	   levels.	   (Burd	  et	  al.,	  2008).	  The	   increase	   in	  MPD	  is	   thought	  to	  replenish	   intracellular	  
	  5	  
amino	  acid	  pools,	   a	   consequence	  of	  MPS	  drawing	  upon	   those	  pools	   for	   the	   incorporation	  into	  body	  proteins	  (Burd,	  2008).	  Current	  recommendations	  state	  that	  dietary	  protein	  intake	  should	  be	  equal	  to	  0.8g	  of	   protein,	   per	   kg	   BW/day	   (S.	   Phillips,	   2016).	   This	   blanket	   approach	   to	   dietary	   protein	  recommendations	   has	   been	   challenged	   due	   to	   the	   complexities	   and	   deviations	   from	  “normal”	  that	  many	  populations	  experience	  ie.	  age,	  disease,	  and	  athletes.	  Growing	  evidence	  supports	  an	  increase	  in	  dietary	  protein	  recommendations	  (S.	  Phillips,	  2016).	  For	  example,	  aging	   individuals	   are	   subject	   to	   age-­‐related	   losses	   in	   skeletal	   muscle	   mass,	   known	   as	  sarcopenia.	   Increasing	   dietary	   protein	   ingestion	   above	   the	   current	   recommendations	   in	  these	   individuals	  has	  been	   shown	   to	   slow	   the	   effects	  of	   sarcopenia	   (Bradlee	   et	   al.,	   2017;	  Morley	  &	  Phillips,	  2013;	  S.	  Phillips,	  2016;	  Volpi	  et	  al.,	  2013;	  Wolfe,	  2012).	  	  
Myogenic	  Differentiation/Muscle	  Regeneration	  	  
mTOR function and regulation 
 Before	   delving	   into	   the	   complicated	   signalling	   pathways	   involved	   in	   myogenic	  differentiation,	   it	   is	   important	   to	   introduce	   the	   central	   hub	   to	  which	   all	   these	   signalling	  pathways	  converge	  upon.	  	  Perhaps	   the	  most	   important	   protein	   complex	   involved	   in	   protein	  metabolism	   and	  whole	   cell	   function	   is	   the	   mechanistic	   (mammalian)	   target	   of	   rapamycin	   (mTOR).	   This	  section	  will	   explore	   the	   function	  and	   relevance	  of	   this	   far-­‐reaching	  metabolic	   integration	  centre,	  which	  is	  integral	  to	  all	  cell	  functions.	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The	  discovery	  of	  mTOR	  was	  preceded	  by	  two	  main	  events.	  The	  first	  event	  was	  the	  discovery	  of	  what	  would	  be	  the	  eventual	  inhibitor	  of	  the	  mTORC1	  complex.	  This	  inhibitory	  chemical	   is	   produced	   by	   the	   bacterium	   Streptomyces	  hygroscopicus,	   found	   in	   the	   soils	   of	  Easter	  Island	  in	  1975	  by	  Suren	  Sehgal	  et	  al.,	  which	  they	  named	  rapamycin,	  paying	  homage	  to	  the	  native	  name	  for	  the	  island,	  Rapa	  Nui	  (Sehgal	  et	  al.,	  1975).	  The	  second	  event	  would	  not	  be	  until	  1991,	  where	  Heitman	  et	  al.	  described	  rapamycin’s	  effects	  in	  arresting	  cell	  cycle	  progression	   in	   the	   G1	   phase	   in	   yeast	   cells	   (Heitman,	   2015).	   	   Building	   upon	   the	   genes	  identified	   via	   generation	   of	   rapamycin-­‐resistant	   yeast	  mutants	   by	  Heitman	   et	   al.,	   (TOR1,	  TOR2,	  and	  FKBP12),	  Sabatini	  et	  al.	  discovered	  the	  mammalian	  orthologs	  of	  the	  TOR1	  and	  TOR2	  complexes	  (Sabatini	  et	  al.,	  1994).	  Similarly	  to	  yeast	  TOR,	  mTOR	  exists	  as	  two	  distinct	  complexes	   in	   mammalian	   cells,	   mTORC1	   and	   mTORC2.	   Rapamycin	   sensitive	   mTOR,	   or	  mTORC1,	  represents	  a	  central	  component	   to	   the	   translational	  efficiency	  and	  translational	  capacity	  of	  a	  cell	  (McGlory	  et	  al.,	  2016).	  	  mTORC1	   is	   a	   multi-­‐subunit	   protein	   complex	   consisting	   of	   five	   subunits:	   mTOR,	  regulatory	   associated	   protein	   of	  mTOR	   (RAPTOR),	   proline-­‐rich	   AKT	   substrate	   of	   40	   kDa	  (PRAS40),	  mammalian	   lethal	  with	   SEC13	   protein	   8	   (mLST8),	   and	   DEP	   domain-­‐containing	  mTOR-­‐interacting	  protein	  (DEPTOR).	  RAPTOR	  facilitates	  rapamycin’s	  inhibition	  of	  mTORC1	  activity,	  through	  its	  ability	  to	  bind	  the	  FK506-­‐binding	  protein	  of	  12	  kDa	  (FKBP12).	  RAPTOR	  is	  also	   thought	   to	   regulate	   the	  complexes	  assembly	  upon	  activation	   (Laplante	  &	  Sabatini,	  2009).	   While	   MLST8’s	   function	   remains	   undefined,	   PRAS40	   and	   DEPTOR	   function	   as	  negative	  regulators	  of	  the	  complex	  (Peterson	  et	  al.,	  2009).	  	  mTORC1	   has	   been	   described	   as	   a	   signal	   integration	   centre	   that	   regulates	   cellular	  growth	   and	   proliferation.	   Upon	   the	   presence	   of	   adequate	   growth	   factors,	   amino	   acids,	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oxygen	   and	   cellular	   energy	   status,	  mTORC1	   is	   activated	   (Laplante,	   2009).	   p70	   ribosomal	  protein	  S6	  kinase	  (S6K1)	  and	  eukaryotic	  translation	  initiation	  factor	  4E	  binding	  protein	  1	  (4E-­‐BP1)	  are	  the	  best-­‐characterized	  downstream	  substrates	  of	  mTORC1	  (depicted	  in	  fig	  1-­‐
1).	   Activation	   of	   these	   two	   substrates	   following	   the	   upstream	   activation	   of	   mTORC1,	  triggers	   a	   cascade	   of	   events	   culminating	   in	   an	   increased	   translational	   efficiency	   and	  capacity	   of	   the	   cell.	   S6K1	   and	   4E-­‐BP1	   phosphorylation	   stimulates	   ribosomal	   biogenesis	  (the	  protein	  making	  machinery	  of	  the	  cell),	  in	  addition	  to	  promoting	  ribosomal	  binding	  to	  mRNA	   (enhances	   translational	   efficiency)	   (McGlory,	   2016).	  
	  
Figure	  1-­‐1.	  mTORC1	  signalling	  pathway	  schematic,	  displaying	  both	  the	  inactive	  (left	  panel)	  and	   active	   (right	   panel)	   complex	   organizations.	   The	   central	   figure	   depicts	   the	   simplified	  signalling	   pathway	   containing	   the	   most	   well	   defined	   mTORC1	   substrates.	   Mechanistic	  target	   of	   rapamycin	   complex	   1	   (mTORC1),	   regulatory-­‐associated	   protein	   of	   mTOR	  (RAPTOR),	  mammalian	  lethal	  with	  SEC13	  protein	  8	  (mLST8),	  proline-­‐rich	  AKT1	  substrate	  1	  (PRAS40),	  	  domain-­‐containing	  mTOR-­‐interacting	  protein	  (DEPTOR).	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   mTORC1	  activity	   is	  determined	  by	   four	   factors	  as	  previously	  mentioned,	   the	  most	  actively	  studied	  of	  these	  factors	  include	  amino	  acids	  and	  growth	  factors.	  The	  binding	  of	  a	  growth	   factor	   such	   as	   insulin-­‐like	   growth	   factor-­‐1	   (IGF-­‐1)	   to	   its	   membrane	   localized	  receptors	  triggers	  the	  downstream	  activation	  of	  protein	  kinase	  B/AKT,	  ultimately	   leading	  to	   the	   phosphorylation	   of	   tuberous	   sclerosis	   complex	   (TSC).	   TSC	   is	   a	   heterodimeric	  complex	   that	  directly	   inhibits	  Ras	  homolog	  enriched	   in	  brain	   (Rheb)	  via	   its	  GAP	  activity,	  keeping	  Rheb	  in	  an	  inactive	  GDP-­‐loaded	  state	  (Laplante,	  2009).	  The	  phosphorylation	  of	  TSC	  complex	   by	   AKT	   results	   in	   its	   dissociation,	   allowing	   GTP	   loading	   of	   Rheb	   and	   the	   direct	  activation	  of	  mTORC1	  through	  a	  poorly	  defined	  mechanism	  (Laplante,	  2009).	  The	  amino	  acid	   sensing	  mechanisms	  of	   the	   cell	   are	  extremely	   complex	  with	  much	  research	   indicating	   that	   the	   main	   site	   of	   AA-­‐induced	   mTORC1	   activation	   lies	   at	   the	  lysosomal	   membrane	   (depicted	   in	   the	   right	   side	   panel	   of	   Fig	   1-­‐1).	   Emerging	   evidence	  suggests	  that	  AA-­‐induced	  mTORC1	  activation	  can	  occur	  at	  other	  cellular	  organelles	  such	  as	  the	  Golgi	   apparatus,	   although	  more	   research	  needs	   to	  be	   conducted	   (Zheng	  et	   al.,	   2016).	  Currently,	   three	   defined	   signalling	   molecules	   exist	   that	   link	   AA	   sensing	   to	   mTORC1	  activation.	  Firstly,	  the	  heterodimeric	  Rag	  GTPases	  (Rags),	  (RagA/B	  –	  RagC/D)	  represent	  the	  machinery	   necessary	   for	   mTORC1	   translocation	   to	   the	   lysosomal	   membrane	   to	   become	  fully	  activated	  (Zheng,	  2016).	  There	  are	  four	  Rag	  GTPases	  and	  current	  research	  indicates	  a	  redundancy	  between	  RagA/B,	  and	  for	  RagC/D.	  Upon	  AA	  stimulation	  Rag	  A/B	  becomes	  GTP	  loaded,	  and	  RagC/D	  GDP	  loaded,	  representing	  their	  active	  forms.	  Upon	  arrival	  of	  the	  Rags	  and	   mTORC1	   to	   the	   lysosomal	   membrane,	   the	   second	   signalling	   molecule,	   Ragulator,	  tethers	   the	   Rags	   to	   the	   membrane	   when	   in	   the	   presence	   of	   amino	   acids.	   Ragulator	   is	  thought	  to	  operate	  as	  a	  guanine	  nucleotide	  exchange	  factor	  (GEF)	  towards	  RagA/B,	  which	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leads	   to	   their	   GTP-­‐loaded	   active	   state,	   consequently	   upregulating	  mTORC1	   activity	   (Bar-­‐Peled	  et	  al.,	  2012;	  Zheng,	  2016).	  The	  third	  component,	  vacuolar	  H+	  ATPase	  (v-­‐ATPase)	   is	  not	  well	  characterized	  in	   its	   functioning.	  v-­‐ATPase	  is	   located	  in	  the	   lysosomal	  membrane,	  and	   is	   thought	   to	  sense	  amino	  acids	   in	   the	   lysosomal	   lumen	  by	  an	   inside-­‐out	  mechanism	  (Zoncu	  et	  al.,	  2011).	  Sabatini	  and	  colleagues	  believe	  it	  functions	  as	  a	  mediator	  of	  nucleotide	  loading	  of	  the	  Rags,	  and	  their	  subsequent	  activation,	  indicating	  it	  is	  a	  necessary	  component	  in	  the	  amino	  acid	  sensing	  activation	  of	  mTOR1	  (Zoncu,	  2011).	  The	  regulation	  of	  muscle	  mass	  is	  regulated	  by	  both	  nutrition	  and	  the	  tension	  loading	  of	   skeletal	   muscle	   (Dickinson	   et	   al.,	   2011).	   Since	   mTORC1	   is	   well	   defined	   as	   a	   nutrient	  sensor	   it	   is	   logical	  to	  assume	  that	   it	  mediates	  the	  responses	  of	  anabolic	  signalling.	  This	   is	  because	   AAs	   act	   not	   only	   as	   substrates	   for	   endogenous	   proteins,	   but	   can	   also	   activate	  mTORC1.	  	  It	  is	  well	  accepted	  that	  resistance	  exercise	  (RE)	  increases	  MPS,	  a	  key	  component	  of	  the	   hypertrophic	   response	   in	   skeletal	   muscle	   (Adegoke,	   2012).	   Many	   studies	   in	   rodents	  have	   shown	   impairments	   of	   adaptive	   hypertrophy	   following	   the	   administration	   of	  rapamycin,	   suggesting	  mTORC1	   is	   a	   critical	   regulator	   of	  muscle	   fibre	   size	   (Bodine	   et	   al.,	  2001).	   	   Additional	   studies	   have	   shown	   acute	   bouts	   of	   RE	   stimulate	   muscle	   protein	  synthesis	   (MPS),	  hypertrophy,	  and	  ribosomal	  biogenesis	   (Figueiredo	  et	  al.,	  2015;	  West	  et	  al.,	  2016;	  Wilkinson,	  2008).	  These	  effects	  are	  all	  attenuated	  by	  rapamycin	  administration	  confirming	  a	  definitive	   role	   for	  mTORC1	   in	   these	  RE-­‐induced	  responses	   (Marcotte,	  2015;	  Ogasawara	  et	  al.,	  2016).	  	  Prolonged	  stimulation	  of	  mTORC1	  signalling	  caused	  by	  concurrent	  training	  (endurance	  exercise	  (EE)	  and	  RE	  together)	  in	  the	  past	  has	  been	  shown	  to	  diminish	  some	  of	  the	  positive	  effects	  of	  RE	  (Hickson,	  1980;	  Leveritt	  et	  al.,	  1999).	  Studies	  have	  shown	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that	   chronic	   RE	   results	   in	   a	   reduction	   in	   the	   phosphorylation	   of	   S6K1,	   although	   it	   is	  reversible	  given	  a	  recovery	  period	  (Ogasawara	  et	  al.,	  2013).	  A	  recent	  study	  has	  found	  that	  EE	   training	   does	   not	   attenuate	   increases	   in	   muscle	   strength	   and	   fibre	   hypertrophy	  resultant	   from	  successive	  RE	   training	  bouts	   (Kazior	  et	  al.,	  2016).	   	  Although	  some	  studies	  have	   displayed	   contrary	   data	   supporting	  mTORC1	   signalling	   in	   RE,	   the	   bulk	   of	   available	  data	  suggests	  mTORC1	  is	  essential	  for	  increasing	  MPS,	  muscle	  hypertrophy	  and	  ribosomal	  biogenesis.	  Future	  research	  into	  the	  mechanisms	  regulating	  mTORC1’s	  roles	  in	  RE	  and	  EE	  training	   needs	   to	   be	   completed	   to	   clarify	   the	   extent	   to	   which	   mTORC1	   regulates	   these	  processes.	  
Regulation of Myogenic Differentiation/Muscle Regeneration 
 Myogenesis	  is	  the	  complex	  process	  of	  muscle	  formation.	  It	  is	  through	  this	  process	  in	  which	  muscle	  is	  developed	  during	  embryonic	  development,	  in	  mature	  skeletal	  muscle	  this	  process	  is	  referred	  to	  as	  either	  secondary	  myogenesis	  or	  muscle	  regeneration.	  Myogenesis	  begins	   during	   embryogenesis.	   Originating	   from	   the	   paraxial	   mesoderm,	   primary	   muscle	  cells	  will	  set	  the	  groundwork	  for	  later,	  or	  secondary-­‐myogenesis	  to	  build	  upon.	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Figure	  1-­‐2.	  Schematic	  of	  myogenesis	  displaying	  the	  temporal	  rise	  and	  fall	  of	  myogenic	  regulatory	  factors	  during	  differentiation	  from	  satellite	  cells,	  to	  mature	  skeletal	  muscle.	  Paired	  box	  7	  (Pax7),	  Myogenic	  differentiation	  1,	  or	  myogenic	  factor	  3	  (MyoD),	  Myogenic	  factor	  5	  (Myf5),	  Myogenic	  regulatory	  factor	  4,	  or	  herculin	  (Mrf4)	  Image	  modified	  from	  (Hettmer	  &	  Wagers,	  2010)	  	  	  
Myogenic	  regulatory	  factors	  	  	   The	  myogenic	   regulatory	   factors	   (MRFs)	   belong	   to	   the	   superfamily	   of	   basic-­‐loop-­‐helix	   (bHLH)	   transcription	   factors.	   The	  HLH	  domain	   triggers	   a	   dimerization	  of	   the	  MRFs	  with	   E-­‐proteins.	   Upon	   heterodimerization	   the	   affinity	   for	   the	   E-­‐box	   promoter	   via	   a	  consensus	   DNA	   sequence	   (CANNTG)	   on	   many	   muscle	   specific	   genes	   increases,	   thereby	  enhancing	  the	  transcription	  of	  those	  muscle-­‐specific	  genes	  (Lassar	  et	  al.,	  1989;	  Murre	  et	  al.,	  1989).	  There	  are	   four	  main	  MRFs	   that	  will	  be	   the	   focus	  of	  discussion	   in	   this	  section.	  The	  four	   MRFs	   include:	   	   Myogenic	   factor	   5	   (Myf5),	   Myogenic	   differentiation	   1	   or	   myogenic	  factor	   3	   (MyoD),	  myogenin,	   and	  Myogenic	   regulatory	   factor	   4	   or	   herculin	   (Mrf4).	   These	  MRFs	   appear	   throughout	   myogenesis	   in	   a	   temporal	   manner	   committing	   myogenic	  progenitors	   towards	   terminal	   differentiation	   as	   depicted	   in	   Fig	   1-­‐2.	   Gene	   inactivation	  studies	   provided	   much	   of	   the	   groundwork	   of	   understanding	   for	   this	   relatively	   new	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research	  field.	  Studies	  investigating	  MyoD	  and	  Myf5	  gene	  inactivation	  revealed	  redundant	  functioning	  between	  these	  two	  early	  regulators	  of	  myogenesis	  (Braun	  et	  al.,	  1992;	  Rudnicki	  et	  al.,	  1992).	  Verifying	  this	  redundancy	  became	  clear	  when	  double	  homozygous	  knockouts	  in	   mice	   for	   MyoD	   and	   Myf5	   were	   completed,	   showing	   no	   signs	   of	   muscle	   formation	  (Rudnicki	   et	   al.,	   1993).	   However,	   individual	   knockouts	   for	   either	   yielded	   limited	  deficiencies	   in	  muscle	   formation	   (Braun,	   1992;	  Rudnicki,	   1992).	   Clearly,	  MyoD	  and	  Myf5	  are	  required	  for	  muscle	  cell	  differentiation,	  particularly	  in	  the	  early	  stages.	  	  These	   early	   studies	   have	   determined	   that	   MyoD	   and	   Myf5	   are	   essential	   to	   the	  determination	   towards	   myogenic	   lineage	   and	   that	   their	   expression	   precedes	   that	   of	  myogenin	   and	   MRF4.	   Myogenin	   is	   essential	   to	   muscle	   differentiation.	   Its	   expression	  commences	   at	   the	   onset	   of	   differentiation	   in	  myoblasts,	   immediately	   following	  myoblast	  proliferation.	   Mice	   depleted	   of	   myogenin	   die	   at	   birth,	   due	   to	   severe	   skeletal	   muscle	  deficiencies.	  Although	  the	  embryonic	   lethality	  of	   the	  myogenin-­‐null	  mice	  results	   from	  the	  failure	   of	  muscle	   fibre	   formation,	   myoblast	   number	   in	   this	  mice	   remains	   normal,	   which	  suggests	  that	  myogenin	  may	  regulate	  myoblast	  fusion	  (Nabeshima	  et	  al.,	  1993;	  Venuti	  et	  al.,	  1995).	   Myogenin	   has	   been	   shown	   to	   regulate	   proteins	   involved	   in	   the	   cell	   cycle	   and,	  through	  a	  p38	  MAPK-­‐dependent	  manner,	  it	  promotes	  cell	  cycle	  arrest,	  an	  essential	  step	  for	  differentiation	  to	  occur.	  One	  mechanism	  through	  which	  myogenin	  suppresses	  the	  cell	  cycle	  is	  by	  its	  direct	  regulation	  of	  miR-­‐20a,	  a	  micro	  RNA	  that	  is	  known	  to	  deplete	  levels	  of	  E2F1	  and	  E2F3	  transcription	  factors	  (Liu	  et	  al.,	  2012).	  E2F	  transcriptional	  activity	  is	  essential	  for	  cell	   cycle	   progression,	   thereby,	   suggesting	   myogenin	   regulates	   the	   cell	   cycle	   by	   down	  regulating	  E2F	   transcriptional	   activity.	  Myogenin	   is	   required	   for	   terminal	   differentiation.	  Inactivation	  of	  myogenin	  causes	  cleavage	  of	   fully	  matured	  myotubes	   into	  mononucleated	  
	  13	  
cells	   (Mastroyiannopoulos	   et	   al.,	   2012).	   These	   mononucleated	   cells	   are	   then	   able	   to	   re-­‐enter	   the	   cell	   cycle,	   although	   this	   mechanism	   is	   not	   thought	   to	   be	   a	   purely	   myogenin	  dependent	  process.	  Lastly,	   the	   fourth	  MRF,	  MRF4,	  has	  much	   less	  known	  about	   its	   role	   in	  muscle	   differentiation.	   MRF4	   is	   expressed	   in	   a	   biphasic	   manner,	   where	   it	   is	   initially	  expressed	  during	  embryonic	  myogenesis,	  and	  once	  again	  during	  muscle	  regulation.	  MRF4	  is	  expressed	   in	  mature	  skeletal	  muscle	   in	  response	   to	  muscle	  damage,	  although	   its	   levels	  are	  not	  detectable	  during	  satellite	  cell	  proliferation	  or	  early	  differentiation	  (Hinterberger	  et	  al.,	  1991;	  Pavlath	  et	  al.,	  2003;	  Z.	  Zhou	  &	  Bornemann,	  2001).	  MRF4	  appears	  to	  share	  some	  redundancy	   with	   myogenin,	   when	   mice	   were	   depleted	   of	   MRF4	   the	   authors	   found	  myogenin	   mRNA	   increased	   four-­‐fold,	   which	   they	   concluded	   as	   the	   compensatory	   factor	  leading	  to	  a	  relatively	  normally	  muscle	  phenotype	  (Zhang	  et	  al.,	  1995)	  Taken	   together,	   these	   gene	   inactivation	   studies	   indicate	   that	  MyoD	   and	  Myf5	   are	  important	  for	  determination	  to	  myogenic	  lineage,	  while	  myogenin	  and	  MRF4	  are	  necessary	  for	  terminal	  differentiation	  of	  adult	  muscle	  fibres.	  
Satellite	  cell’s	  role	  in	  myogenesis	  
	   Myogenesis	   in	   a	   post-­‐natal	   context	   is	   largely	   dependent	   upon	   a	   sub-­‐population	  of	  quiescent	   cells	   that	   contain	  myogenic	   potential	   termed	   satellite	   cells.	   Post-­‐natal	   satellite	  cell	   populations	   are	  maintained	  by	   the	   expression	  of	   a	   transcription	   factor,	   paired	  box	  7	  (Pax7).	  These	  cells	  remain	  in	  a	  dormant	  phase	  until	  signaled	  by	  stress	  or	  trauma	  (Seale	  et	  al.,	  2000;	  von	  Maltzahn	  et	  al.,	  2013).	  Pax7	  null	  mice	  have	  the	  same	  number	  of	  satellite	  cells	  at	   birth	   as	   WT	   controls,	   only	   to	   be	   lost	   in	   a	   temporal	   manner	   (Philippos	   et	   al.,	   2012).	  Therefore,	   Pax7	   expressing	   satellite	   cells	   are	   essential	   to	   maintaining	   satellite	   cell	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populations.	  It	  has	  been	  shown	  that	  Pax7	  levels	  decrease	  upon	  myoblasts	  expansion,	  with	  a	  corresponding	  rise	  in	  MyoD	  levels,	  followed	  by	  an	  increase	  in	  myogenin	  expression	  (Halevy	  et	  al.,	  2004).	  During	  this	  process	  MyoD	  regulates	  the	  differentiation	  potential	  of	  myoblasts,	  while	  Myf5	  controls	   their	  proliferation	  potential	   (Gayraud-­‐Morel	  et	  al.,	  2007).	  The	  rise	   in	  the	  number	  of	  cells	  co-­‐expressing	  MyoD	  and	  myogenin	  determines	  the	  intermediate	  stage	  of	   adult	   myogenesis,	   where	   the	   expanded	  myoblast	   population	   begins	   to	   fuse	   and	   form	  multi-­‐nucleated	   myotubes	   (Myer	   et	   al.,	   2001).	   Therefore,	   tightly	   regulated,	   temporal	  expression	  of	   these	  myogenic	  regulatory	   factors	  orchestrates	   the	  proliferation	  of	  satellite	  cells	  and	  ultimately	  their	  differentiation	  and	  fusion	  onto	  existing	  muscle	  fibres.	  
Cell	  cycle	  exit	  	   Following	   satellite	   cell	   expansion,	   cell	   cycle	   arrest	   is	   essential	   to	   committing	  myoblasts	  towards	  the	  differentiation	  pathway	  and	  successful	  muscle	  regeneration.	  There	  are	  two	  primary	  cell	  cycle	  inhibitors	  intricately	  involved	  in	  myogenesis,	  they	  are	  p21	  and	  retinoblastoma	  (Rb).	  p21	   is	  essential	   to	   terminal	  differentiation	  and	  permanent	  cell	  cycle	  exit	   following	   satellite	   cell	   expansion.	   The	   rise	   in	   p21	   transcription	   can	   be	   partially	  attributed	   to	   the	   increase	   MyoD	   expression,	   through	   a	   p53-­‐independent	   mechanism	  (canonical	  regulation	  of	  p21	   is	  controlled	  by	  p53)	  (Halevy	  et	  al.,	  1995;	  Walsh	  &	  Perlman,	  1997).	   Once	   p21	   expression	   has	   been	   stimulated,	   subsequently	   facilitating	   cell	   cycle	  withdrawal,	   its	   levels	   remain	   constitutively	   elevated,	   even	   upon	   re-­‐stimulation	   with	  mitogens	   (Walsh,	   1997).	   In	   a	   low-­‐serum	   (<2%	   fetal	   bovine	   serum	   or	   horse	   serum)	  environment,	   myoblasts	   begin	   to	   express	   myogenin,	   followed	   by	   the	   increase	   in	   the	  transcription	  of	  p21,	  demonstrating	  a	  commitment	  towards	  differentiation	  (Walsh,	  1997).	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Simultaneously,	  the	  tumour	  suppressor	  protein	  Rb,	  is	  essential	  for	  terminal	  differentiation	  and	   suppressing	   apoptotic	   signalling	   in	   myotubes.	   The	   cyclin-­‐dependent	   kinases	  phosphorylate	  Rb,	  inactivating	  it,	  allowing	  E2F	  transcription	  factors	  to	  be	  freely	  expressed.	  The	  E2F	  transcription	  factors	  then	  drive	  the	  cell	  cycle	  through	  the	  G1	  phase,	  allowing	  for	  progression	   into	   S-­‐phase	   (Bartek	   et	   al.,	   1996).	   In	   the	   event	   where	   Rb	   is	   in	   a	  hypophosphorylated	  state	  (active),	  S-­‐phase	  entry	  is	  blocked,	  thereby	  promoting	  cell	  cycle	  arrest,	   a	   step	   required	   for	   satellite	   cells	   to	   differentiate,	   fuse,	   and	   form	  multi-­‐nucleated	  myotubes.	  
Nutrition’s effects on Myogenic Differentiation/Muscle Regeneration  	  Muscle	   regeneration	   is	   an	   energy-­‐dependent	   process,	   involving	   the	   accretion	   of	  myofibrillar	   proteins.	   In	   this	   section	   the	   nutritional	   effects	   of	   dietary	   carbohydrates	   and	  protein	  on	  muscle	  regeneration	  will	  be	  assessed.	  	  	  Because	  muscle	  regeneration	   is	  a	  costly	  metabolic	  process,	  adequate	  energy	  must	  be	  provided	   to	   the	   system.	  Carbohydrates	   are	   one	  of	   the	  body’s	   primary	   sources	   of	   fuel,	  thus,	   direct	   provision	   of	   carbohydrates	  may	   effect	  muscle	   regeneration.	   One	   study	   using	  C2C12	  myoblasts	   saw	   a	   significant	   reduction	   in	   the	  myoblast	   fusion	   index	   and	  myotube	  formation	   in	   a	   5mM	   glucose	   supplemented	   medium,	   compared	   to	   a	   25mM	   medium	  concentration	  (Fulco	  et	  al.,	  2008).	  It	  is	  interesting	  to	  note	  that	  upon	  retroviral	  induction	  of	  a	   dominant	   negative	   AMPK	   that	   differentiation	  was	   rescued	   in	   its	   entirety,	   suggesting	   a	  definitive	  role	  for	  AMPK	  signalling	  in	  cell	  energy	  status	  regulation	  and	  subsequent	  control	  over	   a	   cells	   capacity	   to	   differentiate	   (Fulco,	   2008).	   	   Currently	   only	   a	   few	   comparative	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studies	   exists	   in	   vivo	   looking	   at	   the	   effects	   of	   carbohydrates	   on	   skeletal	   muscle	  development.	   One	   such	   study	   showed	   that	   in	   fish	   a	   diet	   comprised	   of	   15-­‐25%	  carbohydrates	   optimally	   stimulated	   myogenic	   regulatory	   factors	   such	   as	   MyoD,	   Myf5,	  myogenin,	   and	   the	   Pax7:MyoD	   ratio	   (an	   indicator	   of	   satellite	   cell	   myogenesis	   in	  vertebrates)	  (Chapalamadugu	  et	  al.,	  2009).	  Another	  study	  in	  fish	  sought	  out	  to	  determine	  the	   effects	   of	   carbohydrate	   restriction	   on	   protein	   turnover,	   a	   proxy	   measure	   of	   muscle	  regeneration.	   There	   were	   two	   experimental	   conditions,	   one	   being	   the	   control	   diet,	   the	  second	  being	  a	  diet	   completely	  void	  of	   carbohydrates.	  Although	   this	  experimental	  design	  seemed	   unnecessarily	   extreme,	   the	   data	   regarding	   protein	   turnover	   rates	   were	  informative.	  The	  fish	  in	  the	  carbohydrate	  depleted	  diet	  group	  saw	  no	  differences	  in	  protein	  synthesis	  rates,	  yet	  protein	  turnover	  was	  drastically	  upregulated.	  This	  effect	  was	  due	  to	  the	  near	   8-­‐fold	   increase	   in	   muscle	   protein	   degradation	   rates,	   proving	   that	   carbohydrate	  provision	   limits	   the	   breakdown	   of	   muscle	   proteins	   for	   the	   purpose	   of	   meeting	   energy	  requirements,	   via	   amino	   acid	   oxidation,	  while	   not	   limiting	   the	   rates	   of	   protein	   synthesis	  (Peragon	   et	   al.,	   1999).	   Taken	   together,	   carbohydrates	   appear	   to	   be	   required	   to	   sustain	  energy	   levels	   so	   that	  muscle	   regeneration	   can	   occur,	   principally	   by	   limiting	   the	   rates	   of	  protein	   degradation.	   However,	   these	   effects	   are	   likely	   confined	   to	   energy	   provision,	  thereby,	  lipids	  may	  regulate	  these	  effects	  to	  a	  similar	  degree.	  Once	  we	  can	  establish	  that	  the	  energy	  demands	  of	  a	  cell	  are	  met,	  the	  next	  question	  seeks	   to	   answer	   how	   protein	   metabolism	   effects	   muscle	   regeneration.	   Dietary	   protein	  ingestion	  provides	  the	  amino	  acids	  necessary	  for	  protein	  synthesis,	  a	  process	  required	  for	  muscle	   regeneration.	   Not	   only	   do	   these	   amino	   acids	   act	   as	   substrate	   for	   translation,	   but	  also	   are	   essential	   to	   the	   signalling	   cascades	   that	   lead	   to	   protein	   synthesis,	   or	   in	   their	  
	  17	  
absence,	   protein	   breakdown.	   The	   first	   challenge	  was	   identifying	   the	   amino	   acid	   sensing	  mechanisms	   of	   a	   cell.	   As	   alluded	   to	   in	   the	  mTOR	   section	   of	   this	   review,	   the	   answer	   lied	  within	  mTORC1’s	   ability	   to	   sense	   intracellular	   amino	   acids	   concentrations.	  Many	   studies	  have	   investigated	   the	   potential	   of	   individual	   amino	   acids	   to	   stimulate	   muscle	   protein	  synthesis	   and	   the	   subsequent	   muscle	   hypertrophy.	   However,	   not	   many	   studies	   have	  investigated	   how	   single	   amino	   acids	   regulate	   myogenic	   differentiation/muscle	  regeneration.	  	  One	  study	  investigated	  the	  effect	  leucine	  plays	  in	  proliferation	  and	  differentiation	  of	  primary	  satellite	  cells	  excised	  from	  preterm-­‐rats	  (Dai	  et	  al.,	  2015).	  Dai	  et	  al.,	  (2015)	  found	  that	  leucine	  promoted	  both	  the	  proliferation	  and	  differentiation	  of	  these	  satellite	  cells,	  and	  that	  MyoD	  and	  myogenin	  protein	  expression	  was	  positively	  correlated	  with	  leucine	  dosage.	  When	  these	  cells	  were	  co-­‐incubated	  with	  leucine	  (2mM	  –	  highest	  experimental	  dose)	  and	  rapamycin	  (50nM)	  the	  expression	  of	  MyoD	  protein	  was	  more	  than	  halved,	  while	  myogenin	  expression	  remained	  elevated	  (Dai,	  2015).	  One	  issue	  with	  the	  Dai	  et	  al.,	  (2015)	  study	  was	  that	  the	  leucine	  +	  rapamycin	  experiments	  only	  lasted	  for	  a	  mere	  8-­‐hours	  of	  differentiation.	  This	   short	   time	   course	   did	   not	   allow,	   or	   account	   for,	   the	   complex	   milieu	   of	   myogenic	  regulators	   that	   changes	   over	   the	   full	   72-­‐hours	   of	   differentiation,	   as	   they	   themselves	  depicted	   in	   their	   control	   studies.	   Therefore,	   the	   claim	   that	   leucine’s	   action	   on	   MyoD	   is	  sustained	  throughout	  the	  whole	  process	  of	  differentiation	  may	  be	  erroneous.	  	  Furthermore,	   another	   group	   has	   shown	   using	   C2C12	   myoblasts	   and	   primary	  satellite	  cells	  from	  mice	  that	  cells	  deprived	  of	  leucine	  fail	  to	  differentiate.	  Additionally,	  the	  expression	   of	   MyoD	   is	   also	   suppressed	   under	   such	   conditions,	   while	   Myf5	   mRNA	   is	  elevated	   (Averous	   et	   al.,	   2012).	   Unlike	   the	   study	   by	   Dai	   et	   al.,	   (2015)	   the	   authors	   also	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showed	  that	   leucine’s	  effect	  on	  MyoD	  expression	  was	  apparent	   from	  day	  0	  all	   the	  way	  to	  day	  5	  of	  differentiation.	  In	  this	  experiment	  leucine	  deprivation	  was	  able	  to	  suppress	  MyoD	  expression	  significantly	  from	  8-­‐hours	  to	  the	  end	  of	  their	  differentiation	  protocol	  on	  day	  5.	  Most	  interestingly,	  the	  authors	  suggest	  leucine’s	  main	  role	  in	  early	  differentiation	  may	  not	  necessarily	  be	  promoting	  MyoD	  expression,	  but	  this	  lack	  of	  MyoD	  may	  be	  explained	  by	  the	  mere	  absence	  of	  differentiation.	  The	  authors	  also	  note	  that	  Myf5’s	  role	  in	  differentiation	  is	  not	   well	   defined,	   although	   the	   rise	   in	   Myf5	   mRNA	   may	   support	   the	   notion	   that	   Myf5	  regulates	  a	  cells	  ability	   to	  differentiate	   in	   the	  absence	  of	  MyoD,	  or	  causes	  cells	   to	  enter	  a	  quiescent	   state	   (Young	   &	  Wagers,	   2010),	   which	   is	   also	   seen	   in	   a	   portion	   of	   cells	   when	  leucine	  is	  deprived.	  	  Pereira	  et	  al	  (2014)	  devised	  a	  model	  to	  test	  leucine’s	  effect	  on	  muscle	  regeneration	  in	  mice.	  The	  authors	  subjected	  2-­‐month	  old	  mice	  to	  cryolesion	  of	  the	  soleus	  muscle	  while	  being	  supplemented	  with	  leucine,	  beginning	  3-­‐days	  prior	  to	  muscle	  injury,	  outwards	  to	  day	  10	   post-­‐injury.	   It	   was	   found	   that	   leucine	   supplementation	   increased	   myofiber	   size,	   in	  addition	   to	   lowering	   collagen	   type	   III	   accumulation	   on	   day	   10	   post-­‐injury	   (indicative	   of	  poorer	   injury	   recovery).	   Leucine	   supplementation	   was	   also	   shown	   to	   decrease	   the	  activation	  of	  autophagy	  mediators,	  such	  as	  FOXO3a,	  as	  well	  as	  reducing	  the	  accumulation	  of	  ubiquitinated	   proteins	   (Pereira	   et	   al.,	   2014).	  Not	   only	  were	   these	   leucine-­‐derived	   effects	  seen	  at	  a	  molecular	  level,	  they	  were	  also	  witnessed	  at	  the	  level	  of	  muscle	  function.	  Leucine	  supplemented	   mice	   experienced	   a	   reduction	   in	   strength	   losses	   following	   muscle-­‐injury,	  while	   fatigue	   resistance	  of	   the	   soleus	  was	   also	   elevated	  when	   compared	   to	   controls.	  The	  authors	  concluded	  that	  the	  positive	  effects	  of	   leucine	  on	  muscle	  regeneration	  in	  this	  case,	  was	   not	   being	   facilitated	   through	   the	   PI3K	   –	   AKT	   –	   mTOR	   axis,	   but	   its	   role	   was	   more	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pertinent	   to	   the	   inhibition	   of	   proteolysis	   via	   reductions	   in	   protein	   ubiquitination	   and	  FOXO3a	   activity.	   Although	   this	   may	   come	   as	   a	   surprise,	   the	   authors	   make	   note	   that	  prolonged	   leucine	   supplementation	   loses	   its	   ability	   to	   stimulate	   both	   the	   PI3K	   –	   AKT	   –	  mTOR	  pathway	  and	  protein	  synthesis	  (Macotela	  et	  al.,	  2011;	  Suryawan	  et	  al.,	  2011).	  Taken	  together,	   the	   lack	  of	  mTOR	  activity	  and	  the	  downregulation	  of	  FOXO3a	  and	  ubiquitinated	  proteins	   in	   the	   face	   of	   leucine	   supplementation,	   suggests	   leucine	   positively	   regulates	  muscle	  regeneration	  via	  its	  ability	  to	  suppress	  proteolysis.	  	  
Factors and signalling pathways regulating myogenesis 
mTor	  and	  myogenesis	  	  	   The	   first	   instances	   of	   mTOR’s	   regulatory	   control	   of	   myogenesis	   became	   evident	  when	  many	   studies	   reported	   impaired	   differentiation	   in	   various	  muscle	   cell	   lines	   in	   the	  presence	   of	   rapamycin	   (Conejo	   et	   al.,	   2001;	   Coolican	   et	   al.,	   1997;	   Erbay	   &	   Chen,	   2001).	  Rapamycin,	   as	  previously	  discussed	   is	   an	   inhibitor	  of	  mTORC1.	   Interestingly,	   rapamycin-­‐resistant	   mTOR	   mutants	   rescued	   C2C12	   differentiation	   in	   the	   presence	   of	   rapamycin	  (Erbay,	   2001).	   This	   suggests	   that	  mTOR-­‐mediated	   differentiation	   functions	   through	  both	  rapamycin-­‐dependent	   and	   independent	   mechanisms.	   Cells	   expressing	   kinase-­‐inactive	  mTOR	  mutants	  were	  also	  able	  to	  differentiate	  in	  the	  presence	  of	  rapamycin,	  implying	  that	  the	   rapamycin-­‐independent	   function	   of	   mTOR	   might	   also	   be	   independent	   of	   its	   kinase	  activity	  (Ge	  et	  al.,	  2009).	  Much	   of	   the	   research	   involving	   mTOR’s	   role	   in	   differentiation	   is	   studied	   by	  examining	   the	   role	   of	   mTORC1	   subunit,	   RAPTOR.	   Experiments	   knocking	   out	   or	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overexpressing	  RAPTOR	  had	  positive	  and	  negative	  effects	  on	  differentiation,	   respectively	  (Ge,	   Yoon,	   et	   al.,	   2011).	   	   It	   is	   postulated	   that	   RAPTOR’s	   negative	   influence	   over	  differentiation	  may	  be	  acting	  through	  the	  uncoupling	  of	  the	  PI3K/Akt	  signalling	  pathway,	  via	  serine	  phosphorylation	  of	  insulin-­‐like	  substrate-­‐1	  (IRS1)	  (Ge,	  2011).	  A	  major	   discovery	   of	  mTOR’s	   role	   in	   differentiation	   is	   its	   regulatory	   control	   over	  insulin-­‐like	   growth	   factor-­‐2	   (IGF-­‐2).	   A	   simple,	   yet	   elegant	   experiment	  was	   conducted	   by	  Erbay	  et	  al.	  (2003)	  where	  they	  took	  two	  groups	  of	  C2C12	  myoblasts,	  one	  being	  the	  control	  or	   “donor”	   group,	   the	   other	   to	   be	   incubated	   with	   rapamycin,	   the	   experimental	   or	  “recipient”	   group.	   The	   donor	   group	   was	   induced	   to	   differentiate	   24	   hours	   prior	   to	   the	  recipient	  group.	  At	  the	  24-­‐hour	  mark	  the	  now	  “conditioned-­‐medium”	  from	  the	  donor	  group	  was	   transferred	   to	   the	   recipient	   group	   and	   supplemented	   with	   100nM	   concentration	   of	  rapamycin.	   	   This	   medium	   exchange	   occurred	   two	   more	   times,	   until	   the	   cells	   had	  differentiated	  for	  72	  hours.	  Differentiation	  in	  the	  recipient	  group	  was	  completely	  rescued	  by	  the	  conditioned	  medium,	  despite	  the	  presence	  of	  rapamycin.	  Erbay	  et	  al.	   (2003)	  knew	  this	  supported	  the	  notion	  that	  a	  secreted	  factor	  was	  mediating	  differentiation,	  which	  was	  confirmed	   to	   be	   IGF-­‐2.	   It	   turns	   out	   that	   mTOR	   mediates	   the	   transcription	   of	   IGF-­‐2	  independently	  of	  its	  kinase	  activity	  through	  a	  muscle	  specific	  enhancer	  (Erbay	  et	  al.,	  2003).	  One	   proposed	   mechanism	   of	   this	   effect	   is	   through	   mTOR’s	   suppression	   of	   mir-­‐125b,	   a	  microRNA	   that	   targets	   IGF-­‐2,	   triggering	   its	   suppression	   (Ge,	   Sun,	   et	   al.,	   2011).	   Another	  mechanism	   regulating	   IGF-­‐2	   expression	   is	   mTOR’s	   direct	   kinase	   activity	   towards	   IGF-­‐2	  mRNA-­‐binding	  protein	  (IMP2),	  which	  enhances	  IGF-­‐2	  translation	  (Dai	  et	  al.,	  2011).	  Taken	  together,	  IGF-­‐2’s	  regulatory	  control	  over	  differentiation	  appears	  to	  be	  primarily	  regulated	  by	  both	  kinase	  dependent	  and	  independent	  functions	  of	  mTOR.	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AKT	  and	  Myogenesis	  	  	  	   Protein	   Kinase	   B	   or	   AKT	   is	   a	   serine/threonine	   kinase,	   which	   acts	   as	   part	   of	   the	  PI3K/AKT/mTOR	  signalling	  pathway.	  There	  are	  three	  known	  isoforms	  of	  AKT	  (1-­‐3).	  AKT1	  is	   involved	   mainly	   with	   cell	   growth	   and	   proliferation	   (Li	   et	   al.,	   2013)	   and	   muscle	  hypertrophy	   (Bodine,	   2001).	   AKT2	   has	   been	   linked	   to	   glucose	   homeostasis	   thus,	   is	  understandably	   expressed	   in	   insulin-­‐sensitive	   tissues	   (Cho	   et	   al.,	   2001).	   Lastly,	   AKT3	   is	  expressed	  primarily	  in	  lung,	  kidney	  and	  brain	  (Brodbeck	  et	  al.,	  1999).	  For	  our	  purposes	  the	  focus	   is	   on	   AKT1	   and	   AKT2.	   Depletion	   of	   AKT1	   in	   10T1/2	  mouse	   embryonic	   fibroblasts	  (MEFs)	  impaired	  myotube	  formation	  by	  80%	  and	  myocyte	  fusion	  index	  by	  90%	  (Wilson	  &	  Rotwein,	   2007),	   adding	   to	   the	   body	   of	   evidence	   that	   AKT1	   serves	   an	   important	   role	   in	  muscle	  regeneration.	  	  Insulin	  and	  insulin-­‐like	  growth	  factor	  (IGF)	  activate	  AKT	  through	  their	  interactions	  with	   the	   insulin-­‐like	   growth	   factor	   receptor	   (IGFR).	   IGFR	   is	   a	   tyrosine	   kinase,	   which	  activates	  insulin-­‐receptor	  substrate	  (IRS)	  via	  phosphorylation	  (Virkamäki	  et	  al.,	  1999).	  The	  phosphorylation	  of	  IRS	  triggers	  the	  translocation	  of	  phosphatidylinositol	  3-­‐kinase	  (PI3K)	  to	  the	  inner	  border	  of	  the	  cell	  membrane.	  	  PI3K	  contains	  catalytic	  subunits	  that	  produces	  the	  membrane	   bound	   phosphatidylinositol	   (3,4)-­‐bisphosphate	   and	   eventually	  phosphatidylinositol	  (3,4,5)-­‐trisphosphate	  (PIP3).	   	  PIP3	  then	  causes	  the	  localization	  of	  all	  pleckstrin	  homology	  domain	  containing	  proteins	  to	  the	  cell	  membrane,	  one	  being	  AKT	  and	  its	  direct	  activator	  phosphoinositide-­‐dependent	  kinase	  1	  (PDK1)	  (Virkamäki,	  1999).	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   Surprisingly,	   fairly	   few	   studies	   have	   investigated	   the	   role	   AKT	   serves	   in	   skeletal	  muscle	  differentiation.	  One	  study	  shows	  that	  AKT1	  expression	  is	  required	  for	  the	  activity	  of	  the	  transcription	  factor	  MyoD,	  although	  its	  actions	  are	  independent	  of	  MyoD	  levels	  (Wilson,	  2007).	   The	   authors	   also	   found	   that	   AKT1	   depletion	   had	   no	   effect	   on	   cell	   viability	   or	  proliferation,	   which	   contradicts	   another	   study	   that	   stated	   AKT1	   was	   required	   for	   cell	  proliferation	  (Heron-­‐Milhavet	  et	  al.,	  2006).	  Heron-­‐Milhavet	  at	  al.	  (2006)	  saw	  reductions	  in	  cyclin	  A	  expression,	  and	  failure	  to	  enter	  S-­‐phase	  of	  the	  cell	  cycle	  in	  response	  to	  interference	  RNA	   targeted	   at	   AKT1.	   AKT2	   too	   has	   been	   implicated	   in	   the	   regulation	   of	   myogenic	  differentiation.	   Two	   studies	   so	   far	   have	   implicated	   its	   role	   in	  muscle	   cell	   differentiation.	  The	   first	   proposed	   mechanism	   of	   AKT2’s	   effect	   on	   cell	   cycle	   exit	   described	   by	   Heron-­‐Milhavet	   et	   al.	   (2006)	   states	   that	  AKT2	  binding	   to	  p21,	   a	   cell	   cycle	   inhibitor,	   leads	   to	   its	  nuclear	   accumulation,	   triggering	   cell	   cycle	   exit.	   The	   second	   proposed	   role	   of	   AKT2-­‐mediated	   myogenic	   differentiation	   is	   via	   its	   inhibitory	   action	   towards	   Prohibitin2	  (PHB2)/Repressor	   of	   estrogen	   activity	   (REA),	   a	   negative	   regulator	   of	   differentiation.	  PHB2/REA	   has	   been	   found	   to	   bind	   and	   inhibit	   MyoD,	   in	   addition	   to	   reducing	   MEF2	  transcriptional	   activity,	   thereby	   impairing	   differentiation	   (Sun	   et	   al.,	   2004).	   	   Early	  experiments	   by	   Sun	   et	   al.	   (2004)	   had	   shown	   that	   AKT2	   and	   PHB2/REA	   are	   inversely	  expressed	   at	   the	   onset	   of	   myogenic	   differentiation,	   and	   that	   during	   unperturbed	  differentiation	  AKT2	   levels	  rise	  while	  PHB2/REA	   levels	   fall	   (Héron-­‐Milhavet	  et	  al.,	  2008).	  Additional	  experiments	  showed	  that	  co-­‐expression	  of	  AKT	  and	  PHB2	  resulted	  in	  a	  decline	  of	  MyoD-­‐PHB2	  binding,	   rescuing	  muscle	   cell	   differentiation	   (Sun,	  2004).	   Loss	  of	   function	  experiments	   that	  were	   conducted	  on	  AKT2	   resulted	   in	   the	   failure	  of	   cells	   to	   exit	   the	   cell	  cycle,	   alongside	   a	   rise	   in	   the	   expression	   of	   PHB2/REA,	   subsequently	   impairing	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differentiation	   (Héron-­‐Milhavet,	   2008).	  Taken	   together	   the	   current	   literature	  proves	   that	  AKT	   and	   at	   least	   two	   of	   its	   different	   isoforms	   are	   essential	   to	   cellular	   proliferation,	   cell	  cycle	  arrest,	  differentiation,	  and	  hypertrophy.	  
MAPK	  Signalling	  and	  Myogenesis	  
	   Multiple	  signalling	  cascades	  converge	  to	  properly	  regulate	  myogenesis,	  one	  of	  them	  being	   mitogen-­‐activated	   protein	   kinases	   (MAPKs).	   MAPKs,	   as	   the	   name	   suggests,	   are	  responsive	   to	   mitogenic	   signals.	   These	   mitogenic	   signals	   regulate	   many	   cell	   functions	  including	  proliferation,	  differentiation	  (Madhala-­‐Levy	  et	  al.,	  2012)	  and	  apoptosis	  (Keren	  et	  al.,	   2006).	   	   The	   MAPK	   superfamily	   is	   highly	   conserved	   in	   mammals.	   It	   is	   principally	  comprised	   of	   the	   extracellular	   signal	   regulated	   kinases	   (ERKs),	   p38	   MAPKs,	   Jun	   amino-­‐terminal	  kinases	  (JNKs)	  and	  Stress-­‐activated	  protein	  kinases	  (SAPK)	  (Segalés,	  Perdiguero,	  et	  al.,	  2016).	  This	  literature	  review	  will	  focus	  on	  p38	  MAPKs	  due	  to	  their	  established	  role	  in	  various	   stages	   of	  myogenesis.	   In	  mammals	   there	   exists	   four	  p38	  MAPK	   family	  members:	  p38α,	  p38β,	  p38ϒ,	   and	  p38δ.	   	   Specific	   inhibitors	   to	  p38α/p38β	  have	  aided	   in	   identifying	  many	  physiological	  functions	  carried	  out	  by	  these	  kinases.	  One	  study	  found	  that	  myoblast	  fusion,	   and	   eventual	   myotube	   formation	   is	   ablated	   in	   the	   presence	   of	   p38α/p38β	  inhibitors.	   ((Lluís	   et	   al.,	   2006).	   However,	   when	   the	   master	   p38	   kinase,	   MKK6,	   is	  overexpressed,	   muscle	   cells	   are	   able	   to	   overcome	   the	   inhibitors,	   expressing	   myogenic	  markers	   and	   the	   formation	   of	   myotubes	   (Lluís,	   2006).	   This	   suggests	   the	  activation/phosphorylation	   of	   p38α/p38β	   is	   required	   for	   myotube	   formation.	   	   A	   more	  recent	   study	   in	   C2C12	  myoblasts	   using	   genome-­‐wide	   based	   analyses	   of	   p38α	   found	   that	  during	  muscle	  cell	  differentiation	  p38α	  was	  bound	  to	  a	  large	  number	  of	  active	  and	  inactive	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promoters,	   further	   providing	   evidence	   of	   p38α’s	   role	   in	   the	   transcriptional	   regulation	   of	  myogenic	  differentiation	  (Segalés,	  Islam,	  et	  al.,	  2016).	  	  Furthermore,	   p38α/p38β	   has	   also	   been	   shown	   to	   be	   necessary	   for	   satellite	   cell	  activation	  and	  the	  transcription	  of	  MyoD	  (Jones	  et	  al.,	  2005).	  Once	  MyoD	  transcription	  has	  been	   initiated,	   p38α/p38β	   has	   been	   found	   to	   promote	   its	   association	   with	   the	   E-­‐box	  protein,	   E47,	   via	   direct	   phosphorylation	   (Lluís	   et	   al.,	   2005).	   The	   heterodimerization	   of	  MyoD	  and	  E47	   is	   essential	   for	  muscle-­‐specific	   gene	   transcription	   (Lluís,	   2005).	   Lastly,	   at	  the	   onset	   of	   myoblast	   differentiation	   cell	   cycle	   arrest	   needs	   to	   occur.	   One	   of	   the	  mechanisms	  regulating	  this	   is	  p38α.	  p38α-­‐induced	  cell	  cycle	  arrest	   is	  ultimately	  achieved	  via	   the	   downregulation	   of	   cyclin	   D1	   expression,	   in	   a	   JNK	   pathway	   dependent	   manner	  (Perdiguero	   et	   al.,	   2007).	   Even	   later	   in	   the	   differentiation	   process	   p38α	   coordinates	  myoblast	   fusion	   via	   the	   upregulation	   of	   the	   tetraspanin,	   CD53,	   a	   prominent	  mediator	   of	  myoblast	   fusion	   (Liu,	   2012).	   In	   conclusion,	   p38	  MAPK	   signalling	   is	   a	   large	   and	   essential	  contributor	  to	  muscle	  cell	  differentiation.	  
Notch	  Signalling	  and	  Myogenesis	  
	   Notch	   signaling	   is	   a	   highly	   complex	   and	   evolutionarily	   conserved	   pathway	  overseeing	  many	  roles	  in	  embryogenesis	  (Artavanis-­‐Tsakonas	  et	  al.,	  1999),	  tumorigenesis	  (Evans	  &	  Calvi,	  2015),	  metabolism	  (Pajvani	  et	  al.,	  2011),	  stem	  cell	  population	  maintenance	  (Androutsellis-­‐Theotokis	   et	   al.,	   2006),	   and	   myogenesis	   (Conboy	   &	   Rando,	   2002).	   	   The	  components	  of	  the	  Notch	  signalling	  pathway	  are	  comprised	  of	   four-­‐mammalian	  receptors	  (NOTCH1-­‐4),	   five-­‐ligands,	   and	   both	   an	   extracellular	   (NECD)	   and	   intracellular	   (NICD)	  domains.	  Ligand	  binding	  occurs	  with	  the	  larger	  NECD,	  and	  conveys	  the	  signal	  to	  the	  smaller	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NICD.	  Following	  ligand	  binding,	  a	  cleavage	  event	  separates	  the	  NICD	  from	  the	  intracellular-­‐side	  of	  the	  cell	  membrane,	  allowing	  it	  to	  translocate	  to	  the	  nucleus	  where	  it	  binds	  Rbp-­‐j	  and	  transcribes	  notch	  target	  genes	  (Kopan	  &	  Ilagan,	  2009).	  	  	   The	   onset	   of	   muscle	   regeneration	   in	   adult	   tissues	   begins	   with	   an	   early	   muscle	  progenitor-­‐type	  cells,	   satellite	   cells.	   In	   response	   to	   stress	  or	   injury,	   satellite	   cells	   awaken	  from	  their	  quiescent	  state	  and	  enter	  the	  cell	  cycle	  so	  that	   they	  can	  provide	  the	  necessary	  nuclei	   to	   support	   the	   repair	   of	   existing	   muscle	   fibers.	   Notch	   signalling	   is	   required	   for	  satellite	  cell	  proliferation	  and	  population	  maintenance,	  in	  addition	  to	  its	  effects	  in	  blocking	  differentiation	   (Conboy,	   2002;	   Shan	   et	   al.,	   2017).	   Notch	   signalling’s	   role	   in	   satellite	   cell	  population	  maintenance	  is	  achieved	  by	  positively	  expressing	  the	  transcription	  factor	  Pax7,	  without	  which	  would	  result	  in	  dedifferentiation,	  away	  from	  a	  myogenic	  lineage	  (Shan	  et	  al.,	  2016).	   Experiments	   in	   which	   the	   Notch	   target	   Rbp-­‐j	   is	   inactivated	   during	   development,	  satellite	   cell	   population	   levels	   decline,	   leading	   to	   the	   impairment	   of	  muscle	   regeneration	  (Vasyutina	  et	  al.,	  2007).	  In	  mature	  skeletal	  muscle	  that	  same	  inactivation	  of	  Rbp-­‐j	  results	  in	  a	  decline	  of	   satellite	   cell	  population,	  which	   is	   accompanied	  by	   their	   immediate	  myogenic	  differentiation.	   This	   causes	   the	   prevention	   of	   S-­‐phase	   entry,	   resulting	   in	   the	   failure	   of	  satellite	   cell	   expansion,	   an	   essential	   step	   in	  muscle	   regeneration	   (Bjornson	   et	   al.,	   2012).	  Studies	  overexpressing	  a	  constitutively	  active	  NICD	  found	  that	  Notch	  signalling’s	  induction	  of	   Pax7	  was	   directly	   regulated	   via	   its	   interaction	  with	   Rbp-­‐j,	   which	   colocalizes	  with	   the	  NICD	   to	   the	   Pax7	   promoter,	   promoting	   its	   activation	   (Figure	   1-­‐3)	   (Wen	   et	   al.,	   2012).	  	  Further	  experiments	  by	  Wen	  et	  al.	  (2012)	  used	  a	  lentivirus-­‐mediated	  knockdown	  of	  Rbp-­‐jκ,	  which	  completely	  removed	  any	  NICD	  association	  with	  the	  Pax7	  promoter	  region,	   thereby	  preventing	  Pax7	  expression.	  This	  resulted	  in	  premature	  satellite	  cell	  cell-­‐cycle	  exit,	  failure	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of	   satellite	   cell	   expansion	   and	   the	   subsequent	   impairment	   of	   differentiation.	   Notch	  signalling	   is	   also	   involved	   in	   the	   negative	   regulation	   of	   MyoD	   and	   myogenin,	   which	   is	  believed	  to	  be	  distinct	  from	  the	  NICD-­‐Rbp-­‐jκ	  interaction,	  and	  instead	  be	  regulated	  through	  canonical	  notch	  signalling	   (depicted	  on	   the	  right	  side	  of	  Figure	   1-­‐3)	   (Olguin	  et	  al.,	  2007;	  Wen,	   2012).	   All	   together,	   the	   growing	   literature	   around	   Notch	   signalling	   confirms	   its	  importance	   in	   regulating	   satellite	   cell	   population,	   cell	   fate	   determination,	   and	   its	  requirement	  for	  muscle	  regeneration.	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Figure	   1-­‐3.	   Notch	   signalling	   effects	   on	   satellite	   cell	   activation	   and	   early	   differentiation.	  Quiescent	   satellite	   cells	   predominantly	   express	   Pax7.	   Upon	   activation	   the	   satellite	   cells	  start	   to	  upregulate	   their	  expression	  of	  MyoD	  while	  Pax7	  expression	   falls	  proportionately.	  Following	  the	  rise	  of	  MyoD	  and	  fall	  of	  Pax7	  expression	  the	  cells	  exit	  the	  cell	  cycle	  and	  begin	  to	   differentiate.	   Notch	   signalling	   promotes	   the	   binding	   of	   the	   NICD	   with	   Rbp-­‐j κ	   which	  upregulates	   the	   transcription	  of	   Pax7.	  The	   canonical	   targets	   of	  Notch	   signalling,	  Hes	   and	  Hey	   family	   proteins,	   are	   also	   activated	   to	   suppress	   MyoD	   expression.	   Overall,	   Notch	  signalling	   decreases	   as	   the	  myoblasts	   begin	   to	   differentiate.	   Image	  modified	   from	   (Wen,	  2012).	   Recombining	   binding	   protein	   suppressor	   of	   hairless	   (Rbpj),	   Notch	   intracellular	  domain	  (NICD),	  Hairy	  and	  enhancer-­‐of-­‐split	  (HES),	  Hes-­‐related	  repressor	  (HEY).	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Mitochondrial	  Regulation	  of	  Myogenesis	  
	   The	  mitochondrion	  has	  many	  functions	  within	  the	  cell.	  Recently,	  mounting	  evidence	  suggests	   that	   they	   may	   also	   be	   regulating	   cell	   differentiation,	   particularly	   muscle	   cell	  differentiation.	   In	  vitro	   studies	   investigating	   the	  mitochondrial	   changes	   that	  occur	  during	  myoblast	  differentiation	  have	  shown	  a	  dramatic	  increase	  in	  mitochondrial	  enzyme	  activity	  (Barbieri	  et	  al.,	  2011;	  Moyes	  et	  al.,	  1997;	  Remels	  et	  al.,	  2010).	  	  Additionally,	  mitochondrial	  biogenesis	   has	   been	   found	   to	   increase	   during	   myoblast	   differentiation	   and	   muscle	  regeneration	  (Barbieri,	  2011;	  Duguez	  et	  al.,	  2002;	  Remels,	  2010;	  Wagatsuma	  et	  al.,	  2011).	  	  These	   factors	   alone	   are	   convincing	   enough	   that	   mitochondrial	   function	   is	   required	   for	  myoblast	   differentiation,	   leading	   to	   the	   question,	   “Do	   mitochondria	   regulate	   myoblast	  differentiation	   through	   an	   energy-­‐mediated	  mechanism,	   or	   through	   other	  mitochondrial	  functions?”	  	   	  A	  study	  examining	  mitochondrial	  function	  and	  its	  importance	  in	  differentiation	  was	  conducted	   using	   human	   primary	  muscle	   cultures.	   Ethidium	  bromide	  was	   used	   to	   inhibit	  mitochondrion	   DNA	   replication	   and	   transcription,	   which	   impaired	   myotube	   formation	  (Herzberg	   et	   al.,	   1993).	   Another	   study	   using	   C2C12	  muscle	   cells	   found	   that	   inhibition	   of	  mitochondrial	   protein	   synthesis	   via	   tetracycline	   treatment	   also	   impaired	   terminal	  differentiation,	   while	   showing	   that	   these	   effects	   were	   independent	   of	   cell	   energy	   status	  (Hamai	  et	  al.,	  1997).	  Rochard	  et	  al.	   (2000)	  showed	  that	   the	   impairment	  of	  mitochondrial	  translation	   by	   chloramphenicol	   treatment	   negatively	   affected	   myoblast	   differentiation.	  This	  treatment	  perturbs	  proper	  assembly	  of	  4	  out	  the	  5	  respiratory	  complexes,	  rendering	  the	   organelle	   inert,	   yet	   this	   did	   not	   affect	   cell	   viability	   (Rochard	   et	   al.,	   2000).	   They	   also	  showed	   that	   increasing	   mitochondrial	   activity	   via	   p43	   expression	   enhanced	   myoblast	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differentiation	   (Rochard,	   2000).	   p43	   overexpression	   has	   been	   shown	   to	   stimulate	  mitochondrial	   gene	   transcription,	   ultimately	   leading	   to	   a	   rise	   in	   mitochondrial	   protein	  synthesis	   (Casas	  et	  al.,	  1999).	   Impressively,	   this	  enhancement	   in	  myoblast	  differentiation	  was	   accomplished	   in	   10%	   serum	   conditions,	   meaning	   the	   QM7	   myoblasts	   were	   able	   to	  overcome	   the	   cell-­‐cycle	   promoting	   effects	   of	   a	   high-­‐serum	   condition	   (Rochard,	   2000).	  These	   results	   were	   replicated	   using	   two	   additional	   mitochondrial	   function	   inhibitors,	  oligomyosin	  and	  carbonyl	  cyanide	  p-­‐	   (trifluoromethoxy)	  phenylhydrazone	  (FCCP).	  Lastly,	  Rochard	  et	  al.	  (2000)	  showed	  that	  disruption	  of	  mitochondrial	  activity	  negatively	  affected	  myogenin	   expression,	   in	   addition	   to	   drastically	   diminishing	   the	   expression	   of	   the	  acetylcholine	  receptor	  subunit	  alpha	  (AchRα),	  another	  marker	  of	  differentiation	  (Rochard,	  2000).	  A	  follow-­‐up	  study	  was	  completed	  by	  the	  same	  laboratory	  investigating	  the	  role	  that	  c-­‐myc	   plays	   in	   mitochondrial-­‐mediated	   myogenesis.	   Their	   main	   findings	   indicate	   that	  mitochondrial	   activity	   negatively	   regulates	   c-­‐myc	   expression,	   which	   leads	   to	   permanent	  cell	   cycle	  withdrawal	   for	  myoblasts.	   Using	   FACS	   analysis,	   Seyer	   et	   al.	   (2006)	   found	   that	  overexpression	  of	  p43	  increased	  the	  number	  of	  cells	  in	  the	  G0/G1	  phase,	  conversely,	  c-­‐myc	  overexpression	   stimulated	   cell	   cycle	   progression	   into	   S-­‐phase,	   which	   also	   mirrored	   the	  response	   to	   chloramphenicol	   treatment.	  A	  possible	   explanation	   is	   that	   c-­‐myc	   is	   a	   known	  suppressor	  of	  p21	  expression,	  which	  is	  a	  major	  component	  of	  the	  cellular	  machinery	  that	  induces	   cell	   cycle	   arrest	   (Seyer	   et	   al.,	   2006).	   In	   conclusion,	   mitochondrial	   function	  independent	  of	  energy	  production	  is	  required	  for	  proper	  myoblast	  differentiation.	  Further	  study	  to	  discern	  the	  exact	  mechanisms	  involved	  are	  warranted.	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BCAA	  metabolism	  	  
	   BCAA	  catabolism	   is	  often	  dysfunctional	  during	  diseased	  states	   including	  obesity	  &	  type	  2	  diabetes	  mellitus	  (Lynch,	  2014a;	  Mccormack,	  2013;	  She,	  2009),	  heart	  disease	  (Wang,	  2016),	  and	  maple	  syrup	  urine	  disease	  (MSUD)	  (Indo,	  1987).	  Specifically,	  MSUD,	  a	  condition	  involving	  a	  loss-­‐of-­‐function	  mutation	  in	  BCKD,	  displays	  signs	  of	  skeletal	  muscle	  impairment	  (Ferriere	  et	  al.,	  1984).	  Dysregulation	  of	  BCAA	  metabolism	  in	  those	  diseased	  states	  may	  just	  be	  a	  symptom,	  or	  they	  could	  represent	  a	  primary	  driver	  in	  muscle	  impairment.	  	  
Impaired BCAA metabolism and disease 	   Many	   studies	   have	  begun	   looking	   into	  whole	   body	  BCAA	  metabolism	  due	   to	   their	  metabolic	   dysregulation	   in	  many	   diseased	   states	   including	   types	   1	   and	   2	   diabetes,	   renal	  failure,	  and	  heart	  disease.	  She	  et	  al.	  (2007)	  conducted	  a	  study	  utilizing	  a	  transgenic	  mouse	  depleted	  of	  global	  BCATm.	  Interestingly,	  a	  plethora	  of	  metabolic	  changes	  were	  present	   in	  these	   mice.	   Phenotypic	   changes	   included	   reductions	   in	   body	   weight	   (~10-­‐15%)	   and	  adiposity,	   while	   also	   displaying	   resistance	   to	   high-­‐fat	   diet	   induced	   obesity,	   despite	  increases	   in	   food	   intake	   (She	   et	   al.,	   2007).	   The	   starkest	   metabolic	   change	   was	   the	  improvement	   in	   insulin	   sensitivity,	   observed	   by	   basal	   plasma	   insulin	   levels	   falling	   from	  0.75	  ng/ml	  to	  0.26	  ng/ml	  (She,	  2007).	  The	  authors	  also	  noted	  a	  significant	  rise	  in	  protein	  turnover,	   evident	   from	   the	   increase	   in	   protein	   synthesis	   rates	   in	   all	   tissues	   measured	  (heart,	  gastrocnemius,	  kidney,	  epididymal	  fat,	  and	  liver),	  while	  also	  noting	  a	  rise	  in	  urine	  3-­‐methylhistidine	   levels,	   indicative	  of	  protein	  degradation	  (She,	  2007).	   It	  was	  hypothesized	  that	   the	   high	   leucine	   concentrations	   resultant	   from	   the	   removal	   of	   its	   primary	   catabolic	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enzyme	   (BCATm)	   was	   causing	   an	   upregulation	   in	   protein	   translation,	   due	   to	   leucine’s	  ability	  to	  stimulate	  mTORC1	  activity.	  This	  rise	  in	  protein	  turnover	  may	  explain	  the	  increase	  in	  energy	  expenditure	  observed	  in	  the	  BCATm	  knockout	  mice.	  	  In	   a	   follow-­‐up	   study	   She	   et	   al.,	   (2010)	   sought	   out	   to	   assess	   the	   effects	   of	   BCATm	  depletion	  on	  energy	  metabolism	  and	  exercise	  performance.	  The	  authors	  hypothesized	  that	  the	   drastic	   rise	   in	   plasma	   BCAA	   levels	   from	   the	   previous	   study	   could	   impact	   exercise	  performance,	  based	  upon	  past	  literature	  investigating	  BCAA	  supplementation	  and	  exercise	  performance.	  BCATm	  depleted	  mice	  were	  subjected	  to	  a	  treadmill	  test	  starting	  with	  a	  short	  endurance-­‐training	   period	   (3-­‐days)	   followed	   by	   the	   incremental-­‐intensity	   test	   until	  exhaustion.	  Following	  training	  the	  transgenic	  mice	  ran	  for	  a	  reduced	  time	  (32%	  reduction)	  and	   distance	   (24%	   reduction)	   compared	   to	   littermate	   controls	   (She	   et	   al.,	   2010).	   The	  BCATm	  depleted	  mice	  displayed	  significant	  exercise	  capacity	  impairment,	  evident	  by	  a	  rise	  in	  plasma	  ammonia	  and	   lactate	   levels.	  Additionally,	   intramuscular	   levels	  of	   the	   lactate	   to	  pyruvate	   ratio	   increased	   similarly	   to	   plasma	   levels.	   Overall,	   the	   BCATm	   depleted	   mice	  appear	  to	  be	  in	  energy	  crisis	  based	  upon	  the	  significant	  reductions	  of	  gastrocnemius	  ATP	  concentrations,	  the	  accumulation	  of	  plasma	  ammonia	  and	  lactate,	  and	  the	  seven-­‐fold	  rise	  in	  muscle	   inosine	   monophosphate	   (IMP)	   levels,	   indicative	   of	   an	   upregulated	   purine	  nucleotide	   cycle	   (PNC).	   These	   changes	   may	   represent	   a	   compensatory	   mechanism	   to	  replenish	   TCA	   cycle	   intermediates	   that	   are	   lacking	   in	   the	   knockout	   mice.	   A	   likely	  explanation	  for	  the	  rise	  in	  PNC	  activity	  could	  be	  from	  the	  reduction	  in	  glutamate	  synthesis,	  a	   product	   of	   BCAA	   transamination	   that	   is	   catalyzed	   by	  BCATm	   (She,	   2010).	   The	   authors	  argue	  that	  this	  reduction	  in	  glutamate	  synthesis	  causes	  a	  decrease	  in	  the	  malate-­‐aspartate	  shuttle	   system	   activity,	   which	   leads	   to	   a	   rise	   in	   cytosolic	   NADH	   and	   is	   associated	   with	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lactate	  accumulation.	  Recently,	  a	  metabolic	  analysis	  study	  was	  completed	  comparing	  type	  2	  diabetic	   (T2D)	   patients	   against	   BMI-­‐matched	   controls.	   Remember	   that	   T2D	   patients	   are	  one	   of	   the	   populations	   that	   have	   altered	   BCAA	   metabolisms,	   particularly	   noted	   by	  increased	  plasma	  BCAA	  levels.	  The	  authors	  found	  during	  baseline	  measurements	  that	  the	  T2D	   group	   had	   significantly	   reduced	   activities	   of	   malate-­‐aspartate	   shuttle	   enzymes	  (cytosolic:	  aspartate	  aminotransferase	  -­‐	  25%,	  mitochondrial:	  aspartate	  aminotransferase	  -­‐	  30%,	  and	  malate	  dehydrogenase	  -­‐	  45%)	  (Hussey	  et	  al.,	  2013).	  The	  reductions	  in	  the	  malate-­‐aspartate	  shuttle	  system	  enzymes,	  as	  alluded	  to	  by	  She	  et	  al.,	  (2010)	  could	  be	  caused	  by	  an	  impairment	   of	   glutamate	   synthesis,	   which	   the	   BCATm	   enzyme	   regulates.	   These	   findings	  suggest	  that	  BCAA	  metabolic	  dysfunction	  in	  T2DM	  may	  be	  due	  to	  the	  impairment	  of	  BCATm	  functioning,	  providing	  a	  link	  between	  BCATm	  dysregulation	  and	  T2D.	  	  There	   exist	   3	   studies	   to	   date,	   to	   my	   knowledge,	   that	   assess	   the	   effects	   of	   BDK	  knockout	  in	  mice.	  BDK	  is	  the	  enzyme	  that	  negatively	  regulates	  BCKD	  activity,	  and	  thus	  the	  activity	   of	   the	   entire	   BCAA	   catabolic	   pathway.	   The	   first	   study	   conducted	   in	   2006	  was	   a	  whole-­‐body	  knockout,	  which	  saw	  15%	  reductions	  in	  body	  weight,	  alongside	  reductions	  in	  brain,	  muscle,	   and	   adipose	   tissue,	  while	   liver	   and	   kidney	  weights	   increased	   (Joshi	   et	   al.,	  2006).	   Most	   notably	   these	   mice	   suffered	   neurological	   abnormalities	   involving	   epileptic	  seizures.	   The	   authors	   believed	   this	   might	   have	   been	   due	   to	   a	   hyper-­‐phosphorylation	   of	  eIF2-­‐alpha	   in	  brain	   tissue	   that	  would	   result	   in	   a	  decrease	   in	  protein	   synthesis.	  However,	  body	  weight	   and	   general	   appearance	   of	   the	   BDK	   knockout	  mice	  was	   rescued	   by	   a	   high-­‐protein	  diet	  (50%	  kcal	  from	  protein).	  But	  the	  authors	  did	  not	  mention	  what	  affect	  this	  had	  on	  the	  severity	  or	  frequency	  of	  the	  seizures.	  This	  study	  improves	  our	  understanding	  of	  how	  essential	  a	  properly	  regulated	  BCAA	  catabolic	  pathway	  is	  to	  health.	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The	   second	   study	  was	   completed	   in	   2017.	   It	   sought	   out	   to	   assess	   how	   a	  muscle-­‐specific	   knockout	   of	   BDK	   would	   affect	   protein	   metabolism.	   Plasma	   BCAAs	   were	  significantly	   reduced	   in	   the	   muscle-­‐specific	   BDK	   knockout	   mice,	   similarly	   to	   that	   of	   the	  whole	   body	  BDK	  knockout	  mice.	   The	   degree	   at	  which	   the	  muscle-­‐specific	   BDK	  knockout	  effects	  plasma	  BCAA	  concentrations	  proves	  the	  central	  role	  skeletal	  muscle	  plays	  in	  global	  BCAA	  metabolism.	  On	  the	  other	  hand,	  this	  fails	  to	  explain	  the	  absence	  of	  any	  tissue	  or	  body	  weight	  changes,	  in	  addition	  to	  the	  absence	  of	  any	  neurological	  abnormalities	  witnessed	  in	  the	   whole	   body	   BDK	   knockout	   mice	   (Ishikawa,	   2017).	   The	   main	   findings	   included	   an	  increased	  sensitivity	  of	  mTORC1	  to	  high-­‐protein	  diet	   feedings,	  or	  BCAA	  supplementation.	  The	  authors	  speculated	  that	  the	  increase	  in	  mTORC1	  sensitivity	  may	  be	  due	  to	  the	  chronic	  reduction	   in	   BCAA	   levels,	   leading	   to	   a	   hyper-­‐sensitization	   to	   BCAAs.	   Additional	  experiments	  showed	  a	  50%	  reduction	  in	  mTORC1	  activity	  when	  animals	  were	  placed	  on	  a	  low-­‐protein	  diet	  (8%	  of	  kcals	  from	  protein)	  and	  was	  accompanied	  by	  significant	  reductions	  in	  myofibrillar	  proteins	  (Ishikawa,	  2017).	  Upon	  BCAA	  supplementation	  these	   losses	  were	  attenuated	  and	  mTORC1	  activity	  was	  fully	  restored/enhanced.	  In	  a	  follow-­‐up	  study,	  which	  used	  the	  same	  muscle-­‐specific	  BDK	  knockout	  model,	  the	  authors	   investigated	   its	   effects	   on	   endurance	   exercise	   and	   energy	   metabolism.	  Interestingly,	   there	   were	   no	   basal	   differences	   in	   exercise	   performance,	   only	   post-­‐endurance	   exercise	   training	   saw	   a	   difference	   in	   performance	   (~12%	   reduction	   in	   BDK	  knockout	   performance)	   (Xu	   et	   al.,	   2017).	   The	   authors	   also	   noted	   reductions	   in	   muscle	  glycogen	   in	   the	   knockout	   mice	   post	   training,	   in	   addition	   to	   a	   rise	   in	   the	   acyl-­‐carnitine	  production,	  which	  they	  claim	  may	  impair	  energy	  metabolism	  in	  muscle	  (Xu,	  2017).	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These	   three	   studies	   show	   the	   importance	   and	   impact	   that	   BDK	   has	   over	   BCAA	  metabolism	  and	  the	  subsequent	  effects	  that	  an	  accelerated	  BCAA	  catabolic	  pathway	  has	  on	  global	  energy	  and	  protein	  metabolism.	  
 
The BCAA catabolic pathway 
	   Two	   mitochondrial	   enzymes	   regulate	   the	   initial	   two	   steps	   in	   the	   BCAA	   catabolic	  pathway,	   branched-­‐chain	   amino	   acid	   transferase-­‐2	   (BCAT2/BCATm)	  and	  Branched-­‐chain	  alpha	  keto-­‐acid	  dehydrogenase	  (BCKD).	  BCAT2	  oversees	  the	  transamination	  of	  BCAAs	  into	  their	   respective	   keto-­‐acids,	   which	   are	   then	   further	   catabolized	   by	   BCKD.	   BCKD	   is	   a	  mitochondrial	   inner-­‐membrane	   localized	   protein	   complex	   that	   shares	   structural	   and	  functional	  similarities	  to	  both	  pyruvate	  dehydrogenase	  and	  α-­‐ketoglutarate	  dehydrogenase	  (Indo,	  1987).	  	  It	  orchestrates	  the	  decarboxylation	  of	  BCAA	  derived	  keto-­‐acids,	  representing	  the	  first	  irreversible	  and	  rate-­‐limiting	  step	  in	  BCAA	  catabolism.	  BCKD	  is	  comprised	  of	  three	  component	   parts:	   the	   heterotetrameric	   branched-­‐chain	   α-­‐keto-­‐acid	   decarboxylase	  component	   (E1:	  2α-­‐subunits	  &	  2β-­‐subunits),	   dihydrolipoyl	   transacylase	   component	   (E2),	  and	   the	  dihydrolipoyl	  dehydrogenase	   component	   (E3)	   (Matsumoto	  et	   al.,	   2010).	  BCKD	   is	  under	   tight	   regulation	   between	   a	   phosphatase	   and	   kinase	   that	   positively	   and	   negatively	  regulate	   its	   activity,	   respectively.	   The	   phosphatase	   termed	   protein	   phosphatase	   2Cm	  (PP2Cm)	   is	   a	   mitochondrial	   matrix	   phosphatase.	   This	   enzyme	   has	   been	   linked	   to	   cell	  survival,	  embryonic	  development	  and	  cardiac	  function	  (Lu	  et	  al.,	  2007).	  	  PP2Cm	  positively	  regulates	   BCKD	   activity	   via	   the	   removal	   of	   a	   phosphorylation	   on	   S293	   of	   BCKD’s	   E1α	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subunit	  (Fig.	  1-­‐4).	  The	  inhibitory	  phosphorylation	  is	  catalyzed	  by	  branched-­‐chain	  α-­‐keto-­‐acid	   dehydrogenase	   kinase	   (BDK).	   Regulation	   of	   these	   two	   proteins	   has	   garnered	   some	  attention	  because	  of	  their	  potential	  to	  modulate	  BCAA	  homeostasis.	  	  
	   	  
Figure	   1-­‐4.	   	   Branched-­‐chain	   amino	   acid	   catabolic	   pathway.	   Schematic	   of	   the	   BCAA	  catabolic	   pathway,	   depicting	   its	   two	   main	   catabolic	   enzymes,	   BCATm	   and	   BCKD,	  respectively.	   BCATm	   controls	   the	   reversible	   transamination	   step	   that	   converts	   all	   three	  BCAAs	  into	  their	  keto-­‐acid	  derivatives,	  while	  simultaneously	  converting	  α-­‐ketoglutarate	  to	  glutamate.	  The	  second	  step	   is	   the	   irreversible	  decarboxylation	  of	   the	  BCAA	  derived	  keto-­‐acids,	   forming	   their	   acyl-­‐CoA	  derivatives,	  which	   can	  be	   siphoned	  off	   at	   any	   time	   for	   free	  fatty	   acid	   synthesis,	   ketone	   production	   and	   other	   cellular	   functions.	   Abbreviations:	   α-­‐Ketoglutarate	   (αKG),	   Branched-­‐chain	   amino	   acid	   (BCAA),	   mitochondrial	   branched-­‐chain	  amino	  acid	  transferase	  (BCATm),	  Branched-­‐chain	  alpha	  keto-­‐acid	  dehydrogenase	  (BCKD).	  Figure	  modified	  from	  (She	  et	  al.,	  2013).	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Protein Phosphatase 2Cm (PP2Cm) 
 Although	  the	  inhibitory	  kinase	  (BDK)	  of	  BCKD	  has	  been	  known	  for	  more	  than	  three	  decades,	   the	   characterization	   and	   cloning	   of	   its	   activating	   phosphatase	   has	   remained	  elusive	  up	  until	  recently	  (Y	  Shimomura	  et	  al.,	  1990).	  Encoded	  by	  the	  PPM1K	  gene,	  protein	  phosphatase	  2Cm	  (PP2Cm)	  is	  a	  mitochondrial	  Ser/Thr	  phosphatase	   localized	   to	   the	  matrix,	   is	   a	  member	  of	   the	  protein	  phosphatase	  2C	  family,	  and	  is	  highly	  conserved	  among	  vertebrates	  (Lu,	  2007).	  PP2Cm	  has	  been	  shown	  to	  be	   essential	   in	   the	   following	   cell	   functions:	   development,	   cell	   survival,	   apoptosis	   and	  metabolism.	  However,	   this	   phosphatase	   is	   not	   ubiquitously	   expressed,	   the	   highest	   levels	  have	  been	  found	  in	  brain,	  heart,	  kidney	  and	  hepatic	  tissues,	  while	  being	  lowly	  expressed	  in	  skeletal	  muscle	  (M.	  Zhou	  et	  al.,	  2012).	  Additionally,	  a	   loss	  of	   function	  mutation	  of	  PP2Cm	  results	  in	  a	  mild	  phenotype	  of	  MSUD,	  typically	  witnessed	  in	  cases	  where	  BCKD	  is	  mutated	  (Oyarzabal	  et	  al.,	  2013).	  Using	   X-­‐ray	   crystallography	   PP2Cm	   structure	   has	   been	   identified	   by	  Wynn	   et	   al.,	  (2012),	   its	   notable	   feature,	   a	   10-­‐Ångstrom	   wide	   cleft,	   was	   determined	   to	   be	   the	  phosphatase’s	  active	  site.	  They	   further	  cloned	  PP2Cm	  and	   found	  that	   its	  activity	  requires	  the	  binding	  of	  two	  Mn2+	  ions,	  disruption	  of	  these	  binding	  sites	  results	  in	  enzyme	  inactivity	  (Wynn	   et	   al.,	   2012).	   Arg-­‐104	   within	   PP2Cm’s	   active	   site	   is	   essential	   to	   substrate	  recognition.	  When	  the	  Arg-­‐104	  is	  mutated	  to	  alanine,	  PP2Cm’s	  Km	  for	  the	  phosphorylated	  BCKD	  catalytic	  moiety	  increases	  60-­‐fold	  (Wynn,	  2012).	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Under	   conditions	   of	   reduced	   BCAA	   concentrations	   PP2Cm	   is	   transcriptionally	  downregulated	   (M.	   Zhou,	   2012),	   whereas	   BDK	   translation	   would	   consequently	   increase	  (Doering	  et	  al.,	  2000;	  Harris	  et	  al.,	  2001).	  The	  antagonism	  between	  these	  two	  enzymes	   is	  dynamically	   regulated	   by	   BCKA	   concentrations,	   where	   high	   BCKA	   concentrations	   up-­‐regulate	   PP2Cm	   activity	   towards	   BCKD,	   and	   down-­‐regulate	   BDK	   activity,	   and	   vice-­‐versa	  with	  respect	  to	  low	  BCKA	  concentrations	  (M.	  Zhou,	  2012).	  Impairments	   in	   BCAA	   catabolism	   are	   not	   limited	   to	   patients	   with	   MSUD	   related	  genetic	  defects.	   Impaired	  BCAA	  catabolism	   is	  also	  present	   in	   cases	  of	   ischemia	  and	  heart	  failure,	  resulting	  in	  high	  BCAA	  concentrations	  in	  myocardial	  tissue	  (Wang,	  2016;	  M.	  Zhou,	  2012).	   One	   of	   the	   first	   studies	   describing	   PP2Cm	   found	   that	   its	   levels	   decreases	   under	  myocardial	  stress	  (Lu,	  2007).	  Zhou	  et	  al.,	  (2012)	  suggested	  PP2Cm	  regulation	  may	  not	  be	  restricted	   to	   just	   myocardial	   stress,	   but	   by	   widespread	   oxidative	   stress,	   witnessed	   in	  obesity	  and	  type	  2	  diabetes.	  Zhou	  et	  al.,	  (2012)	  also	  found	  that	  PP2Cm	  expression	  is	  linked	  to	   nutrient	   availability,	   similarly	   to	   its	   counterpart	   BDK.	   However,	   to	   date,	   there	   is	   no	  information	   regarding	   the	   mechanisms	   regulating	   PP2Cm’s	   reduction	   following	   cardiac	  stress,	   albeit,	   research	   investigating	   PP2Cm’s	   function	   is	   growing.	   A	   study	   using	   mouse	  embryonic	   stem	   cells	   displaying	   PP2Cm	   deficiencies	   showed	   marked	   increases	   in	  superoxide	  and	  ROS	  production,	  and	  ectopic	  expression	  of	  PP2Cm	  returned	  their	  levels	  to	  baseline.	  	  Clearly,	  PP2Cm	  serves	  a	  role	  in	  managing	  oxidative	  stress,	  although	  further	  study	  is	  warranted	  to	  determine	  whether	  this	  is	  through	  direct	  or	  indirect	  mechanisms.	  However,	  PP2Cm’s	   role	   in	   skeletal	   muscle	   remains	   to	   be	   defined,	   as	   previously	   stated	   PP2Cm	  expression	   in	   skeletal	   muscle	   is	   relatively	   lower	   than	   in	   the	   myocardium.	   Therefore,	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research	  investigating	  PP2Cm	  is	  required	  to	  elucidate	  its	  physiological	  relevance	  in	  skeletal	  muscle	  metabolism.	  	  	  
Branched chain alpha-keto dehydrogenase kinase (BDK) 
	   BDK	   is	   a	   nuclear-­‐encoded	  mitochondrial	   protein	   kinase	   (Muller	  &	  Danner,	   2004).	  BDK’s	   kinase	   activity,	   phosphorylating	   serine	   293	   and	   serine	   303	   on	   BCKD’s	   E1-­‐alpha	  subunit,	  show	  that	  it	  indeed	  functions	  as	  a	  serine/threonine	  kinase.	  However,	  its	  sequence	  and	   some	   structural	   characteristics	   show	   it	   is	   more	   similar	   to	   histidine	   kinases,	   which	  would	  be	  debated	  during	  the	  early	  characterization	  of	  BDK.	  Later	  studies	  would	  show	  that	  BDK	   could	   not	   function	   as	   a	   histidine	   kinase	   for	   two	   reasons.	   One,	   the	   phosphorylation	  event	  on	  BCKD’s	  E1-­‐alpha	  subunit	  was	  not	  a	  result	  of	  histidine-­‐mediated	  phosphotransfer,	  as	  shown	  by	  Davies	  et	  al.,	  (1995)	  and	  two,	  the	  conserved	  histidine	  residue	  is	  centralized	  to	  BDK’s	  hydrophobic	  core,	  meaning	  it	  is	  inaccessible	  for	  histidine-­‐mediated	  phosphotransfer	  in	  the	  first	  place	  (Attwood,	  2013;	  Davie	  et	  al.,	  1995).	  	  	  Rat	  BDK	  exists	  in	  a	  dimer-­‐tetramer	  equilibrium,	  although	  characterization	  using	  X-­‐ray	   crystallography	   yields	   only	   the	   dimer	   organization,	   while	   the	   relevance	   of	   BDK	  tetramerization	   is	  unknown	  (Machius	  et	  al.,	  2001).	  The	   two	  domains	  of	  BDK	  (K	  and	  B	  as	  denoted	   by	   Machius	   et	   al.,	   (2001))	   each	   contain	   unique	   features.	   The	   K	   domain	   shares	  structural	   homology	   to	   protein	   histidine	   kinases	   in	   its	   nucleotide-­‐binding	   domain,	  while	  the	  B	  domain	  has	  a	  structure	  containing	  a	  four-­‐helix	  bundle	  domain,	  which	  appear	  in	  two-­‐component	   signal	   transduction	   (TCST)	   systems	   (Machius,	   2001).	   A	   TCST	   system	  coordinates	   stimulus-­‐response	   signals	   in	   a	   cell,	   typically	   in	   response	   to	   changing	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environmental	  conditions,	  and	   is	   the	  principle	  signalling	  mechanism	   in	  bacteria	   (Stock	  et	  al.,	  2000).	  	  BDK’s	   kinase	   activity	   requires	   two	   cofactors	  magnesium	  and	  potassium	   (Machius,	  2001).	  	  Additionally,	  in	  its	  inactive	  state	  BDK	  is	  ADP-­‐loaded,	  which	  needs	  to	  be	  removed	  for	  its	   full	   activation.	   It	   is	   thought	   that	   the	   lipoyl-­‐bearing	  domain	  of	   E2	   (a	   subunit	   of	  BCKD)	  could	  facilitate	  its	  removal	  rendering	  it	  active	  (Machius,	  2001).	  	  Mitochondrial	   extracts	   from	   C57BL/6	  mice	   displayed	   high	   levels	   of	   expression	   of	  BDK	   in	   skeletal	  muscle,	   and	   at	   lower	   levels	   in	   kidney,	   brain,	   and	   liver,	   respectively.	  BDK	  mRNA	  levels	  were	  not	  expressed	  in	  parallel	  with	  protein	  expression,	  suggesting	  that	  there	  are	  additional	  regulatory	  factors	  controlling	  translation	  (Muller,	  2004).	  Muller	  et	  al.,	  (2004)	  went	   on	   to	   define	   an	   upstream	   open	   reading	   frame	  within	   the	   5’-­‐untranslated	   region	   of	  BDK	  mRNA,	  which	  contains	  elements	  that	  negatively	  regulate	  BDK	  translation.	  Once	   expressed	  BDK	   is	   localized	   to	   the	  mitochondrial	  matrix	  where	   its	   activity	   is	  regulated	   via	   allosteric	   inhibition.	   The	   branched-­‐chain	   alpha	   keto-­‐acids	   (BCKAs)	   in	  particular	  are	  the	  most	  potent	  endogenous	  BDK	  inhibitors.	  A	  study	  conducted	  by	  Paxton	  &	  Harris	   (1984)	  using	   a	  perfused	   rat	  heart	  model,	   established	   the	  Km	   values	  of	   the	  BCKAs	  towards	  BDK,	  their	  concentrations	  were	  as	   follows	  for	  α-­‐ketoisocaproate	  (KIC),	  α-­‐keto	  ß-­‐methylvalerate	  (KMV),	  and	  ketoisovalerate	  (KIV),	  70μM,	  100μM,	  and	  250μM,	  respectively	  (Paxton	  &	  Harris,	  1984).	  Exogenous	  inhibitors	  of	  the	  BDK	  complex	  do	  exist,	  although	  KIC’s	  affinity	   for	   BDK	   seems	   to	   be	   greater	   than	   most	   of	   them.	   Therefore,	   reducing	   the	  concentrations	  of	  BCKAs,	  as	  would	  be	   the	  case	  under	  protein	  restriction,	   should	   increase	  BDK	  activity,	  subsequently	  decreasing	  BCKD	  activity.	  Evidence	  supporting	  this	  assumption	  showed	   that	   rats	   on	   a	   low	  protein	   diet	   had	   increased	  BDK	   activity	   in	   liver	   extracts;	   this	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increase	  is	  thought	  to	  be	  facilitated	  through	  the	  increased	  expression	  of	  BDK,	  and	  thereby,	  an	  increase	  in	  its	  association	  with	  BCKD	  (Popov	  et	  al.,	  1995).	  Conversely,	  high	  protein	  diets	  decrease	   the	   expression	  of	  BDK	   (Lynch,	   2014a).	  Altogether,	  BDK	  expression	   is	   regulated	  translationally,	  in	  a	  tissue-­‐dependent	  manner,	  while	  its	  activity	  is	  under	  tight	  control	  of	  the	  BCAA	  derived	  keto-­‐acids.	  	   Recent	   evidence	   has	   suggested	   that	   yet	   another	   layer	   of	   complexity	   exists	   in	  regulating	   the	   function	   of	   the	   BCAA	   catabolic	   pathway.	   BCATm	   and	   BCKD	   have	   been	  introduced	   in	   this	   literature	   review	   as	   two	   distinctly	   separate	   enzymes,	   each	   having	   a	  unique	  primary	  function.	  One	  study	  by	  Islam	  et	  al.,	  (2007)	  challenges	  this	  assertion	  based	  on	   what	   they	   believe	   occurs	   between	   these	   two	   complexes.	   The	   term	   supramolecular	  complex,	  or	  metabolon,	  refers	  to	  the	  physical	  interaction	  between	  the	  two	  complexes.	  The	  significance	   of	   this	   supramolecular	   complex-­‐interaction	   resides	   in	   the	   efficiency	   of	  substrate	   channeling	   from	   one	   complex	   to	   the	   other.	   The	   physical	   interaction	   occurs	  between	   the	   E1-­‐alpha	   subunit	   of	   BCKD	   and	   the	   PLP-­‐linked	   BCATm,	   PLP	   is	   the	   BCATm	  cofactor	   pyridoxal	   5-­‐phosphate	   (Islam	   et	   al.,	   2007),	   ultimately	   promoting	   the	   efficient	  transfer	   of	   BCKAs.	   Experiments	   completed	   by	   Islam	   et	   al.,	   (2007)	   observed	   a	   12-­‐fold	  increase	   in	   the	   catalytic	   E1-­‐alpha	   BCKD	   subunit	   activity,	   when	   in	   the	   presence	   of	   PLP-­‐hBCATm.	   Two	   factors	   promote	   the	   dissociation	   of	   the	  metabolon,	   the	   first	   being	   a	   high	  phosphorylation	  status	  of	  BCKD,	  and	  second,	  the	  local	  rise	  in	  the	  NADH/NAD+	  ratio	  (Islam,	  2007).	  Both	  of	   these	   factors	  would	  be	  present	  under	   conditions	   that	   reduce	   intracellular	  BCAA	  levels,	  such	  as	  protein	  restriction	  or	  fasting.	  This	  pioneering	  study	  has	  improved	  our	  understanding	   of	   the	   complexities	   involved	   within	   the	   BCAA	   catabolic	   pathway	   and	   a	  better	  understanding	  of	  the	  kinetics	  of	  BCAA	  catabolism.	  
	  41	  
BCAA metabolites effects on skeletal muscle anabolism Two	   metabolites	   of	   leucine	   metabolism	   are	   at	   the	   forefront	   of	   BCAA	   mediated	  anabolism	  research.	  These	  are	  β-­‐hydroxy	  β-­‐methylbutyrate	  (HMB)	  and	  α-­‐ketoisocaproate	  (KIC).	  Similar	  to	  leucine,	  both	  KIC	  (Yoshizawa	  et	  al.,	  2004)	  and	  HMB	  (Pimentel	  et	  al.,	  2011)	  are	   able	   to	   activate	   mTORC1,	   based	   on	   the	   increased	   phosphorylation	   of	   mTORC1	  substrates,	   p70S6K1	   and	   4E-­‐BP1.	   KIC	   has	   been	   also	   shown	   to	   promote	   MPS	   in	   piglets	  (Escobar	   et	   al.,	   2010).	   However,	   the	   anabolic	   effects	   of	   HMB	   have	   received	   greater	  attention,	   showing	   that	   supplementation	   in	   rats	   and	   piglets	   has	   been	   found	   to	   stimulate	  muscle	   protein	   synthesis,	   reduce	   muscle	   protein	   breakdown	   (Gerlinger-­‐Romero	   et	   al.,	  2017;	  Giron	  et	  al.,	  2016;	  Noh	  et	  al.,	  2014)	  and	  increase	  satellite	  cell	  proliferation	  	  (Kao	  et	  al.,	  2016).	   A	   controversy	   regarding	   KIC	   studies	   and	   its	   ability	   to	   stimulate	   muscle	   protein	  synthesis	   questions	  whether	   KIC	   is	   having	   this	   effect,	   or	   if	   it	   is	  merely	   the	   result	   of	   KIC	  being	  transaminated	  back	  into	  leucine	  (Moghei	  et	  al.,	  2016).	  However,	  one	  study	  using	  rats	  showed	   that	   KIC	   can	   increase	   protein	   synthesis	   without	   changing	   intracellular	   leucine	  concentrations	  (Chua	  et	  al.,	  1979).	  Currently,	  the	  mechanism	  of	  HMB-­‐mediated	  anabolism	  remains	  poorly	  understood.	  HMB	  has	  recently	  been	  shown	  to	  dampen	  the	  fasting	  induced	  rise	  in	  atrogenes,	  specifically,	  Bbox32	   &	   Trim63,	   possibly	   explaining	   the	   anti-­‐catabolic	   effects	   of	   HMB	   administration	  (Gerlinger-­‐Romero,	   2017).	   Furthermore,	   research	   has	   indicated	   that	   HMB	   reverses	  glucocorticoid-­‐induced	  myopathies	  through	  the	  inhibition	  of	  FOXO1	  nuclear	  translocation,	  ultimately	   decreasing	   ubiquitin	   proteasome	   system	   (UPS)	   responses,	   reversing	   losses	   in	  grip	  strength,	  muscle	  mass,	  and	  muscle	  damage	  (Noh,	  2014).	  Not	  only	  does	  HMB	  stimulate	  global	  protein	  synthesis,	  its	  effects	  on	  muscle	  protein	  synthesis	  appear	  to	  be	  greater	  than	  in	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visceral	   tissues	   (Kao,	   2016).	   However,	   in	   this	   study	   HMB	   supplementation	   appeared	   to	  have	  no	  impact	  on	  the	  autophagy-­‐lysosomal	  or	  ubiquitin-­‐proteasome	  pathways;	  this	  could	  possibly	  be	  explained	  due	   to	   the	  short-­‐time	  period	  of	   the	  study,	   lasting	  only	  26.25	  hours	  (Kao,	  2016).	  	  Clearly	   some	   contradictory	   evidence	   exists,	   whether	   or	   not	   KIC	   and	   HMB	  contributes	   to	   both	   sides	   of	   the	   protein	   balance	   equation	   (increase:	   muscle	   protein	  synthesis,	   decrease:	  muscle	   protein	  breakdown).	   Therefore,	   additional	   research	  needs	   to	  be	  completed,	  however,	  at	  this	  time	  the	  majority	  of	  research	  emphasizes	  their	  anabolic	  and	  anti-­‐catabolic	  effects	  on	  SM.	  	  
BCAAs	  and	  their	  metabolites	  effects	  on	  skeletal	  muscle	  differentiation	  	  	   There	  have	  been	  relatively	  few	  studies	  investigating	  the	  effects	  of	  BCAAs	  on	  skeletal	  muscle	   differentiation.	   Much	   of	   the	   research,	   as	   previously	   alluded	   to,	   has	   been	  investigated	   in	   existing	  muscle,	   centralized	   around	   the	  hypertrophic	   responses	  mediated	  by	   the	   BCAAs.	   One	   recent	   study	   has	   investigated	   the	   effects	   of	   varying	   BCAA	   ratios	   on	  C2C12	   proliferation	   and	   differentiation.	   (Duan	   et	   al.,	   2017).	   The	   authors	   found	   that	   an	  optimal	   ratio	  of	  BCAAs	   (Leucine	   -­‐	   1;	  Valine	   -­‐	   0.25;	   Isoleucine	   -­‐	   0.25)	   stimulated	  multiple	  myogenic	   regulatory	   factors	   in	   both	   the	   proliferative	   and	   differentiation	   phases.	   The	  optimal	   BCAA	   ratio	   shifted	   more	   cells	   into	   S-­‐phase,	   when	   compared	   to	   the	   two	   other	  experimental	  BCAA	  ratio	  groups	   (No	  BCAAs	   -­‐	  decrease	  20%,	  1:1:1	  BCAA	  ratio	   -­‐	  decrease	  10%)	  (Duan,	  2017).	  Gene	  expression	  of	  mTOR	  related	  genes	  and	  of	  MRFs	  were	  generally	  upregulated	  during	  both	  proliferation	  and	  differentiation	  phases	  under	  the	  optimal	  BCAA	  ratio	   condition,	  where	  MuRF1	  and	  MAFbx	  gene	  expression	  was	  generally	  downregulated	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(Duan,	  2017).	  This	  new	  data	  supporting	  the	  positive	  effects	  that	  an	  optimal	  ratio	  of	  BCAAs	  has	   on	   muscle	   cell	   proliferation	   and	   differentiation,	   provides	   novel	   insight	   into	   BCAAs	  capacity	  to	  improve	  muscle	  regeneration.	  Surprisingly,	  this	  is	  the	  only	  study	  to	  date,	  to	  our	  knowledge,	   which	   looks	   explicitly	   at	   muscle	   cell	   differentiation	   in	   response	   to	   BCAA	  manipulation.	  Research	  investigating	  BCAA	  catabolism	  and	  its	  effects	  on	  muscle	  cell	  differentiation	  are	  still	  in	  its	  infancy.	  With	  that	  being	  said,	  the	  combination	  of	  recent	  research	  with	  older	  studies	   novel	   findings	   may	   be	   more	   pertinent	   now	   than	   they	   once	   were.	   Two	   studies	  investigating	   the	   effects	   of	   a	   hyperlipidemic	   correcting	   drug,	   chlorophenoxyisobutyrate,	  otherwise	  known	  as	  clofibrate,	   found	  cases	  where	   it	  was	  causing	  what	   they	  described	  as	  
muscular	  syndrome	  (Paul	  &	  Adibi,	  1979;	  Teräväinen	  et	  al.,	  1977)	  The	  condition	  exhibited	  signs	   and	   symptoms	   of	  muscle	   soreness,	   weakness,	   and	   tenderness,	   accompanied	   by	   an	  increase	  in	  serum	  creatine	  phosphokinase	  (indicative	  of	  muscle	  damage)	  and	  transaminase	  activity.	   Additionally,	   it	   was	   found	   that	   a	   2-­‐week	   clofibrate	   treatment	   in	   rats	   elicited	  multiple	   metabolic	   changes	   including:	   a	   reduction	   in	   gastrocnemius	   weight	   and	   protein	  content,	  a	  decrease	  (40%)	  in	  fasting	  insulin,	  an	  increase	  in	  liver	  mass	  and	  protein	  content,	  and	  finally,	  a	  reduction	  in	  glycogen	  stores	  in	  both	  liver	  and	  gastrocnemius	  (Paul,	  1979).	  A	  few	  years	  later	  another	  group	  would	  define	  the	  endogenous	  inhibitor	  of	  the	  BCKD	  complex,	  BDK,	   which	   is	   now	   known	   to	   be	   directly	   inhibited	   by	   clofibrate	   (Harris	   et	   al.,	   1982).	  Similarly	   to	   the	   leucine	  metabolite,	  KIC,	   clofibrate	   inhibits	   the	   interaction	  between	  BCKD	  and	   BDK,	   which	   consequently	   upregulates	   the	   BCAA	   catabolic	   pathway	   (Yoshiharu	  Shimomura	   et	   al.,	   2006).	   Shimomura	   et	   al.,	   (2006)	  postulates	   that	   the	   clofibrate	   induced	  myopathies	   may	   be	   a	   result	   of	   an	   accelerated	   BCAA	   catabolic	   pathway.	   The	   well-­‐
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established	   effects	   that	   BCAAs,	   particularly	   leucine,	   have	   on	   MPS,	   as	   well	   as	   leucine’s	  insulinotropic	   effects,	   account	   well	   for	   the	   signs	   &	   symptoms	   of	   clofibrate	   induced	   -­‐	  
muscular	  syndrome.	  	  
Research	  Objectives	  	  	   The	  process	  of	  skeletal	  muscle	  formation	  is	  immensely	  complex,	  and	  is	  consequently	  subject	   to	   a	   vast	   number	   of	   complications	   along	   its	   many	   checkpoints.	   Through	   the	  assessment	  of	  some	  of	  these	  checkpoints	  our	  study	  will	  explore	  the	  role	  the	  BCAA	  catabolic	  pathway	  serves	  in	  the	  process	  of	  muscle	  cell	  differentiation.	  It	  has	  been	  shown	  previously	  in	  our	  lab	  that	  the	  two	  main	  catabolic	  enzymes	  of	  the	  BCAA	  catabolic	  pathway	  are	  essential	  to	  the	  proper	  progression	  of	  differentiation.	  If	  either	  one	  of	  the	  enzymes	  are	  removed	  from	  muscle	  cells,	  myotube	  formation	  is	  absent.	  Therefore,	  this	  study	  will	  explore	  how	  the	  flux	  through	   this	  pathway	  changes	  during	  differentiation,	   and	  how	  altering	   this	   catabolic	   flux	  will	  affect	  differentiation.	  	  	  	  	  	   My	  study’s	  goal	  was	  to	  determine	  the	  regulatory	  role	  BCKD	  has	  during	  skeletal	  muscle	  differentiation.	   Much	   of	   the	   existing	   literature	   has	   investigated	   the	   anabolic	   responses	  elicited	  by	  the	  branched-­‐chain	  amino	  acids	  in	  mature	  skeletal	  muscle.	  However,	  much	  less	  research	   has	   been	   done	   to	   elucidate	   how	   this	   subset	   of	   amino	   acids	   regulates	   skeletal	  muscle	  differentiation	  in	  vitro.	  My	  study	  aims	  to:	  i. Measure	   the	   expression	   of	   enzymes	   responsible	   for	   regulating	   BCKD	   activity,	   and	  thus,	   the	   activity	   of	   entire	   BCAA	   catabolic	   pathway,	   during	   muscle	   cell	  differentiation.	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ii. Determine	   how	   the	   activity	   of	   the	   rate-­‐limiting	   enzyme	   of	   the	   BCAA	   catabolic	  pathway	  (BCKD)	  changes	  during	  muscle	  cell	  differentiation.	  iii. Determine	  whether	  altering	  the	  activity	  of	  BCKD	  during	  muscle	  cell	  differentiation	  affects	   myotube	   formation,	   and	   which	   signalling	   mechanisms	   are	   regulating	   this	  change?	  iv. Evaluate	   if	   supplementing	   BCAA-­‐derived	   metabolic	   products,	   of	   which	   BCKD	  regulates	  endogenously,	   can	  rescue	  muscle	  cell	  differentiation	  under	  conditions	  of	  BCKD	  depletion?	  
Study	  Hypotheses	  
	   i. That	   the	   kinase	   and	   phosphatase	   responsible	   for	   inhibiting	   and	   promoting	   BCKD	  activity,	  respectively,	  will	  change	  during	  differentiation.	  	  ii. That	  BCKD	  activity	  will	  increase	  similarly	  in	  parallel	  with	  the	  levels	  of	  the	  catalytic	  subunit	  of	  BCKD	  during	  differentiation.	  iii. Depleting	  myoblasts	  of	  BDK	  will	  positively	  affect	  muscle	  cell	  differentiation.	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Abstract	  	   Branched-­‐chain	   amino	   acids	   and	   their	   metabolites	   have	   been	   shown	   to	   possess	  anabolic-­‐signalling	   characteristics	   in	   existing	   skeletal	   muscle.	   They	   have	   also	   displayed	  pro-­‐myogenic	   characteristics	   in	   both	   in	   vitro	   and	   in	   vivo.	   In	   our	   lab	  we	   have	   shown,	   via	  siRNA	   mediated	   depletion	   studies,	   that	   the	   two	   main	   catabolic	   enzymes	   of	   the	   BCAA	  catabolic	  pathway	  are	  essential	  to	  successful	  L6	  muscle	  cell	  differentiation.	  In	  this	  current	  study	   we	   have	  modified	   an	   assay	   that	   measures	   BCKD	   (the	   rate-­‐limiting	   enzyme	   in	   the	  BCAA	  catabolic	  pathway)	  activity,	  and	  for	  the	  first	  time	  measured	  it	  during	  L6	  muscle	  cell	  differentiation.	  It	  was	  found	  that	  BCKD	  activity	  decreases	  significantly	  following	  the	  onset	  of	  differentiation	  (p	  <	  0.01).	  Additionally,	  we	  have	  shown	  that	  increasing	  the	  flux	  through	  the	  BCAA	  catabolic	  pathway	  via	  depletion	  of	  the	  negative	  regulator	  of	  BCKD	  activity,	  BDK,	  augmented	   differentiation	   (p	   <	   0.05).	   BDK	   depletion	   has	   also	   caused	   a	   trend	   for	   AKT	  activation	   to	   increase	   at	   the	   onset	   of	   differentiation	   when	   compared	   to	   controls.	   These	  results	   suggest	   that	   an	   intact	   BCAA	   catabolic	   pathway	   is	   required	   for	   muscle	   cell	  differentiation,	   and	   further	   research	   is	   warranted	   into	   accessing	   the	   downstream	  metabolites	  of	  the	  pathway,	  and	  how	  they	  may	  regulate	  skeletal	  muscle	  protein	  and	  energy	  metabolism.	  	  
Introduction	  	   Preventive	  medicine	  and	  therapy	  is	  becoming	  commonplace	  when	  discussing	  health	  care.	   One	   of	   the	   largest	   preventative	   and	   modifiable	   factors	   effecting	   health	   is	   dietary	  nutrition.	  Westernized	  countries	  especially,	  are	  experiencing	  an	  obesity	  epidemic	   leading	  to	  an	  increase	  in	  mortality	  and	  morbidities,	  adding	  to	  the	  ever-­‐increasing	  economic	  burden	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of	  an	  aging	  population	  (Dietz,	  2015;	  Hruby	  &	  Hu,	  2015;	  Trasande	  &	  Elbel,	  2012).	  Lifestyle	  choices	   centered	   on	   physical	   activity	   and	   nutrition	   can	   modify	   the	   risk	   of	   developing	  chronic,	  non-­‐communicable	  diseases	  such	  as	  (i)	  cardiovascular	  disease	  (Konstantinidou	  et	  al.,	  2014)	  ,	  (ii)	  T2DM	  (Ley	  et	  al.,	  2014),	  (iii)	  and	  most	  cancers	  (Mayne	  et	  al.,	  2016).	  Many	  of	  the	  benefits	  derived	  from	  physical	  activity	  can	  be	  traced	  back	  to	  skeletal	  muscle	  health	  and	  function.	  The	  principal	  reasons	  skeletal	  muscle	  is	  so	  important	  to	  metabolic	  health	  are	  its	  roles	   in	   energy	   and	   protein	   metabolism.	   In	   fact,	   skeletal	   muscle	   is	   responsible	   for	   the	  majority	  (80%)	  of	  insulin-­‐stimulate	  glucose	  uptake	  in	  the	  body	  (Olefsky,	  1999)	  and	  is	  the	  body’s	   main	   reservoir	   of	   amino	   acids	   (Argilés	   et	   al.,	   2016).	   Metabolic	   dysfunction	   is	  primarily	  associated	  with	  a	  reduction	  in	  insulin	  sensitivity	  and	  having	  greater	  muscle	  mass	  is	  inversely	  associated	  with	  insulin	  resistance	  and	  prediabetes	  (Srikanthan	  &	  Karlamangla,	  2011).	  Therefore,	  nutritional	   interventions	   that	  aim	  to	   increase	  muscle	  mass	  are	  of	  great	  importance	  to	  metabolic	  health	  and	  essential	  to	  minimizing	  co-­‐morbidities.	  Branched-­‐chain	  amino	  acids	  are	  at	   the	   forefront	  of	  skeletal	  muscle	  metabolism	  research,	  because	  of	   their	  role	   in	   skeletal	   muscle	   anabolism,	   and	   because	   their	   catabolism	   is	   dysregulated	   in	  metabolic	  diseases	  like	  T2DM.	  The	  particular	  focus	  on	  skeletal	  muscle	  metabolism	  is	  due	  to	  the	  uniqueness	  of	  the	  BCAA	  catabolic	  pathway	  that	  is	  primarily	  localized	  to	  skeletal	  muscle.	  The	  metabolites	   of	   BCAA	  metabolism	  have	   also	   garnered	   attention	   due	   to	   their	   anabolic	  effects	   in	  existing	  skeletal	  muscle,	  but	   their	  ability	   to	  effect	  muscle	   regeneration	  remains	  much	  less	  well	  understood.	  	  Thus,	  determining	  the	  contribution	  of	  BCAA	  catabolism	  and	  its	  metabolites	   to	   the	   enhancement	   of	   muscle	   regeneration,	   and	   consequently	   the	  maintenance	  of	  muscle	  mass	  are	  of	  paramount	  importance	  to	  the	  prevention	  of	  metabolic	  diseases.	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Materials	  and	  Methods	  	  
Cell culture  	   Using	  either	  L6	  or	  C2C12	  cell	  lines	  from	  American	  Type	  Culture	  Collection,	  cells	  were	  cultured	  in	  either	  10cm,	  6-­‐well,	  or	  12-­‐well	  plates	  using	  either	  α–modified	  MEM	  (AMEM)	  for	  L6	  cells,	  or	  Dulbecco's	  Modified	  Eagle's	  Medium	  (DMEM)	  for	  C2C12	  cells.	  	  Growth	  medium	  (GM)	   was	   made	   by	   supplementing	   AMEM	   or	   DMEM	   with	   10%	   FBS	   and	   1%	  antibiotic/antimycotic	   agents:	   (FBS	   -­‐	   Gibco	   #10082147:	   antibiotic/antimycotic	   -­‐	   Wisent	  #450-­‐115-­‐EL).	   To	   ensure	   cell	   retained	   the	   ability	   to	   differentiate	   properly	   cells	   were	  passed	  every	  second	  day	  upon	  reaching	  70%	  confluency.	  
 
mRNA isolation – BDK	  and	  PP2Cm	  experiments L6	   myoblasts	   were	   seeded	   in	   10cm	   plates	   and	   differentiated	   for	   5	   days.	  Commencing	  on	  day	  0	  of	  differentiation	  RNA	  was	  isolated	  from	  cells	  using	  TRIzol	  Reagent	  and	   PureLink	   RNA	   Mini	   Kit	   (Life	   Technologies:	   #12183018A)	   following	   manufacturer’s	  instructions.	   Following	   RNA	   isolation,	   RNA	   integrity	   (A260/280	   –	   1.7-­‐2.0)	   and	  concentration	   was	   established	   using	   Smart	   SpecTM	   Plus	   (Bio-­‐Rad	   Laboratories	   Ltd	   Life	  Science	   Group).	   RNA	   samples	   were	   then	   stored	   at	   -­‐80°C.	   cDNA	   was	   synthesized	   using	  iScript	   Advanced	   cDNA	   Synthesis	   Kit	   (Bio-­‐Rad	   Laboratories	   #172-­‐5038)	   following	  manufacturer’s	   instructions.	   Real-­‐time	   (RT)	   Polymerase	   Chain	   Reaction	   (PCR)	   was	  completed	   using	   SsoAdvanced™	   Universal	   SYBR®	   Green	   Supermix	   (Bio-­‐Rad	   #1725271)	  using	   the	   Real-­‐Time	   PCR	   Detection	   System	   (Bio-­‐Rad	   CFX96™).	   Data	   was	   then	   analyzed	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using	   Bio-­‐Rad	   -­‐	   CFX	  Manager™	   software	   using	   the	   2-­‐ΔΔCT	  method.	   HPRT	   [Forward:	   5’-­‐GCTTTCCTTGGTCAAGCAC-­‐3’	  -­‐	  Reverse:	  5’-­‐TCCAACAAAGTCTGGCCTGA-­‐3’]	  
Gene knockdown – BDK	  and	  BCKD	  Knockdown	  Experiments Knockdown	  experiments	  utilized	  siRNA	  oligonucleotides	  for	  target	  genes,	  using	  the	  reverse	   transfection	  method.	   L6	   or	   C2C12	  myoblasts	  were	   seeded	   (2.5	   x	   105	   cells/well)	  into	   6-­‐well	   culture	   plates.	   After	   adding	   cells	   to	   the	   wells	   they	   were	   incubated	   in	   either	  control	  transfection	  medium,	  or	  transfection	  medium	  containing	  siRNA	  targeted	  towards	  a	  specific	   gene	   of	   interest.	   Control	   medium	   contained	   scramble	   oligonucleotides	   (Sigma-­‐Aldrich:	   #SIC001)	   (final	   concentration	   at	   30nM/well),	   lipofectamine	   RNAiMAX	   (Life	  Technologies	   #13778150),	   Opti-­‐MEM	   (Life	   Technologies	   #31985070),	   and	   1ml	   of	  antibiotic/antimycotic	   free	   medium	   (10%	   FBS:	   AMEM/DMEM),	   at	   ratios	   according	   to	  manufacturers	  instructions.	  Cells	  were	  transfected	  with	  the	  above	  constituents	  at	  the	  same	  ratios,	  replacing	  scramble	  oligonucleotides	  with	  BDK	  oligonucleotides	  (Sigma:	  NM_019244	  -­‐	  SASIRn01_00080842	  -­‐	  CUAUGCAUGGCUUUGGCUU)	  (final	  concentration	  at	  30nM/well)	  or	  BCKD	   oligonucleotides	   (Sigma:	   NM_012782	   -­‐	   SASI_Rn01_00064150	   -­‐	  CAGAUCGUGAUCUGUUACU)	   (final	   concentration	  at	  30nM/well).	  Twenty-­‐four	  hours	  post-­‐transfection,	   1ml	   of	   medium	   (10%FBS,	   1%	   antibiotic/antimycotic:	   AMEM/DMEM)	   was	  added	  to	  each	  well.	  Following	  an	  additional	  24	  hours	  period,	  cells	  were	  either	  shifted	  into	  differentiation	  medium	   (2%	   horse	   serum,	   1%	   antibiotic/antimycotic:	   AMEM/DMEM),	   or	  harvested	  using	  a	  lysis	  buffer,	  as	  previously	  described.	  	  	  
BCKD Activity Assay	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The	   branched-­‐chain	   alpha-­‐keto	   dehydrogenase	   (BCKD)	   complex	   oversees	   the	  irreversible	  oxidative	  decarboxylation	  of	  the	  BCAA	  derived	  keto-­‐acids	  into	  their	  respective	  Acyl-­‐coA	  derivatives.	  Cells	  were	  seeded	  with	  either	  105	  x	  1.5	  –	  2.5	  L6	  myoblasts,	  in	  12,	  or	  6-­‐well	  cell	  culture	  plates,	  respectively.	  The	  resultant	  CO2	  given	  off	  via	  BCKD’s	  decarboxylation	  activity	   towards	   the	  keto-­‐acid	  derived	   from	  1-­‐14C	   labelled	  valine	   (American	  Radiolabeled	  Chemicals	  #ARC	  0277-­‐50	  µCi)	   is	   collected	  on	   	   [2M]	  NaOH	  soaked	   filter	  paper	  wicks.	  The	  now	  radiolabelled	  bicarbonate	  on	  the	  filter	  paper	  wicks	  is	  inserted	  into	  20ml	  scintillation	  vials	   (Perkin-­‐Elmer	   #6008118)	   containing	   3.5ml	   of	   scintillation	   fluid	   (Ecolite+	   -­‐	   MP	  Biomedicals	   #01882475).	   The	   wick	   containing	   vials	   were	   then	   subjected	   to	   radiation	  counting	   (Tri-­‐Carb	   Liquid	   Scintillation	   Counter),	   equated	   to	   protein	   content	   (Pierce	   BCA	  Protein	  Assay	  Kit	  -­‐	  Thermo	  Scientific	  #23225),	  and	  expressed	  as	  relative	  values	  of	  counts-­‐per-­‐minute	  (CPM)/	  μg	  of	  protein.	  The	  assay	  development	  went	  through	  three	  generations	  of	  testing,	  with	  the	  third	  being	  the	  final	  version.	  The	  second-­‐generation	  assay	  was	  used	  for	  the	   BCKD	   activity	   during	   differentiation	   experiments	   (Fig	   2-­‐4).	   The	   second-­‐generation	  assay	   was	   also	   used	   for	   the	   first	   two	   BDK	   knockdown	   experiments	   measuring	   BCKD	  activity	  (Fig	  2-­‐5a),	  while	  the	  third	  generation	  was	  used	  for	  the	  remaining	  BDK	  knockdown	  experiments	   (Fig	   2-­‐5b).	   Details	   of	   the	   assay	   development	   can	   be	   found	   in	   the	   results	  section.	  
 
Harvesting Cells  Cells	  were	  harvested	  with	  50μl	   or	   100μl	   of	   lysis	   buffer,	  which	  was	   added	   to	   each	  well	   in	  experiments	  using	  12	  or	  6-­‐well	  plates,	   respectively.	  All	  experiments	   followed	  this	  harvesting	  method,	  with	  the	  exception	  of	  the	  mRNA	  experiments.	  Lysis	  Buffer	  formulation	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(diluting	  in	  ddH2O)(Final	  Concentrations):	  1mM	  	  ethylenediaminetetraacetic	  acid	  (EDTA)	  ,	  	  2%	   sodium	   dodecyl	   sulfate	   (SDS),	   	   25	  mM	   Tris-­‐HCl	   pH	   7.5,	   10	   μl/ml	   protease	   inhibitor	  cocktail	   (Sigma	  #P8340),10	  μl/ml	   phosphatase	   inhibitor	   cocktail	   (Sigma	  #P5726),	   1	  mM	  dithiothreitol	   (DTT).	   Cells	   were	   then	   collected	   from	   the	   wells	   using	   a	   cell	   scraper.	   The	  lysate	  was	  then	  passed	  up	  and	  down	  to	  lyse	  the	  cell	  membranes	  using	  a	  1-­‐ml	  syringe	  fitted	  with	  a	  26-­‐guage	  needle.	  Cell	  Lysates	  were	  immediately	  put	  on	  ice	  and	  stored	  at	  -­‐20°C	  until	  used	  for	  analysis.	  
Western blotting Following	   sample	   collection,	   protein	   concentration	   was	   determined	   using	   Pierce	  BCA	   Protein	   Assay	   Kit	   (Thermo	   Scientific	   #23225).	   Samples	   were	   then	   mixed	   with	   4x	  Laemmli	  loading	  buffer	  at	  a	  ratio	  of	  3:1	  (sample:	  loading	  buffer).	  Equal	  amounts	  of	  protein	  were	   boiled	   for	   5	   minutes,	   vortexed,	   and	   then	   loaded	   into	   10%	   or	   15%	   SDS-­‐page	   gels,	  depending	   upon	   proteins	   to	   be	   blotted.	   Following	   electrophoresis,	   proteins	   were	  transferred	   to	   PVDF	  membranes	   overnight	   at	   4°C.	   Following	   transfer,	   membranes	   were	  blocked	  in	  5%	  non-­‐fat	  milk	  for	  1	  hour	  at	  room	  temperature,	  and	  then	  rinsed	  3x	  5-­‐minutes	  in	  TBST.	  Membranes	  were	  then	  incubated	  in	  primary	  antibody	  (diluted	  in	  2.5%,	  non-­‐sterile	  bovine	   serum	   albumin)	   overnight	   at	   4°C.	   The	   next	   day	   membranes	   were	   rinsed	   3	   x	   5-­‐minute	   in	   TBST,	   then	   incubated	   with	   either	   HRP-­‐conjugated	   anti-­‐rabbit	   or	   mouse	  secondary	  antibody	  diluted	  in	  5%	  non-­‐fat	  milk	  for	  3	  hours	  at	  room	  temperature.	  Following	  an	   additional	   3	   x	   5-­‐minute	   washes	   in	   TBST,	   membranes	   were	   incubated	   in	   HRP	  chemiluminescent	   substrate	   (Millipore	   #WBKLS0500)	   for	   5	   minutes.	   Luminescence	   was	  then	  obtained	  using	  Bio-­‐Rad	  ChemiDoc	  MP	   imager,	   and	  signals	  were	  analyzed	  using	  Bio-­‐Rad:	  Image	  Lab	  5.2	  software.	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BCKD knockdown supplemented with BCKD metabolic products 	   To	   assess	   the	   effects	   of	   reinstituting	   the	   downstream	  metabolites	   of	   BCKD	   under	  BCKD	  depleted	  conditions	  on	  muscle	  cell	  differentiation,	  L6	  muscle	  cells	  (2.5	  x	  105)	  were	  seeded	   in	   6-­‐well	   culture	   plates	   the	   same	   day	   as	   transfection.	   The	   transfection	   medium	  contained	   lipofectamine	   RNAiMAX	   (Life	   Technologies	   313778150)	   +	   Opti-­‐MEM	   (Life	  Technologies	  #31985070)	  +	  1ml	  /well	  of	  antibiotic	   free	  GM	  (AMEM	  medium	  +	  10%	  FBS)	  and	  either	  scrambled	  oligonucleotides	  (Sigma-­‐Aldrich:	  #SIC001),	  or	  BCKD	  oligonucleotides	  (Sigma:	  NM_012782	  -­‐	  SASI_Rn01_00064150	  -­‐	  CAGAUCGUGAUCUGUUACU).	  After	  24	  hours	  post-­‐seeding	   an	   additional	   1ml	   of	   GM	  was	   added	   to	   each	  well	   (AMEM	  +	   10%	  FBS	   +	   1%	  antibiotic/	   antimycotic)	   and	   cells	  were	  allowed	   to	  proliferate	   for	   an	  additional	  24	  hours.	  Once	   the	  cells	   reached	  >90%	  confluency,	   they	  were	   rinsed	   in	  warm	  PBS	  and	  shifted	   into	  DM	  (AMEM	  +	  2%	  horse	  serum	  +	  1%	  	  	  antibiotic/	  antimycotic).	  A	  third	  of	  the	  well	  conditions	  received	  both	  BCKD	  siRNA	  transfection	  medium	  supplemented	  with	  the	  following	  at	  [3μM]:	  isovaleryl-­‐CoA	   –	   (Sigma	   Aldrich	   I9381),	   isobutyryl-­‐CoA	   -­‐	   (Sigma-­‐Aldrich	   I0383),	   2-­‐methylbutyryl-­‐L-­‐carnitine	  -­‐	  (Sigma	  Aldrich	  50405),	  β-­‐hydroxyisovaleric	  acid-­‐d8	  -­‐	  (Toronto	  Research	  Chemicals	  H943607).	  Supplemented	  medium	  was	  refreshed	  every	  day	  with	   the	  other	  DM	  until	  day	  5	  of	  differentiation.	  Samples	  were	  harvested	  using	  100μl	  of	  lysis	  buffer	  and	  stored	  at	  20°C	  until	  used	  for	  analysis.	  	  
Primary	  antibodies:	  anti-­‐mouse	  -­‐	  myosin	  heavy	  chain-­‐1	  (1:500	  dilution	  of	  a	  27μg/ml	  stock	  concentration:	  Developmental	  Studies	  Hybridoma	  Bank	  #MF20),	  anti-­‐mouse	  -­‐tropomyosin	  (1:500	  dilution	  of	  a	  27μg/ml	  stock	  concentration),	  anti-­‐rabbit	  -­‐	  BCKDHA	  (1:1000	  dilution:	  Abcam	   –	   ab90691),	   anti-­‐rabbit	   -­‐	   BCKDK	   (BDK)	   (1:2000	   dilution:	   Thermo	   Fisher	   –	   PA5-­‐
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31455),	  anti-­‐rabbit	  -­‐	  PARP	  (1:1000	  dilution:	  Cell	  Signaling	  Technologies	  (CST)#9532),	  anti-­‐rabbit	   -­‐	   caspase-­‐7	   (1:1000:	   CST#12728),	   anti-­‐rabbit	   -­‐	   phospho-­‐Akt	   (Ser473)(1:1000	  dilution	   –	   CST	  #4060),	   	   anti-­‐mouse	   -­‐	   gamma	   tubulin	   (1:10,000	  dilution:	   Sigma	  #T6557).	  anti-­‐rabbit	  -­‐	  succinate	  dehydrogenase	  (SDHA)	  (1:1000	  dilution:	  CST#11998).	  
Secondary	   Antibodies:	  HRP-­‐conjugated	   anti-­‐rabbit	   IgG	   (1:	   10,000	   dilution:	   CST	   #7074),	  Anti-­‐mouse	  IgG-­‐HRP-­‐conjugated	  (1:10,000	  dilution:	  CST	  #7076).	  
Statistics 
	  Two-­‐tailed,	  unpaired	  t-­‐test	  was	  used	  to	  assess	  differences	  between	  two	  groups	  (denoted	  using	  	  “*”	  =	  p	  <	  0.05,	  “**”	  =	  p	  <	  0.01).	  Two-­‐way	  ANOVA	  was	  used	  to	  assess	  differences	  between	  more	  than	  two	  groups	  using	  Tukey’s	  multiple	  comparisons	  test	  (letters	  denote	  significant	  differences).	  In	  the	  evident	  that	  a	  group	  variance	  was	  equal	  to	  zero,	  that	  group	  would	  be	  removed	  from	  two-­‐way	  ANOVA	  analysis	  and	  would	  later	  be	  subjected	  to	  unpaired	  T-­‐test	  analysis.	  Results	  are	  expressed	  as	  means	  and	  SEM.	  Significance	  was	  established	  when	  p	  <0.05.	  Graphpad	  Prism	  6/7	  software	  was	  used	  for	  data	  analysis	  and	  graph	  production.	  Figure	  illustrations	  were	  sourced	  from	  Servier	  Medical	  Art	  by	  Servier	  Powerpoint	  image	  bank	  (http://www.servier.com/Powerpoint-­‐image-­‐bank,	  https://creativecommons.org/licenses/by/3.0/).	  
Results	  	  	   To	   understand	   how	   BCKD	   activity	   may	   be	   changing	   during	   differentiation	   its	  negative	  regulator,	  BDK,	  was	  measured	  during	  a	  five-­‐day	  protocol	  of	  C2C12	  and	  L6	  muscle	  cell	  differentiation.	  In	  L6	  muscle	  cells	  BDK	  mRNA	  expression	  was	  elevated	  significantly	  on	  day	  1	  of	  differentiation	  (p	  <	  0.05)	  when	  compared	  to	  day	  2	  and	  5	  of	  differentiation	  (Fig	  2-­‐
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1a).	   However,	   the	   same	   increase	   was	   not	   witnessed	   when	   measuring	   BDK	   protein	  expression	  (Fig	  2-­‐1b).	  To	  test	  whether	  this	  was	  a	  cell	  specific	  response	  or	  antibody	  artifact,	  BDK	   protein	   was	   additionally	   measured	   in	   C2C12	  muscle	   cells,	   which	   yielded	   the	   same	  pattern	   of	   expression	   (Fig	   2-­‐1d).	   The	   positive	   regulator	   of	   BCKD	   activity,	   PP2Cm,	   had	   a	  trend	   for	   its	  mRNA	   to	   increase	   in	   a	   stepwise	  manner,	   reaching	   statistical	   significance	  by	  day	   3	   of	   differentiation	   (Fig	   2-­‐1c).	   However,	   the	   high	   variability	   between	   experimental	  replicates	   is	   the	   likely	   cause	   of	   day	   4	   and	   5	   of	   differentiation	   not	   reaching	   a	   statistical	  significance	  increase.	  Taken	  together,	  BDK	  protein	  expression	  remaining	  unchanged	  during	  differentiation,	   PP2Cm	   mRNA	   expression	   increasing,	   and	   previous	   data	   from	   our	   lab	  showing	  BCKD-­‐E1α	  protein	  expression	  rises	  during	  differentiation,	  it	  is	  likely	  BCKD	  activity	  will	  increase	  comparatively.	  	   The	   BCAA	   catabolic	   enzymes	   have	   been	   shown	   to	   be	   required	   for	   muscle	   cell	  differentiation	   (Zameer	   N	   .	   Dhanani	   and	   Olasunkanmi	   J.	   Adegoke,	   2016),	   therefore	   it	   is	  necessary	  to	  be	  able	  to	  measure	  the	  activity	  of	  the	  rate-­‐limiting	  enzyme	  in	  the	  pathway,	  and	  see	  if	   it	  changes	  throughout	  the	  course	  of	  differentiation.	  A	  BCKD	  activity	  assay	  had	  been	  developed	  by	  Chuang	  et	  al.,	   (2000)	   to	  be	  used	  with	   lymphocytes.	  However,	   there	  was	  no	  existing	   assay	  protocol	   available	   to	  measure	  BCKD	  activity	   in	   adherent	  muscle	   cells.	   The	  BCKD	   complex	   oversees	   the	   irreversible	   oxidative	   decarboxylation	   of	   the	   BCAA	   derived	  keto	   acids	   into	   their	   respective	   acyl-­‐CoA	   derivatives.	   The	   resultant	   CO2	  given	   off	   (when	  radiolabelled)	  can	  be	  collected	  and	  measured,	  as	  an	  indicator	  of	  BCKD	  activity.	  	   In	   the	   first	   test	   I	   used	   12-­‐well	   plates	   with	   homemade	   cell	   insert	   cups	   (modified	  microcentrifuge	  tubes).	  The	  cups	  were	  intended	  to	  suspend	  the	  NaOH	  soaked	  filter	  paper	  wicks	  above	  the	  cells	  and	  reaction	  mixture	  for	  the	  purpose	  of	  collecting	  radiolabelled	  CO2.	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Due	   to	   the	   complexity	   and	  work	   intensiveness	  of	   this	  process	   it	  was	  quickly	   abandoned.	  The	  main	  challenge	  of	  the	  first	  round	  of	  testing	  and	  its	  eventual	  failure	  was	  the	  inability	  to	  create	  the	  integral	  airtight	  seal,	  which	  was	  required	  to	  differentiate	  between	  control	  (GM	  +	  Buffer	   +	   Cells	   without	   1-­‐14C	   labelled	   valine)	   and	   experimental	   (GM	   +	   Buffer	   +	   Cells	   +	  Reaction	  mix	  containing	  1-­‐14C	   labelled	  valine)	  wells.	  The	  first	  successful	  assay	  generation	  alternatively	   used	   filter	   paper	  wicks	   suspended	   from	   the	   tape-­‐covered	   ceiling.	   Radiation	  counts	  from	  the	  first	  generation	  assay	  depicted	  in	  Fig	  2-­‐2a.	  displays	  encouraging	  results.	  However	   the	   “Live”	   (GM	  +	  Buffer	  +	  Cells	  +	  Reaction	  mix	  containing	  1-­‐14C	   labelled	  valine)	  conditions	  had	  too	  a	  large	  range	  and	  were	  too	  similar	  to	  control	  conditions.	  Because	  of	  this	  large	   range	   the	   protocol	   required	   further	   optimization.	   It	   should	   be	   noted	   that	   any	   CPM	  values	   that	   appear	   under	   control	   well	   conditions,	   where	   no	   radiation	   should	   have	   been	  given	  off,	  is	  due	  to	  air-­‐leakage	  from	  adjacent	  “Live”	  wells.	  These	  air-­‐leakages	  are	  due	  to	  the	  quality	  of	  adhesive	  on	  the	  clear	  tape	  used	  to	  form	  the	  well	  ceiling	  and	  human	  error.	  	   The	  second	  generation	  of	  the	  modified	  assay	  involved	  suspending	  filter	  paper	  wicks	  imbedded	  into	  the	  clear	  tape	  used	  to	  seal	  the	  wells.	  The	  initial	  problem	  with	  this	  model	  was	  that	  the	  filter	  papers	  were	  soaked	  in	  a	  NaOH	  solution,	  rendering	  the	  adhesive	  on	  the	  tape	  useless.	  I	  created	  a	  system	  where	  I	  would	  add	  an	  extra	  2-­‐4mm	  of	  width	  to	  the	  filter	  paper	  wicks,	   which	   I	   would	   then	   bend	   at	   a	   ninety-­‐degree	   angle,	   and	   attach	   to	   the	   clear	   tape	  
(Supplementary	  Fig	  2).	   I	   then	  used	  a	  small	  piece	  of	  clear	  tape	  (just	  enough	  to	  cover	  the	  extension	  of	  the	  wick)	  to	  anchor	  the	  small	  tab	  in	  place.	  Using	  this	  method	  the	  bulk	  of	  the	  filter	  paper	  wick	  was	  exposed	  and	  projected	  perpendicularly	  from	  the	  clear	  tape	  roof	  of	  the	  well	  (towards	  the	  bottom	  of	  the	  well)	  and	  was	  free	  to	  get	  coated	  in	  the	  [2M]	  NaOH	  solution.	  The	   resultant	   changes	   in	   the	   second	   generation	   culminated	   in	   much	   smaller	   radiation	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count	  ranges	  and	  larger	  differences	  between	  the	  control	  (GM	  +	  Buffer	  +	  Cells	  without	  1-­‐14C	  labelled	   valine)	   and	   experimental	   (GM	   +	   Buffer	   +	   Cells	   +	   Reaction	  mix	   containing	   1-­‐14C	  labelled	  valine)	  conditions	  (Fig	  2-­‐2b).	  Using	  the	  second	  generation	  of	  the	  assay,	  BCKD	  activity	  was	  measured	  in	  L6	  muscle	  cells	   over	   the	   course	   of	   5	   days.	   The	   first	   round	   of	   testing	   produced	   reliable	   reads,	   with	  minimal	   intra-­‐condition	   variability	   (Fig	   2-­‐3).	   BCKD	   activity	   was	   then	   successfully	  measured	   over	   five	   experimental	   replicates.	   BCKD	   activity	   was	   significantly	   lowered	   by	  36%	  from	  day	  0	  to	  day	  1	  (p	  <	  0.05)	  (Fig	  2-­‐4),	  and	  further	  significant	  reductions	  of~32%	  were	  witnessed	  on	  day	  2	  and	  remained	  lowered	  until	  day	  5	  (p	  <	  0.05)(Fig	  2-­‐4).	  	  Since	   we	   have	   previously	   shown	   that	   BCKD	   knockdown	   impairs	   differentiation.	  Conversely,	  how	  would	  differentiation	  be	  affected	  if	  the	  activity	  of	  that	  same	  enzyme	  were	  to	   be	   increased?	   Increasing	   BCKD	   activity	   is	   achievable	   via	   knockdown	   of	   its	   negative	  regulator	   BDK.	   Under	   conditions	   of	   BDK	   depletion,	   using	   the	   second	   generation	   assay,	  BCKD	   activity	   levels	   doubled	   on	   day	   0	   of	   differentiation	   (p	   <	   0.05)	   (Fig	   2-­‐5a).	   Because	  research	  has	  shown	  that	  BDK	  depletion	  can	  drastically	  upregulate	  BCKD	  activity	  in	  muscle	  (~15-­‐20-­‐fold	  increase	  when	  BDK	  was	  knocked	  out)	  I	  hypothesized	  that	  the	  assay	  may	  be	  reaching	  a	   limit	   in	   its	  ability	   to	  detect	   further	  changes	   in	  BCKD	  activity	  (Ishikawa,	  2017).	  This	  led	  to	  further	  optimization	  of	  the	  assay.	  The	   third	   generation	   of	   the	   modified	   assay	   kept	   many	   aspects	   of	   the	   second	  generation,	  with	  the	  addition	  of	  proportional	   increases	  in:	  reaction	  mix,	  cell	  medium,	  and	  buffer	  volumes.	  Theses	  proportional	  changes	  refer	  to	  the	  doubling	  of	  cells	  and	  well-­‐space	  when	   moving	   from	   the	   12-­‐well	   culture	   plate	   to	   the	   6-­‐well	   plate.	   	   These	   changes	   were	  accompanied	  by	  even	  greater	   increases	   in	  the	  filter	  paper	  wicks	  size	  (5.3-­‐fold	   increase	   in	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area)	  and	  NaOH	  volume	  (3-­‐fold	  increase),	  with	  the	  function	  of	  raising	  the	  limit	  of	  detection,	  or	  saturation	  point,	  of	  the	  assay.	  Taken	  together	  the	  6-­‐well	  plate	  enabled	  us	  to	  work	  with	  higher	   radioactive	   counts,	   which	   yielded	   smaller	   percentage	   error,	   better	   myotube	  formation,	  more	   sample	   lysate	   for	   analysis,	   and	  most	   importantly,	   raising	   the	  maximum	  capacity	  of	  the	  assay	  to	  detect	  radiolabelled	  CO2.	  BCKD	  activity	  was	  found	  to	  increase	  ~5-­‐fold	  on	  day	  0	  of	  cells	  depleted	  of	  BDK	  using	  the	  third	  generation	  assay	  (Fig	  2-­‐5b).	  However,	  western	   blot	   analysis	   showed	  BDK	  knockdown	   efficiency	  was	   reduced	   following	   the	   last	  two	  days	   of	   differentiation	   (Fig	   2-­‐5c).	   The	   reduced	  BDK	  knockdown	   efficiency	   on	  day	  3	  and	   4	   of	   differentiation	   may	   be	   abolishing	   additional	   effects	   on	   the	   later	   stages	   of	  differentiation.	  	  Now	   that	  we	  are	  aware	   that	  BCKD	  activity	  decreases	  during	   the	  normal	   course	  of	  differentiation,	   despite	   the	   concomitant	   rise	   in	   BCKD-­‐E1α.	   We	   hypothesized	   whether	  increasing	  its	  activity	  would	  positively	  affect	  differentiation,	  working	  under	  the	  assumption	  that	   the	   BCKD	   metabolic	   products	   would	   have	   positive	   effects	   on	   differentiation.	   BDK	  depleted	  C2C12	  myoblasts	   displayed	   significant	   increases	   in	  MHC-­‐1	   expression	  on	  day	  3	  and	   4	   of	   differentiation	   (p	   <	   0.05(Fig	   2-­‐6b).	   Additionally,	   tropomyosin	   displayed	  significant	  increases	  under	  BDK	  depleted	  conditions	  on	  day	  1,	  2,	  and	  4	  of	  differentiation	  (p	  <	   0.05),	   yet	   day	   3	   variability	   was	   too	   high	   to	   reach	   significance	   (Fig	   2-­‐6c).	   Clearly,	   the	  increased	   expression	   of	   these	   two	   myofibrillar	   proteins	   indicates	   differentiation	   is	  occurring	  earlier	  and	  to	  a	  greater	  extent	  in	  C2C12	  cells	  depleted	  of	  BDK.	  	  We	   next	   sought	   to	   determine	   whether	   increasing	   the	   flux	   through	   the	   BCAA	  catabolic	   pathway	   could	   be	   causing	   differentiation	   to	   occur	   at	   a	   faster	   rate.	   This	   was	  believed	  because	  BCAAs	  final	  metabolism	  feeds	  into	  the	  citric	  acid	  cycle,	  providing	  carbon	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skeletons	  for	  anaplerosis,	  thereby	  affecting	  cell	  energy	  metabolism.	  BCAAs	  are	  known	  to	  be	  oxidized	   at	   a	   higher	   rate	   during	   instances	   of	   greater	   energy	   demand,	   such	   as	   exercise	  (Yoshiharu	  Shimomura,	  2006).	  Therefore,	  by	  speeding	  up	  the	  BCAA	  catabolic	  pathway	  via	  BDK	   depletion,	   we	   hypothesized	   that	   this	   may	   be	   upregulating	   signalling	   mechanisms	  promoting	   greater	   oxidative	   capacity	   within	   the	   cell.	   Mitochondrial	   content	   increases	  under	  normal	  conditions	  of	  muscle	  cell	  differentiation,	  causing	  glycolytic	  myoblasts	  to	  shift	  towards	   a	   more	   oxidative	   metabolism	   in	   myotubes,	   thus	   we	   measured	   a	   marker	   of	  mitochondrial	   content	   and	   oxidative	   phosphorylation	   (OXPHOS)	   capacity,	   succinate	  dehydrogenase	   (SDHA)	   (Sin	   et	   al.,	   2016).	   SDHA	   levels	   remained	   stable	   during	  differentiation,	  no	  significant	  differences	  were	  found	  between	  the	  control	  and	  intervention	  groups	   (Fig	   2-­‐6d).	   Up	   to	   this	   point,	   no	   proxy	   of	   protein	   synthesis	   had	   been	   measured,	  which	  could	  aide	  in	  explaining	  the	  increased	  accretion	  of	  myofibrillar	  proteins	  under	  BDK	  depleted	  conditions,	  so	  ph-­‐(S473)	  AKT	  was	  measured.	  AKT	  phosphorylation	  had	  a	  trend	  to	  be	   greater	   on	   day	   0,	   under	   BDK	   knockdown	   conditions	   (p	   <	   0.0948)	   (Fig	   2-­‐6e).	   This	  finding	  is	  in	  agreement	  with	  AKT’s	  role	  in	  early	  differentiation,	  in	  addition	  to	  the	  likelihood	  of	  mTORC1	   being	   activated,	  which	   is	   necessary	   for	   differentiation	   (Gardner	   et	   al.,	   2012;	  Heron-­‐Milhavet,	  2006;	  Héron-­‐Milhavet,	  2008).	  Thereby,	  BDK	  depletion	  may	  be	  facilitating	  an	  accelerated	  rate	  of	  differentiation	  through	  this	  pathway.	  	   At	  the	  onset	  of	  differentiation,	  particularly	  on	  day	  1,	  many	  cells	  unadhere	  from	  cell	  culture	   plates	   during	   the	   normal	   course	   of	   differentiation.	   However,	   the	   number	   of	  unadherent	   cells	   present	   in	   the	   BDK	   knockdown	   wells	   appeared	   to	   be	   greater.	   To	   test	  whether	   BDK	   depletion	  was	   affecting	   cell	   death,	  markers	   of	   apoptosis	  were	  measured.	   I	  found	  no	  significant	  treatment	  effects	  on	  the	  expression	  of	  unprocessed	  caspase-­‐7	  or	  poly	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(ADP-­‐ribose)	   polymerase	   (PARP)	   (Fig	   2-­‐7a,	   b).	   Apoptosis	   has	   been	   reported	   to	   be	  necessary	   to	   support	   successful	   differentiation	   (Fernando	   et	   al.,	   2002;	   Nakanishi	   et	   al.,	  2005;	  Sandri	  &	  Carraro,	  1999;	  Schöneich	  et	  al.,	  2014).	  Alternatively,	  measuring	  markers	  of	  another	  catalytic	  process,	  like	  autophagy,	  could	  yield	  additional	  understanding	  of	  the	  effect	  BDK	  depletion	  may	  be	  having	  on	  cell	  viability	  during	  the	  early	  phase	  of	  differentiation.	  As	  previously	  stated	  knockdown	  of	  BCKD-­‐	  E1α	  impaired	  differentiation	  of	  L6	  muscle	  cells	   (Zameer	  N	   .	  Dhanani	  and	  Olasunkanmi	   J.	  Adegoke,	  2016).	  Provision	  of	   the	  substrate	  products	   immediately	   downstream	   of	   BCKD	   may	   rescue	   differentiation.	   L6	   cells	   were	  transfected	  with	  siRNA	  targeted	  against	  BCKD-­‐	  E1α	  and	  were	  supplemented	  with	  three	  of	  the	   BCAA	   derived	   metabolites	   immediately	   downstream	   of	   BCKD,	   isovaleryl-­‐CoA,	  isobutyryl-­‐CoA,	  2-­‐methylbutyryl-­‐CoA,	  and	  β-­‐hydroxy	  β-­‐methylbutyrate(an	  anti-­‐proteolytic	  leucine	  metabolite).	  The	  BCKD	  metabolic	  products	  were	  unable	   to	   rescue	  differentiation,	  MHC-­‐1	   expression	   in	   the	   control	   group	   was	   significantly	   higher	   than	   both	   intervention	  groups,	  which	  both	  remained	  significantly	  lowered	  compared	  to	  the	  control	  (p	  <	  0.01)	  (Fig	  













Figure	   2-­‐5.	   siRNA	   mediated	   BDK	   knockdown	   in	   L6	   muscle	   cells	   significantly	   increases	   BCKD	  
activity	   in	   L6	  muscle	   cells.	  a)	  BCKD	  activity	  was	  measured	  using	   the	   second	  generation	  BCKD	  
activity	  assay	  generation	  up	  to	  day	  4	  of	  differentiation	  	  (n	  =	  2)	  b)	  BCKD	  activity	  was	  measured	  
using	  the	  third	  generation	  BCKD	  activity	  assay	  generation	  up	  to	  day	  4	  of	  differentiation	  (n=3).	  c)	  
Western	   blotting	   analysis	   of	   BDK	   protein	   from	   third	   generation	   BCKD	   activity	   assays	   (n=3).	  





Figure	   2-­‐6.	   siRNA	   mediated	   BDK	   depletion	   in	   C2C12	   muscle	   cells	   during	   4	   days	   of	  
differentiation.	   a)	  Western	   blot	   analysis	   of	   BDK.	  b)	  Western	   blot	   analysis	   of	  MHC-­‐1.	   Second	  
MHC-­‐1	   panel	   is	   of	   a	   longer	   exposure	   time	   c)	  Western	   blot	   analysis	   of	   tropomyosin.	   Second	  
tropomyosin	  panel	   is	  of	  a	   longer	  exposure	  time	  d)	  Western	  blot	  analysis	  of	  SDHA.	  e)	  Western	  
blot	  analysis	  of	  Ph-­‐(S473)-­‐AKT.	  Three	  replicates	  per	  experiment,	  *	  denotes	  significance	  (n	  =	  3,	  p	  
<	   0.05).	   Bar	   graphs	   show	  mean	   ±	   SEM.	   The	   top	   panels	   in	   each	   figure	   display	   the	   protein	   of	  




Fig	   2-­‐8.	   BCKD	   depletion	   impairs	   myotube	   formation	   and	   the	   accretion	   of	   the	   myofibrillar	  
protein	  MHC-­‐1.	  L6	  muscle	  cells	  were	  subject	  to	  three	  conditions:	  1)	  Control,	  2)	  siRNA	  mediated	  
BCKD	   knockdown,	   3)	   siRNA	  mediated	   BCKD	   knockdown	   supplemented	  with	   the	   downstream	  
metabolites	   of	   BCKD.	   The	   blots	   shown	   amalgamate	   two	   membrane	   images	   together.	   a)	  
Western	  blot	  analysis	  of	  MHC-­‐1	  during	  differentiation	  b)	  Western	  blot	  analysis	  of	  ph-­‐(S473)AKT	  
during	  differentiation.	   Three	   replicates	   per	   experiment,	   letters	   denote	   significance	   (n	   =	   2,	   p	   <	  





Figure	   2-­‐9.	   Overall	   schematic	   of	   BCAA	   catabolic	   pathway	   regulation	   and	   muscle	   cell	  
differentiation.	   a)	   In	   vitro	   siRNA	  mediated	   gene	   knockdowns	   of	   the	   BCAA	   catabolic	   pathway	  
inhibit	   muscle	   cell	   differentiation.	   Inhibiting	   either	   one	   of	   its	   two	   main	   catabolic	   enzymes	  
resulted	  in	  the	  impairment	  of	  muscle	  cell	  differentiation.	  b)	  Schematic	  model	  of	  BCAA	  catabolic	  
pathway	   with	   BDK	   depletion	   augments	   myofibrillar	   protein	   accretion	   indicative	   of	   myotube	  
formation.
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Discussion	  	   For	   the	   first	   time	   in	   skeletal	   muscle	   cells	   we	   have	   shown	   that	   BCKD	   activity	  decreases	   throughout	   the	   process	   of	   differentiation.	   This	   finding	  was	   contrary	   to	  what	   I	  had	  hypothesized.	  Previous	  work	  from	  our	  laboratory	  had	  shown	  that	  the	  catalytic	  subunit	  of	  BCKD,	  E1α,	  increased	  throughout	  muscle	  cell	  differentiation.	  The	  increase	  in	  E1α	  protein	  expression	  led	  us	  to	  believe	  that	  the	  activity	  of	  the	  complex	  would	  increase	  concomitantly	  with	  differentiation.	  	  	   I	   began	   by	   assessing	   the	   regulatory	  mechanisms	   of	   BCKD	   via	  measuring	   its	   two-­‐antagonistic	  regulatory	  proteins.	  The	  expression	  of	  BDK	  protein,	  the	  negative	  regulator	  of	  BCKD,	  remained	  unchanged	  throughout	  a	  5-­‐day	  differentiation	  protocol.	  Previous	  reports	  have	  shown	  that	  BDK	  is	  regulated	  at	  the	  level	  of	  translation,	  through	  an	  element	  contained	  within	  BDK	  mRNA’s	  5’	   untranslated	   region	   (Muller,	   2004).	   Yet	  BDK	  mRNA	  was	   assessed	  and	  its	  expression	  was	  elevated	  on	  day	  1	  of	  differentiation,	  significantly	  above	  that	  of	  day	  2	  and	  5	  (p	  <	  0.05).	  BDK	  mRNA	  for	  day	  0,	  3	  and	  4	  did	  not	  reach	  a	  significant	  difference	  from	  day	   1	   levels.	   BDK	   protein	   expression	   has	   been	   shown	   to	   be	   regulated	   by	   nutrient	  availability,	   the	  greater	   the	  concentration	  of	  BCKAs	   in	   the	  cell	   the	   lower	  BDK	  expression,	  and	  vice	  versa	  (Doering,	  2000;	  Lynch	  &	  Adams,	  2014b;	  Popov,	  1995).	  My	  in	  vitro	  protocols	  call	  for	  medium	  replacement	  every	  24	  hours,	  meaning	  that	  the	  nutrient	  conditions	  should	  remain	   rather	   stable,	   thus	  BDK	  expression	  may	   as	  well	   (Fig	   2-­‐1b,	   d).	  However,	   because	  BDK	  had	  never	  been	  studied	  in	  a	  cell	  model	  of	  differentiation,	  and	  the	  enzyme	  it	  regulates	  increases	   during	   differentiation,	   it	   was	  within	   reason	   to	   assume	   BDK	  may	   be	   subject	   to	  additional	  regulatory	  mechanisms.	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One	  point	  that	  needs	  to	  be	  addressed	  in	  regard	  to	  the	  usage	  of	  both	  L6	  and	  C2C12	  muscle	  cells	  is	  due	  to	  antibody	  specificity.	  Commercially	  available	  antibodies	  against	  BDK	  had	  exclusive	  species	  cross-­‐reactivity	  with	  mice	  (C2C12),	  instead	  of	  rats	  (L6).	  Side-­‐by-­‐side	  western	  blots	  were	  later	  run	  to	  access	  the	  antibodies	  validity	  in	  BDK	  detection	  in	  both	  the	  C2C12	  and	  L6	  cell	  lines.	  These	  side-­‐by-­‐side	  blots	  displayed	  similar	  results	  between	  C2C12	  and	  L6	  BDK	   expression,	   blot	   location,	   and	  was	   further	   emphasized	   in	   siRNA	  knockdown	  studies	  using	  L6	  cells.	  	  My	  next	  experiment	  found	  that	  the	  positive	  regulator	  of	  BCKD	  activity,	  PP2Cm,	  had	  a	  trend	  for	  its	  mRNA	  expression	  to	  increase	  during	  differentiation.	  PP2Cm	  mRNA	  levels	  on	  day	  3	  were	  significantly	  different	  than	  day	  0	  (p	  <	  0.05)(Fig	  2-­‐1c),	  although	  generation	  of	  protein	   data	  was	  not	   possible	   due	   to	   antibody	  unavailability.	  However,	   the	   physiological	  relevance	  of	  this	  rise	  in	  PP2Cm	  mRNA	  expression	  may	  be	  limited	  because	  its	  expression	  is	  dwarfed	  by	  that	  of	  BDK	  in	  skeletal	  muscle.	  This	  high	  expression	  of	  BDK	  in	  skeletal	  muscle	  explains	  the	  tissues	  relatively	  low	  basal	  BCKD	  activity,	  whereas	  PP2Cm	  is	  lowly	  expressed	  (M.	  Zhou,	  2012).	  Further	  evidence	  supporting	  BDK’s	  essential	   role	   in	  BCKD	  regulation	   in	  skeletal	   muscle	   has	   become	   evident	   since	   the	   generation	   of	   the	   muscle-­‐specific	   BDK	  knockout	  mouse	  (Ishikawa,	  2017).	  These	  mice	  display	  very	  similar	  BCAA	  plasma	  profiles	  (~40%	   reductions)	   to	  whole-­‐body	   BDK	   knockout	  mice	   (~50%	   reductions),	   emphasizing	  the	  physiological	  relevance	  of	  skeletal	  muscle	  BDK.	  	  Once	   we	   established	   how	   BCKD’s	   regulatory	   factors	   were	   expressed	   during	  differentiation,	  it	  was	  time	  to	  investigate	  BCKD	  activity	  directly.	  Following	  the	  development	  of	  a	  modified	  BCKD	  activity	  assay,	  we	  were	  able	  to	  directly	  measure	  enzymatic	  activity	  of	  BCKD.	  This	   is	   achieved	  using	  1-­‐14C	   labelled	  valine.	  Valine	  was	   the	  molecule	  of	   choice	   for	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measuring	  BCKD	  activity	  because	  it,	  of	  all	  three	  BCAAs,	  is	  catabolized	  at	  the	  highest	  rate	  by	  BCKD	  (Sokatch	  et	  al.,	  1981;	  Yoshida	  et	  al.,	  1986).	  The	  radiolabeled	  valine	  molecule	   is	  not	  uniformly	  labeled,	  we	  purposefully	  chose	  this	  isotope	  because	  only	  carbon-­‐1	  is	  radioactive	  and	  it	  is	  this	  carbon	  that	  is	  removed	  via	  BCKD’s	  decarboxylation	  action.	  The	  modifications	  of	  this	  assay	  were	  rather	  extensive	  and	  many	  rounds	  of	  testing	  were	  conducted	  to	  ensure	  efficacy.	   I	  was	   faced	  with	   two	  main	  challenges	  during	  the	   first	   few	  rounds	  of	   testing.	  The	  first	   challenge	   was	   ensuring	   that	   each	   experimental	   well	   was	   airtight,	   because	   the	  radiolabelled	   carbon	   from	   the	   1-­‐14C-­‐valine	   would	   be	   transferred	   to	   CO2,	   following	   its	  decarboxylation	  by	  BCKD.	  On	  the	  first	  generation	  of	  the	  assay	  I	  tried	  out	  a	  variety	  of	  taping	  methods	   to	  address	   the	  prevention	  of	   air	   leakages,	  because	   the	  efficacy	  of	   the	  assay	  was	  dependent	  upon	  the	  collection	  of	  the	  aforementioned	  radiolabelled	  CO2.	  	  The	   second	   challenge	   involved	   the	   actual	   collection	   of	   the	   radiolabelled	  CO2	  itself.	  The	  purpose	  of	  the	  NaOH	  soaked	  filter	  paper	  wicks	  was	  to	  collect	  the	  radiolabelled	  CO2	  via	  the	   chemical	   reaction	   that	   occurs	   between	   CO2	   and	   NaOH,	   which	   would	   react	   forming	  bicarbonate,	   leaving	   the	   14C	   on	   the	   wicks.	   The	   wicks	   were	   then	   subjected	   to	   radiation	  counting.	  The	  original	  assay	  developed	  by	  Chuang	  et	  al.,	  (2000)	  called	  for	  the	  production	  of	  specialized	  cell	  inserts	  to	  hold	  these	  wicks,	  but	  the	  inserts	  were	  custom	  made	  and	  I	  could	  not	   find	   any	   substitute	   that	  would	   serve	  my	  purposes.	   I	   had	   improvised	   a	  method	  using	  microcentrifuge	   tubes	   that	  were	   transversally	   cut	   through	   the	  midsection,	   inverted	  with	  the	   lid	   closed,	   and	   the	   cap	   was	   wrapped	   with	   Parafilm®	   to	   ensure	   it	   was	   water-­‐tight.	  Although	  this	  method	  could	  have	  worked,	  I	  could	  not	  devise	  a	  way	  to	  suspend	  them	  above	  my	  monolayer	  of	  cells,	  Chuang	  et	  al.,	   (2000)	  had	  designed	  the	  assay	  with	  the	  intention	  of	  using	  suspended	  cells.	  This	  meant	  I	  had	  to	  come	  up	  with	  an	  alternative	  means	  of	  keeping	  
	  72	  
the	  wicks	  contained	  within	  the	  closed	  environment,	  without	  making	  direct	  contact	  with	  the	  1-­‐14C-­‐valine	   containing	  medium.	   I	   finally	   solved	   the	   issue	   by	   suspending	   the	   filter	   paper	  wicks	  from	  the	  ceiling	  of	  each	  well,	  which	  happened	  to	  work	  with	  the	  taping	  method	  I	  had	  devised	  to	  overcome	  the	  first	  challenge.	  Using	  small	  pieces	  of	  tape,	  I	  anchored	  the	  wicks	  to	  the	   tape	   that	   would	   form	   the	   ceiling	   of	   each	   well.	   Finally,	   I	   was	   able	   to	   begin	   testing	  whether	  or	  not	  I	  would	  be	  able	  to	  produce	  reliable,	  reproducible	  results.	  	  I	   began	  my	   testing	   protocols	   using	   four	   different	   conditions.	   	   All	   four	   conditions	  were	  in	  the	  presence	  of	  growth	  medium,	  the	  conditions	  were	  as	  shown	  in	  (Fig	  2-­‐2a).	  The	  condition	   termed,	   “Live”	   had	   all	   the	   final	   components:	   i)	   cells,	   ii)	   growth	   medium,	   iii)	  medium	  buffer,	   iv)	  1-­‐14C-­‐valine	  containing	  reaction	  mix,	  and	  iv)	  NaOH	  soaked	  filter	  paper	  wicks.	   The	   positive	   control	  was	   comprised	   of	   20μl	   of	   the	   1-­‐14C-­‐valine	   containing	   growth	  medium,	  which	  was	   added	   to	   the	   scintillation	   fluid	   and	  was	   then	   subjected	   to	   radiation	  counting.	  The	  remaining	  two	  conditions	  were	  controls,	  missing	  either	  cells,	  or	  1-­‐14C-­‐valine.	  Both	  controls	  contained	  NaOH	  wicks,	  and	  at	  the	  end	  of	  each	  protocol,	  samples	  from	  these	  wells	   too	   were	   counted.	   The	   first	   generation	   assay	   in	   Fig	   2-­‐2a	   displays	   high	   variability	  among	   the	   counts-­‐per-­‐minute	   (CPM)	   of	   the	   “Live”	   (GM	   +	   Buffer	   +	   Cells	   +	   Reaction	   mix	  containing	   1-­‐14C	   labelled	   valine)	   conditions.	   Additionally,	   the	   CPM	   reads	   of	   the	   “Live”	  conditions	  were	  too	  similar	  to	  that	  of	  the	  control	  conditions.	  The	  CPM	  generated	  from	  the	  control	  conditions	  is	  often	  the	  residual,	  or	  basal	  registers	  of	  the	  scintillation	  counter,	  or	  the	  result	  of	  an	  air	   leak	   from	  a	  “Live”	  condition.	   	  The	   two	  problems	  with	   the	   first	  generation	  assay	  were	   improved	   upon	   the	   second	   generation	   development.	   The	   variability	   between	  “Live”	   groups	   was	   lowered	   and	   their	   CPM	   reads	   were	   much	   greater	   than	   the	   control	  conditions	   (Fig	   2-­‐2b).	   	   This	   was	   accomplished	   by	   improvement	   of	   the	   taping	   protocol.	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Once	  optimized,	  I	  was	  able	  to	  measure	  BCKD	  activity	  during	  differentiation	  as	  shown	  in	  the	  first	  test	  round	  (Fig	  2-­‐3).	  	  BCKD	   activity	   declined	   following	   the	   first	   24	   hours	   of	  my	   differentiation	   protocol	  and	  remained	   lowered	  until	   the	  experiments	  cessation	  on	  day	  4	  (Fig	   2-­‐4).	  BCKD	  activity	  fell	  by	  ~36%	  by	  day	  1	  (p	  <	  0.05)	  and	  remained	  significantly	  lowered	  by	  ~68%	  from	  day	  2	  to	   day	   5	   (p	   <	   0.01),	   despite	   the	   concomitant	   rise	   in	   the	   abundance	   of	   BCKD’s	   catalytic	  subunit,	   E1α,	   which	   had	   been	   shown	   in	   prior	   studies	   in	   our	   lab.	   It	   is	   likely	   that	   the	  relatively	   high	   levels	   of	  BCKD	  activity	   on	  day	  0	   and	  day	  1	   are	   a	   result	   of	   growth	   factors	  from	   the	  growth	  medium.	  Not	  only	  was	   there	  a	  ~36%	  drop	   in	  BCKD	  activity,	  which	  was	  consistent	   across	   all	   experiments	   from	   day	   0	   to	   day	   1,	   but	   during	   testing	   rounds	   when	  myotubes	  were	  exposed	  to	  growth	  medium	  (as	  opposed	  to	  DM),	  BCKD	  activity	  rose	  to	  near	  day	   0	   levels	   (Supplementary	   Fig	   1).	   Nevertheless,	   the	   fall	   in	   BCKD	   activity	   during	  differentiation	  suggests	  a	  greater	  association	  between	  BDK	  and	  BCKD,	  which	  is	   indicative	  of	  a	  reduction	  in	  intracellular	  BCAAs,	  and	  thus	  BCKAs	  (She,	  2013).	  However,	  past	  work	  in	  our	  lab	  has	  shown	  that	  BCAA	  levels	  remain	  constant	  in	  differentiating	  L6	  cells,	  meaning	  the	  association	   between	   these	   two	   proteins	   should	   not	   change.	   Because	   BCKD	   activity	   has	  never	  been	  studied	  during	  muscle	  cell	  differentiation	  it	  is	  possible	  that	  it	  may	  be	  subject	  to	  regulation	  via	  an	  alternative	  mechanism	  that	  remains	  to	  be	  defined.	  	  During	   the	   development	   of	   a	   new	   assay,	   it	   is	   essential	   that	   a	   few	   detection	  parameters	  be	  defined.	  The	  modified	  BCKD	  activity	  assay	  has,	  at	  this	  stage,	  proven	  able	  to	  detect	   a	   minimum	   signal	   enabling	   the	   discernment	   between	   BCKD	   decarboxylation	   and	  negative	   control	   conditions.	  However,	   there	   is	   a	   finite	   capacity	  of	   the	  assay	   to	  detect	   the	  main	   output	   product,	   the	   radiolabelled	   CO2,	   because	   the	   available	   NaOH	   may	   become	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saturated	  rendering	  it	  unable	  to	  bind	  additional	  CO2.	  In	  this	  case	  the	  ceiling	  of	  detection,	  or	  the	   “saturation	   point”	   of	   the	   assay	   is	   controlled	   by	   four	   factors:	   i)	   filter	   paper	   size,	   ii)	  amount/concentration	  of	  NaOH	  added	  to	  the	  wicks,	  and	  iii)	  amount/concentration	  of	  1-­‐14C	  labelled	  valine	  in	  the	  reaction	  wells,	  and	  most	  importantly	  the	  number	  of	  cells	  per	  reaction	  (Cell	  number	  is	  controlled	  via	  protein	  concentration).	  	  The	   siRNA-­‐mediated	   knockdown	   of	   BDK	  was	   capable	   of	   raising	   BCKD	   activity	   as	  hypothesized	  (Fig	  2-­‐5a).	  However,	  as	  previously	  mentioned,	  muscle-­‐specific	  BDK	  knockout	  mice	   displayed	   BCKD	   activity	   levels	   between	   15-­‐20-­‐fold	   of	   controls,	   thus	   I	   believed	   the	  doubling	  effect	  witnessed	  in	  Fig	  2-­‐5a	  was	  not	  truly	  reflective	  of	  BCKD’s	  activity.	  Using	  the	  third-­‐generation	   assay	   for	   the	   remaining	   BDK	   depletion	   experiments	   it	   became	   evident	  that	   a	   saturation	   point	   had	   been	   reached	   using	   the	   second-­‐generation	   assay	   (Fig	   2-­‐5b).	  And	  thus,	  the	  highest	  BCKD	  activity	  witnessed	  on	  day	  0	  using	  the	  second	  generation	  assay	  did	  not	  reflect	  the	  true	  increase	  (2-­‐fold	  increase	  from	  day	  0	  control	  to	  knockdown	  in	  BCKD	  activity).	  The	  third-­‐generation	  assay	  clearly	  depicts	  a	  much	  larger	  increase	  in	  BCKD	  activity	  on	  day	  0,	  under	  knockdown	  conditions	  (~5-­‐fold	  increase	  from	  day	  0	  control	  to	  knockdown	  in	  BCKD	  activity)(Fig	  2-­‐5b).	  Increasing	  the	  ceiling	  of	  detection,	  or	  saturation	  point,	  for	  the	  third	  generation	  was	  achieved	  by	   increasing	   the	  size	  and	  volume	  of	   the	   filter	  paper	  wick	  and	  NaOH,	  respectively,	  when	  moving	  from	  a	  12-­‐well	  plate	  to	  a	  6-­‐well	  plate	   format.	  Note	  that	  the	  increase	  in	  filter	  paper	  wick	  size	  (5.3-­‐fold	  increase	  in	  area)	  and	  NaOH	  volume	  (3-­‐fold	   increase)	   exceeded	   the	   doubling-­‐increase	   of	   the	   reaction	   mix,	   cell	   medium,	   cell	  number,	  and	  buffer	  volumes.	  The	  third	  generation	  BCKD	  activity	  assays	  with	  BDK	  depletion	  used	  another	  siRNA	  oligo	  against	  BDK,	  which	  depleted	  BDK	  expression	  to	  similar	  levels	  as	  the	  first	  oligo	  used	  in	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the	  2nd	  generation	  assay	  experiments.	  However,	  upon	  using	   the	  second	  oligo,	   the	  specific	  cell	   line,	   the	   oligo,	   or	   the	   combination	   of	   the	   two,	   resulted	   in	   the	   reduction	   of	   the	  transfected	   cells	   ability	   to	   proliferate.	   This	   led	   to	   a	   sub-­‐optimal	   confluency	   (<90%)	   even	  after	  an	  additional	  24-­‐hour	  period	  to	  allow	  the	  cells	  to	  proliferate.	  Therefore,	  to	  bring	  the	  cells	  back	  up	  to	  the	  appropriate	  confluency	  required	  for	  successful	  differentiation	  I	  needed	  a	   method	   to	   increase	   the	   number	   of	   cells	   per	   well,	   while	   retaining	   efficient	   BDK	  knockdown.	  A	  previously	  used	  technique	   in	  our	   lab	   involved	  transfecting	   three	   times	   the	  number	  of	  cells	  (using	  3x	  the	  number	  of	  wells)	  typically	  used	  per	  experimental	  conditions	  and	   condensing	   them	   into	   a	   single	   well	   (Ratio	   of	   3:1).	   For	   example,	   all	   experiments	  conducted	  had	  three	  technical	  replicates	  per	  condition,	  and	  this	  experiment	  is	  repeated	  for	  five	   days.	   Thus,	   a	   single	   experimental	   replicate	   requires	   15-­‐wells	   per	   condition	   (Control	  and	  BDK	  knockdown).	  On	  the	  day	  of	  transfection,	  I	  transfected	  15-­‐wells	  worth	  of	  cells	  (2.5	  x	   105	   /well)	   under	   the	   control	   condition	   and	   45-­‐wells	   worth	   for	   the	   BDK	   knockdown	  condition.	   I	   allowed	   all	   these	   cells	   to	   proliferate	   over	   the	   next	   24-­‐hours,	   allowing	   for	  sufficient	   time	   to	   pass	   for	   the	   transfection	   to	   have	   an	   effect.	   At	   the	   24-­‐hour	   mark	   I	  trypsinized	  all	   the	  control	  wells,	   centrifuged	  them,	  re-­‐suspended	  them	  in	  15	  milliliters	  of	  medium,	  and	  re-­‐seeded	  them	  into	  15-­‐wells	  (1ml	  of	  suspension/well).	  I	  completed	  the	  same	  procedure	   for	   the	   BDK	   knockdown	   wells,	   however	   when	   I	   re-­‐suspended	   the	   cells	   in	  medium,	   instead	  of	  adding	  45	  milliliters	   I	  added	  only	  15	  milliliters	  of	  medium.	   I	   then	  re-­‐seeded	  those	  cells	  into	  15-­‐wells,	  thereby,	  condensing	  three	  times	  the	  number	  of	  cells	  into	  a	  single	   well.	   This	   procedure	   was	   able	   to	   rescue	   cell	   confluency	   24-­‐hours	   later,	   and	  subsequently	  differentiation.	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I	   next	   sought	   out	   how	   siRNA-­‐mediated	   BDK	   depletion	   would	   affect	   muscle	   cell	  differentiation.	   Because	   the	   removal	   of	   the	   main	   BCAA	   catabolic	   enzymes	   impaired	  differentiation,	   perhaps	   increasing	   flux	   through	   the	   pathway	   would	   positively	   effect	  differentiation.	   These	   experiments	   were	   conducted	   in	   C2C12	   muscle	   cells	   because	   the	  knockdown	  efficiency	  in	  these	  cells	  was	  greater	  and	  lasted	  throughout	  our	  entire	  protocol,	  compared	  to	  L6	  muscle	  cells	  (Fig	  2-­‐6a).	  BDK	  depleted	  cells	  displayed	  a	  premature	  increase	  in	   the	   accretion	   of	   two	  myofibrillar	   proteins,	  MHC	   and	   tropomyosin,	  when	   compared	   to	  control	   cells	   (Fig	   2-­‐6b,	   c).	   There	  was	   also	   a	   trend	   for	   AKT(S473)	   phosphorylation	   (p	   <	  0.0948)	  to	  be	  greater	  under	  BDK	  knockdown	  conditions	  on	  day	  0	  compared	  to	  the	  control	  
(Fig	  2-­‐6e).	  	  Cells	  with	  high	  concentrations	  of	  BCAAs	  elicit	  robust	  mTORC1	  activation,	  which	  has	  been	   shown	   to	   feedback	  onto	   the	  PI3K-­‐AKT	  signalling	  axis,	   uncoupling	   the	  axis	   from	   the	  insulin	  receptor,	  via	  a	  phosphorylation	  event	  on	  insulin	  receptor	  substrate-­‐1	  (Carlson	  et	  al.,	  2004;	   Hançer	   et	   al.,	   2014;	   Smadja-­‐Lamère	   et	   al.,	   2013).	   The	   increase	   in	   AKT(S473)	  phosphorylation	   on	   day	   0	   may	   be	   the	   result	   of	   greater	   signalling	   coupling	   between	   the	  insulin	  receptor	  and	  the	  PI3K	  signalling	  pathway	  (Fig	  2-­‐6e).	  The	  greater	  coupling	  may	  be	  caused	  by	  the	  decrease	  in	  intracellular	  BCAA	  concentrations,	  typically	  observed	  under	  BDK	  depleted	  conditions	  (Ishikawa,	  2017;	  Joshi,	  2006).	  The	  increased	  activation	  of	  AKT	  could	  be	  one	  of	  the	  factors	  accelerating	  differentiation	  under	  BDK	  depleted	  conditions,	  based	  upon	  AKT’s	   role	   in	   early	   differentiation	   (Heron-­‐Milhavet,	   2006;	   Héron-­‐Milhavet,	   2008;	   Sun,	  2004;	  Wilson,	  2007).	  	  Another	   mediator	   involved	   in	   the	   early	   stages	   of	   differentiation	   is	   the	  mitochondrion.	  Mitochondrial	  biogenesis	  has	  been	  shown	  to	  occur	  during	  both	  muscle	  cell	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differentiation	   in	   vitro	   (Sin,	   2016),	   and	  muscle	   regeneration	   in	   vivo	   (Wagatsuma,	   2011).	  Succinate	  dehydrogenase	  (SDHA)	  is	  the	  only	  enzyme	  involved	  in	  both	  the	  citric	  acid	  cycle	  and	   electron	   transport	   chain,	   thereby	   it	   is	   a	   good	   indicator	   of	   mitochondrial	   energy	  capacity.	   However,	   SDHA	   levels	   remained	   unchanged	   during	   differentiation	   and	   no	  differences	  were	  seen	  under	  conditions	  of	  BDK	  depletion	  (Fig	  2-­‐6d).	  Further	  experiments	  will	   measure	   the	   activity	   of	   SDHA	   under	   BDK	   depleted	   conditions	   to	   gain	   a	   better	  understanding	   whether	   or	   not	   SDHA	   function	   is	   altered	   under	   BDK	   depletion.	   The	  increased	  rate	  of	  differentiation	  is	  evident	  due	  to	  the	  aforementioned	  increased	  accretion	  of	  myofibrillar	  proteins,	  MHC	  and	  tropomyosin	  (Fig	  2-­‐6b,	  c).	  A	  possible	  explanation	  is	  that	  differentiation	   is	   simply	   occurring	   at	   a	   faster	   rate,	   thereby,	   a	   faster	   increase	   in	  mitochondrial	   content.	   I	   suspect	   the	   effects	   of	   chronically	   reducing	   intracellular	   BCAAs	  through	  the	  increased	  rate	  of	  BCAA	  catabolic	  flux	  is	  important	  to	  differentiation,	  based	  on	  the	   increased	   activation	   of	   AKT	   and	   the	   likely	   stimulatory	   effect	   it	   exerts	   on	   mTORC1.	  Taken	   together,	   the	   dynamic	   nature	   of	   these	   signalling	   pathways	   and	   their	   effects	   on	  differentiation	  under	  BDK	  depleted	  conditions	  require	  further	  investigation.	  The	  enhancement	  of	  differentiation	  caused	  by	  BDK	  depletion	  may	  be	  mediated	  by	  an	  effect	  on	  cell	  viability,	  during	  the	  early	  stages	  of	  differentiation.	  I	  had	  noticed	  muscle	  cell	  differentiation	  is	  always	  accompanied	  by	  the	  accumulation	  of	  unadherent	  cells	  by	  day	  1	  of	  differentiation,	   especially	   under	   BDK	   knockdown	   conditions,	   which	   is	   indicative	   of	   non-­‐viable	   cells.	   Because	   cell	   viability	   and	   subsequently,	   cell	   confluency,	   have	  been	   shown	   to	  effect	  differentiation,	   I	  measured	  two	  markers	  of	  apoptosis.	  There	  were	  no	  differences	   in	  apoptosis	   between	   the	   BDK	   depleted	   condition	   and	   control,	   based	   on	   the	   unprocessed	  caspase-­‐7	   and	   poly	   (ADP-­‐ribose)	   polymerase	   (PARP)	   (Fig	   2-­‐7a,	   b).	   However,	   cells	   that	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became	   detached	   from	   the	   plate	   are	   washed	   away	   following	   the	   normal	   harvesting	  protocol.	  	  Perhaps	  gathering	  those	  cells	  and	  combining	  them	  with	  the	  rest	  of	  the	  cell	  lysate	  would	  yield	  a	  better	  understanding	  of	   the	  role	  apoptosis	  may	  be	  having	   in	  BDK	  depleted	  cells.	   Another	   explanation	   of	   the	  mass	   of	   unadherent	   cells	   could	   be	   that	   only	   these	   cells	  received	   apoptotic	   signalling	   instruction,	   and	   the	   subset	   of	   cells	   that	   survived	   this	  phase	  never	   had	   a	   significant	   increase	   in	   apoptotic	   signalling.	   Evidence	   supporting	   this	   notion	  refers	  to	  C2C12	  cells	  that	  can	  be	  separated	  into	  subgroupings.	  One	  of	  these	  subgroups	  do	  not	   undergo	   apoptosis,	   nor	   do	   they	   differentiate,	   Schöneich	   et	   al.,	   refer	   to	   them	   as	  “Reserve”	   cells	   (Schöneich,	   2014).	   These	   “Reserve”	   cells	   enter	   a	   quiescent	   state	   upon	  exposure	   to	   DM,	   and	   are	   believed	   to	   reflect	   satellite	   cell	   functioning	   in	   mature	   skeletal	  muscle.	  Additionally,	  it	  has	  been	  shown	  that	  the	  caspase-­‐3	  is	  required	  for	  differentiation	  to	  occur	   in	  C2C12	  cells	   (Fernando,	  2002;	  Larsen	  et	  al.,	  2010),	  however	   in	  mature	  myotubes	  anti-­‐apoptotic	  signalling	  is	  elevated	  (Xiao	  et	  al.,	  2011).	  This	  compartmentalization	  of	  cells	  and	   their	   ability	   to	   serve	   different	   roles	   during	   differentiation	   should	   influence	   our	  assessments	   of	   muscle	   cell	   differentiation,	   and	   perhaps	   we	   should	   investigate	  interventional	  changes	  according	  to	  these	  subgroups	  once	  better	  defined.	  Taken	  together,	  assessment	   of	   other	   mechanisms	   that	   could	   be	   regulating	   cell	   viability	   during	  differentiation,	   like	   autophagy,	   warrant	   further	   study	   because	   of	   its	   established	   role	   in	  myogenic	  differentiation	  (McMillan	  &	  Quadrilatero,	  2014;	  Pizon	  et	  al.,	  2013;	  Sin,	  2016).	  	  Prior	   research	   in	   our	   lab	   has	   shown	   that	   cells	   depleted	   of	   BCKD-­‐E1α	   fail	   to	  differentiate.	  If	  the	  impairment	  in	  differentiation	  is	  due	  to	  the	  absence,	  or	  the	  reduction	  in	  BCKD	  derived	  metabolites,	   it	   is	   logical	   to	   assume	   if	   provided	   exogenously	  differentiation	  may	   be	   rescued.	   I	   then	   supplemented	   the	   BCKD	   depleted	   condition	   with	   each	   of	   the	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immediate	   downstream	   metabolites	   of	   BCKD,	   derived	   from	   the	   BCAA	   keto-­‐acids.	  Supplementation	   with	   BCKD	   products	   was	   unable	   to	   rescue	   differentiation	   under	   BCKD	  depleted	  conditions;	  evident	  by	  MHC-­‐1	  levels	  being	  suppressed	  to	  a	  similar	  degree	  as	  the	  knockdown	   alone	   (Fig	   2-­‐8a).	   In	   addition,	   no	   effect	   of	   either	   intervention	   treatment	  was	  witnessed	   in	  ph(S473)AKT	  analysis.	  This	  may	  be	  a	  product	  of	  a	  reduction	   in	  cell	  viability	  witnessed	  in	  BCKD	  depleted	  muscle	  cells	  (Zameer	  N	  .	  Dhanani	  and	  Olasunkanmi	  J.	  Adegoke,	  2016),	  and	  is	  possibly	  resultant	  from	  the	  accumulation	  of	  intracellular	  BCAAs	  and	  BCKAs.	  
	  
Conclusions	  	  	   We	  have	  presented	  novel	   findings	  observing	  BCKD	  activity	   in	  muscle	  cells.	  To	  our	  knowledge	   this	   is	   the	   first	   time	   BCKD	   activity	   has	   been	   measured	   during	   muscle	   cell	  differentiation	   in	   vitro.	   Because	   of	   the	   decrease	   in	   BCKD	   activity	   and	   the	   constant	  expression	   of	   its	   negative	   regulator,	   BDK,	   the	   association	   between	   the	   two	   must	   be	  increasing	   during	   differentiation.	   However,	   the	   mechanisms	   mediating	   this	   increased	  association	   remain	   to	   be	   elucidated.	   Furthermore,	   siRNA	   mediated	   depletion	   of	   BDK	  resulted	   in	   an	   increased	   and	   premature	   expression	   of	   myofibrillar	   proteins.	   This	   could	  possibly	   be	   explained	   by	   our	   observations	   of	   greater	   AKT	   activation	   during	   early	  differentiation,	   which	   may	   be	   stimulating	   mTORC1	   activity,	   consequently	   upregulating	  cellular	  processes	  necessary	  for	  differentiation.	  	  Taken	  together,	  we	  provide	  greater	  evidence	  supporting	  the	  role	  BCAA	  catabolism	  serves	  as	  a	  regulating	  factor	  involved	  in	  muscle	  cell	  differentiation	  (Fig	  2-­‐9).	  
Future	  Directions	  and	  Study	  Limitations	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Our	  next	  objectives	  include:	  	   1) Determine	   to	   what	   degree	   BDK	   and	   BCKD	   associate	   during	   differentiation	   via	  immunoprecipitation	  studies.	  	  2) Determine	   the	   role	   of	   PP2Cm	   in	  muscle	   cell	   differentiation.	   If	   PP2Cm	  knockdown	  studies	   are	   completed	   will	   this	   yield	   the	   opposite	   result	   witnessed	   during	   BDK	  depletion?	  	  3) Determine	  whether	   the	  past	   increases	   in	  BCAT2	  and	  BCKD-­‐E1α	  proteins	  observed	  during	   differentiation	   were	   not	   merely	   the	   result	   of	   the	   concomitant	   rise	   in	  mitochondrial	   content.	   Measuring	   mitochondrial	   content	   during	   differentiation,	  mainly	   via	   respiratory	   chain	   proteins,	   could	   be	   used	   as	   a	   standard	   for	   the	   rate	  increase	   of	   mitochondrial	   content.	   Then	   by	   comparing	   the	   changes	   in	   BCAA	  catabolic	   expression	   and	   mitochondrial	   content	   via	   regression	   analysis,	   it	   can	   be	  determined	  if	  these	  increases	  in	  BCAA	  catabolic	  enzymes	  are	  rising	  proportionately	  with	  mitochondrial	  content.	  (Isolating	  mitochondria	  may	  be	  favourable	  to	  eliminate	  any	  newly	  translated	  cytosolic	  BCAT2	  or	  BCKD)	  	  4) Investigate	   how	   the	   increase	   in	   BCKD	   flux	   affects	   energy	   metabolism	   during	  differentiation.	  Radiolabelling	  BCAAs	  or	  BCKAs	  represents	  one	  method	  for	  assessing	  the	  contribution	  of	  BCAA	  catabolic	  flux	  to	  the	  TCA	  cycle.	  The	  output	  measure	  of	  this	  experiment	  would	  assess	  the	  incorporation	  of	  those	  radiolabelled	  carbon	  skeletons	  into	   TCA	   cycle	   intermediates.	   Comparing	   the	   amount	   of	   radiolabelled	   TCA	   cycle	  intermediates	  between	  normal	  and	  BDK	  depleted	  conditions	  would	  give	  indication	  whether	   or	   not	   BCAA	   flux	   could	   disproportionately	   effect	   energy	   substrate	  provision.	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5) Investigate	  how	  mTORC1	  activity	  is	  altered	  under	  conditions	  of	  BDK	  depletion.	  The	  most	   well	   defined	   substrates	   of	   mTORC1	   include,	   S6K1,	   S6,	   4E-­‐BP1	   and	   ULK1.	  Measuring	  these	  downstream	  targets	  of	  mTORC1	  will	  determine	  whether	  ribosomal	  biogenesis,	   translation	   efficiency,	   or	   autophagy,	   are	   alternatively	   regulated	   under	  conditions	  of	  BDK	  depletion.	  The	   nature	   of	   in	   vitro	   studies	   is	   to	   determine	   specific	   mechanisms,	   which	   in	   turn,	  subjects	   them	   to	   operating	   under	   isolated	   conditions.	   Further	   study	   in	   vivo	   will	  elucidate	  how	  all	  of	  the	  mammalian	  body	  systems	  affect	  the	  results	  generated	  from	  this	  
in	  vitro	  study.	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Figure	  3.	  siRNA	  mediated	  BDK	  knockdown	  in	  L6	  muscle	  cells	  significantly	  increases	  BCKD	  activity	  
in	   L6	  muscle	   cells.	  a)	  BCKD	  activity	  was	  measured	  using	   the	   second	  generation	  BCKD	  activity	  
assay	  generation	  up	  to	  day	  4	  of	  differentiation	  	  (n	  =	  2)	  b)	  BCKD	  activity	  was	  measured	  using	  the	  
third	   generation	   BCKD	   activity	   assay	   generation	   up	   to	   day	   4	   of	   differentiation	   (n=3).	   Three	  
replicates	  per	  experiment,	  (*=	  p	  <	  0.05	  -­‐	  **	  =	  p	  <0.01)).	  Bar	  graphs	  show	  mean	  ±	  SEM.	  All	  data	  in	  
these	  figures	  are	  normalized	  to	  the	  first	  condition,	  unlike	  the	  CPM	  corrected	  values	  depicted	  in	  













	  	  BCKD	  Activity	  Assay	  	  Materials	  and	  Methods	  	  
• 6-­‐well	  culture	  plate	  
• Clear	  tape	  
• Filter	  paper	  wicks	  (1.3cm	  x	  2cm)	  
• 2	  M	  NaOH	  
• Heat	  Incubator-­‐Shaker	  
• AMEM	  Medium	  (when	  using	  L6	  cells)	  -­‐ Growth	  Medium	  (GM)	  -­‐ Differentiation	  Medium	  (DM)	  
• Krebs	  Ringer	  Phosphate	  Buffer	  (KRB)	  
o KRB	  formulation	  0.018M	  	   NaHPO4	  0.68%	  (w/v)	   NaCl	  0.045%	  (w/v)	   KCl	  0.03%	  (w/v)	   MgSO4	  
	  100	  
0.02%	  (w/v)	   CaCl2	  	  
o 1mg/	  reaction	  well	  -­‐	  Thiamine	  hydrochloride	  
! Working	  dilution:	  1mg	  per	  856μl	  of	  KRB	  =	  14mg	  per	  12ml	  of	  KRB	  
• Reaction	  Mixture	  "	  Typical	  working	  volume	  1ml	  (936.65μl	  PBS,	  43.35μl	  valine	  (50mg/ml	  stock),	  20μl	  1-­‐14C	  labelled	  valine)	  	  
o Phosphate	  Buffer	  Saline	  
o Valine	  50mg/ml	  mixture	  
o 1-­‐14C	  labelled	  valine	  	  
• 15%	  Trichloroacetic	  acid	  (TCA)	  
• Lysis	  Buffer	  	  	  Steps	  	  	   1) Inside	  the	  sterile	  hood	  aspirate	  medium	  from	  all	  wells	  in	  plate,	  replenish	  with	  200ul/well	  of	  GM	  (day	  0)	  or	  DM	  (day	  1	  –	  day	  5).	  2) Move	  to	  radioactive	  bench	  in	  lab,	  immediately	  add	  856	  ul/well	  of	  KRB.	  	  i. KRB	  buffer	  should	  be	  supplemented	  with	  thiamine	  hydrochloride.	  Each	  well	  should	  receive	  1mg	  B1	  (1mg	  per	  856ul	  KRB)	  3) Add	  61ul	  of	  Reaction	  Mixture/well	  –	  Equal	  to	  0.12μCi	  4) Administer	  60ul	  of	  2M	  NaOH	  to	  each	  filter	  paper	  wick,	  while	  they	  are	  anchored	  in	  place	  to	  the	  clear	  strip	  of	  tap	  that	  will	  run	  across	  the	  top	  of	  each	  well.	  (Once	  the	  wicks	  are	  secured	  on	  the	  mounting	  strip,	  place	  the	  mounting	  strip	  on	  its	  side.	  It	  is	  at	  this	  point	  you	  should	  administer	  the	  NaOH).	  5) Place	  clear	  tape	  (mounted	  with	  filter	  paper	  wicks)	  across	  desired	  wells.	  	  i. Ex.	  When	  a	  single	  plate	  contains	  more	  than	  one	  experimental	  condition	  run	  the	  strips	  of	  scotch	  tape	  across	  one	  another	  (as	  shown	  in	  	  Supp.	  Fig	  1b)	  6) Cover	  all	  desired	  wells	  with	  the	  single	  strip	  of	  clear	  tape	  (make	  sure	  the	  wicks	  are	  centralized	  on	  all	  wells).	  7) Make	  sure	  the	  initial	  strips	  of	  clear	  tape	  are	  well	  fastened	  and	  the	  paper	  wicks	  are	  secure	  on	  them	  (not	  hanging	  off	  at	  a	  single	  corner).	  8) Start	  to	  apply	  additional	  strips	  of	  clear	  tape	  starting,	  covering	  the	  remaining	  gaps	  left	  by	  the	  initial	  strips	  of	  clear	  tape	  (Supp.	  Fig	  1c).	  9) Once	  all	  wells	  are	  well	  covered	  make	  sure	  to	  run	  your	  finger	  around	  the	  rim	  of	  each	  well,	  ensuring	  there	  are	  no	  bubbles	  or	  gaps	  compromising	  the	  seal	  of	  EACH	  well.	  10) Place	  6-­‐well	  plate	  lid	  over	  top	  of	  the	  newly	  taped	  plate	  and	  then	  wrap	  a	  single	  piece	  of	  clear	  tape	  around	  the	  entire	  plate	  and	  lid.	  Some	  of	  the	  lids	  (company	  dependent)	  have	  well	  protrusions	  that	  help	  seal	  the	  wells	  (pressing	  the	  tape	  down	  uniformly	  around	  each	  well)(Single	  band	  of	  clear	  tape	  keeping	  the	  lid	  on,	  as	  seen	  in	  Supp.	  Fig	  
2a).	  11) 	  Place	  plate	  in	  heat	  incubator-­‐shaker	  for	  1.5	  hours	  at	  50	  rpm	  and	  at	  37	  degrees	  Celsius.	  12) 	  At	  the	  1.5	  hour	  mark,	  remove	  plate	  from	  heat	  incubator-­‐shaker	  and	  bring	  to	  radiation	  bench.	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13) 	  Using	  a	  21-­‐gauge	  needle	  add	  50ul	  of	  15%	  (w/v)	  TCA	  to	  each	  well,	  to	  stop	  the	  reaction.	  14) 	  Immediately	  following	  step	  12	  cover	  holes	  with	  additional	  strips	  of	  clear	  tape,	  and	  place	  back	  in	  incubator	  for	  30	  minutes.	  15) 	  During	  this	  30	  minute	  waiting	  period	  I	  prepare	  three	  things:	  i. Label	  and	  fill	  20ml	  liquid-­‐scintillation	  vials	  with	  3.5mls	  of	  scintillation	  fluid.	  ii. Label	  centrifuge	  tubes	  required	  for	  cell	  lysate.	  iii. Add	  7ul	  (10ul/ml)	  of	  phosphatase	  inhibitor	  to	  lysis	  buffer	  (usually	  kept	  in	  700ul	  volumes)	  and	  let	  thaw.	  16) 	  Remove	  plate	  from	  heat	  incubator-­‐shaker	  and	  bring	  to	  radiation	  bench,	  using	  a	  small	  set	  of	  scissors,	  make	  an	  incision	  in	  the	  clear	  tape,	  just	  along	  the	  inside	  perimeter	  of	  the	  plate,	  and	  cut	  along	  the	  perimeter	  line	  along	  three	  sides	  (as	  seen	  in	  
Supp.	  Fig	  2b).	  17) 	  At	  this	  stage	  it	  is	  easy	  to	  peal	  back	  all	  of	  the	  clear	  tape	  as	  a	  single	  unit,	  you	  will	  find	  it	  looks	  like	  a	  basket	  weave	  to	  which	  all	  the	  filter	  paper	  wicks	  should	  still	  be	  secured	  (Supp.	  Fig	  2c).	  18) 	  Using	  a	  cleaned	  (70%	  ethanol	  admin	  and	  wiped	  with	  Kim	  wipes)	  set	  of	  forceps	  remove	  the	  blank	  filter	  paper	  wicks	  (the	  two	  that	  were	  placed	  between	  the	  wells)	  and	  place	  into	  their	  respectively	  labelled	  scintillation	  vials.	  19) 	  Then	  remove	  each	  filter	  paper	  wick	  individually	  from	  the	  clear	  tape	  basket	  weave	  and	  place	  into	  their	  respective	  scintillation	  vials.	  20) 	  Aspirate	  the	  contents	  of	  each	  well,	  then	  rinse	  twice	  with	  ice	  cold	  PBS.	  21) 	  Following	  the	  second	  rinse	  with	  ice	  cold	  PBS,	  add	  100ul/well	  of	  lysis	  buffer.	  22) 	  Harvest	  cells	  following	  typical	  cell	  harvesting	  protocol.	  	  	  	  	  
Figure	  1.	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  2.	  	  
	  	  
